<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<title>GRADE: Die Kunst, Beweise zu beurteilen</title>
<link href="https://fonts.googleapis.com" rel="preconnect"/>
<link crossorigin="" href="https://fonts.gstatic.com" rel="preconnect"/>
<link href="https://fonts.googleapis.com/css2?family=Cormorant+Garamond:ital,wght@0,400;0,600;0,700;1,400;1,600&amp;family=Source+Sans+Pro:wght@300;400;600;700&amp;display=swap" rel="stylesheet"/>
<style>
    :root {
      --navy: #1E2761;
      --deep-navy: #141B3D;
      --gold: #D4AF37;
      --cream: #FAF8F5;
      --light-cream: #FFFFFF;
      --text: #2D3748;
      --light-text: #718096;
      --red: #C53030;
      --green: #22c55e;
      --teal: #0f766e;
      --purple: #7c3aed;
      --orange: #f59e0b;
      --transition: 0.5s cubic-bezier(0.4, 0, 0.2, 1);
    }

    * { margin: 0; padding: 0; box-sizing: border-box; }
    html, body {
      height: 100%;
      font-family: 'Source Sans Pro', sans-serif;
      background: var(--deep-navy);
      color: var(--cream);
    }

    .course-container { display: flex; height: 100vh; overflow: hidden; }

    /* Skip Link for Accessibility */
    .skip-link {
      position: absolute;
      top: -40px;
      left: 0;
      background: var(--gold);
      color: var(--navy);
      padding: 8px 16px;
      z-index: 10000;
      text-decoration: none;
      font-weight: 600;
    }
    .skip-link:focus { top: 0; }

    /* ====== SIDEBAR ====== */
    .sidebar {
      width: 300px;
      background: linear-gradient(180deg, var(--deep-navy) 0%, #0a0f1a 100%);
      border-right: 1px solid rgba(212,175,55,0.2);
      display: flex;
      flex-direction: column;
      flex-shrink: 0;
    }

    .sidebar-header {
      padding: 1.25rem;
      border-bottom: 1px solid rgba(212,175,55,0.2);
      text-align: center;
    }
    .sidebar-header h1 {
      font-family: 'Cormorant Garamond', Georgia, serif;
      font-size: 1.3rem;
      font-weight: 700;
      color: var(--gold);
    }
    .sidebar-header p {
      font-size: 0.75rem;
      color: rgba(255,255,255,0.6);
    }

    /* Gamification Stats Panel */
    .stats-panel {
      padding: 1rem;
      background: rgba(212,175,55,0.1);
      border-bottom: 1px solid rgba(212,175,55,0.2);
    }
    .level-display {
      display: flex;
      align-items: center;
      gap: 0.75rem;
      margin-bottom: 0.75rem;
    }
    .level-badge {
      width: 48px;
      height: 48px;
      background: linear-gradient(135deg, var(--gold), #f0c040);
      border-radius: 50%;
      display: flex;
      align-items: center;
      justify-content: center;
      font-size: 1.5rem;
      box-shadow: 0 2px 8px rgba(212,175,55,0.4);
    }
    .level-info { flex: 1; }
    .level-title { font-weight: 700; font-size: 0.9rem; color: var(--gold); }
    .level-subtitle { font-size: 0.7rem; color: rgba(255,255,255,0.6); }
    .xp-bar {
      height: 8px;
      background: rgba(255,255,255,0.1);
      border-radius: 4px;
      overflow: hidden;
      margin-top: 0.5rem;
    }
    .xp-fill {
      height: 100%;
      background: linear-gradient(90deg, var(--gold), var(--orange));
      border-radius: 4px;
      transition: width 0.5s ease;
    }
    .xp-text {
      font-size: 0.65rem;
      color: rgba(255,255,255,0.5);
      text-align: right;
      margin-top: 0.25rem;
    }
    .quick-stats {
      display: grid;
      grid-template-columns: repeat(3, 1fr);
      gap: 0.5rem;
      margin-top: 0.75rem;
    }
    .quick-stat {
      background: rgba(0,0,0,0.2);
      padding: 0.5rem;
      border-radius: 6px;
      text-align: center;
    }
    .quick-stat-value {
      font-size: 1.1rem;
      font-weight: 700;
      color: var(--gold);
    }
    .quick-stat-label {
      font-size: 0.6rem;
      color: rgba(255,255,255,0.5);
    }

    /* Course Progress */
    .course-progress {
      padding: 0.75rem 1rem;
      border-bottom: 1px solid rgba(212,175,55,0.2);
      background: rgba(0,0,0,0.2);
    }
    .course-progress-label {
      display: flex;
      justify-content: space-between;
      font-size: 0.7rem;
      color: rgba(255,255,255,0.6);
      margin-bottom: 0.35rem;
    }
    .course-progress-bar {
      height: 6px;
      background: rgba(255,255,255,0.1);
      border-radius: 3px;
      overflow: hidden;
    }
    .course-progress-fill {
      height: 100%;
      background: linear-gradient(90deg, var(--green), #22d3ee);
      border-radius: 3px;
      transition: width 0.5s ease;
    }

    .module-list { flex: 1; overflow-y: auto; padding: 0.5rem 0; }
    .module-item {
      display: flex;
      align-items: center;
      gap: 0.75rem;
      padding: 0.6rem 1rem;
      cursor: pointer;
      transition: all 0.2s;
      border-left: 3px solid transparent;
    }
    .module-item:hover { background: rgba(212,175,55,0.1); }
    .module-item.active { background: rgba(212,175,55,0.15); border-left-color: var(--gold); }
    .module-item.completed .module-number { background: var(--green); color: white; }
    .module-item.locked { opacity: 0.5; cursor: not-allowed; }
    .module-number {
      width: 26px;
      height: 26px;
      border-radius: 50%;
      background: rgba(255,255,255,0.1);
      display: flex;
      align-items: center;
      justify-content: center;
      font-size: 0.7rem;
      font-weight: 700;
      flex-shrink: 0;
    }
    .module-item.active .module-number { background: var(--gold); color: var(--navy); }
    .module-info { flex: 1; min-width: 0; }
    .module-title { font-size: 0.8rem; font-weight: 600; white-space: nowrap; overflow: hidden; text-overflow: ellipsis; }
    .module-subtitle { font-size: 0.65rem; color: rgba(255,255,255,0.5); }
    .module-xp { font-size: 0.6rem; color: var(--gold); }
    .module-time { font-size: 0.55rem; color: rgba(255,255,255,0.4); display: flex; align-items: center; gap: 0.25rem; margin-top: 0.15rem; }

    /* Badges Panel */
    .badges-panel {
      padding: 1rem;
      border-top: 1px solid rgba(212,175,55,0.2);
    }
    .badges-title { font-size: 0.75rem; font-weight: 600; color: var(--gold); margin-bottom: 0.5rem; }
    .badges-grid { display: flex; flex-wrap: wrap; gap: 0.35rem; }
    .badge-item {
      width: 32px;
      height: 32px;
      background: rgba(255,255,255,0.05);
      border: 2px solid rgba(255,255,255,0.1);
      border-radius: 6px;
      display: flex;
      align-items: center;
      justify-content: center;
      font-size: 0.9rem;
      opacity: 0.3;
      transition: all 0.3s;
      cursor: help;
      position: relative;
      padding: 0;
      color: inherit;
    }
    .badge-item.earned { opacity: 1; background: rgba(212,175,55,0.2); border-color: var(--gold); }
    .badge-item:hover::after {
      content: attr(title);
      position: absolute;
      bottom: 100%;
      left: 50%;
      transform: translateX(-50%);
      background: var(--navy);
      color: white;
      padding: 0.25rem 0.5rem;
      border-radius: 4px;
      font-size: 0.6rem;
      white-space: nowrap;
      z-index: 100;
    }

    /* ====== MAIN CONTENT ====== */
    .main-content { flex: 1; display: flex; flex-direction: column; overflow: hidden; }
    .content-header {
      padding: 0.75rem 1.5rem;
      background: rgba(0,0,0,0.3);
      border-bottom: 1px solid rgba(212,175,55,0.2);
      display: flex;
      align-items: center;
      justify-content: space-between;
    }
    .breadcrumb { font-size: 0.85rem; color: rgba(255,255,255,0.6); }
    .breadcrumb span { color: var(--gold); }
    .header-actions { display: flex; gap: 0.5rem; align-items: center; }
    .streak-display {
      display: flex;
      align-items: center;
      gap: 0.35rem;
      background: rgba(239,68,68,0.2);
      border: 1px solid rgba(239,68,68,0.4);
      padding: 0.35rem 0.75rem;
      border-radius: 20px;
      font-size: 0.8rem;
    }
    .streak-display.active { background: rgba(249,115,22,0.2); border-color: var(--orange); }
    .streak-flame { font-size: 1rem; }
    .streak-count { font-weight: 700; color: var(--orange); }

    .btn {
      padding: 0.5rem 1rem;
      border: 1px solid rgba(212,175,55,0.3);
      border-radius: 6px;
      background: rgba(255,255,255,0.05);
      color: var(--cream);
      font-size: 0.8rem;
      cursor: pointer;
      transition: all 0.2s;
    }
    .btn:hover { background: rgba(212,175,55,0.2); border-color: var(--gold); }
    .btn.primary { background: var(--gold); color: var(--navy); border-color: var(--gold); font-weight: 600; }

    .content-body { flex: 1; overflow: hidden; display: flex; }

    /* ====== SLIDES ====== */
    .slides-container { flex: 1; position: relative; overflow: hidden; }
    .module-slides { display: none; width: 100%; height: 100%; }
    .module-slides.active { display: block; }

    .slide {
      position: absolute;
      top: 0; left: 0;
      width: 100%; height: 100%;
      display: flex;
      flex-direction: column;
      justify-content: flex-start;
      align-items: center;
      padding: 2rem 2rem 4rem;
      opacity: 0;
      visibility: hidden;
      transition: opacity var(--transition), visibility var(--transition);
      overflow-y: auto;
    }
    .slide.active { opacity: 1; visibility: visible; }
    .slide.dark { background: var(--deep-navy); }
    .slide.light { background: var(--cream); color: var(--text); }
    .slide.black { background: #000; }
    .slide.red-bg { background: linear-gradient(135deg, #7f1d1d, #450a0a); }
    .slide.green-bg { background: linear-gradient(135deg, #14532d, #052e16); }
    .slide.purple-bg { background: linear-gradient(135deg, #4c1d95, #2e1065); }
    .slide.orange-bg { background: linear-gradient(135deg, #9a3412, #431407); }

    .slide-progress-bar {
      position: absolute;
      top: 0;
      left: 0;
      height: 3px;
      background: linear-gradient(90deg, var(--gold), var(--orange));
      transition: width 0.3s ease;
      z-index: 50;
    }

    .serif { font-family: 'Cormorant Garamond', Georgia, serif; }
    .title {
      font-family: 'Cormorant Garamond', Georgia, serif;
      font-size: clamp(1.8rem, 4vw, 3rem);
      font-weight: 700;
      margin-bottom: 1rem;
      line-height: 1.2;
      text-align: center;
    }
    .title.gold { color: var(--gold); }
    .title.navy { color: var(--navy); }
    .subtitle {
      font-size: clamp(0.9rem, 2vw, 1.3rem);
      color: rgba(255,255,255,0.7);
      margin-bottom: 1.5rem;
      text-align: center;
    }
    .slide.light .subtitle { color: var(--light-text); }

    .big-number {
      font-family: 'Cormorant Garamond', Georgia, serif;
      font-size: clamp(4rem, 12vw, 8rem);
      font-weight: 700;
      line-height: 1;
    }
    .big-number.gold { color: var(--gold); }
    .big-number.red { color: var(--red); }

    .refrain {
      font-family: 'Cormorant Garamond', Georgia, serif;
      font-size: clamp(1.3rem, 3vw, 2rem);
      font-style: italic;
      color: var(--gold);
      text-align: center;
      max-width: 700px;
    }

    .content { display: flex; flex-direction: column; align-items: center; width: 100%; max-width: 850px; }

    /* Cards */
    .card {
      background: var(--light-cream);
      border: 1px solid var(--gold);
      padding: 1.25rem 1.5rem;
      margin: 0.5rem 0;
      max-width: 750px;
      width: 100%;
      border-radius: 8px;
    }
    .card.navy-bg { background: var(--navy); color: var(--cream); }
    .card.red-border { border: 2px solid var(--red); }
    .card.green-border { border: 2px solid var(--green); }
    .card-label {
      font-size: 0.7rem;
      font-weight: 700;
      color: var(--gold);
      letter-spacing: 0.05em;
      margin-bottom: 0.4rem;
      text-transform: uppercase;
    }
    .card-text { font-size: 0.95rem; line-height: 1.6; }
    .card.navy-bg .card-text { color: var(--cream); }

    /* Story box */
    .story-box {
      background: linear-gradient(135deg, rgba(197,48,48,0.15), rgba(30,39,97,0.2));
      border-left: 4px solid var(--red);
      padding: 1.25rem;
      margin: 0.75rem 0;
      max-width: 750px;
      width: 100%;
      border-radius: 0 8px 8px 0;
    }
    .story-box.success { background: linear-gradient(135deg, rgba(34,197,94,0.15), rgba(30,39,97,0.2)); border-left-color: var(--green); }
    .story-box.warning { background: linear-gradient(135deg, rgba(245,158,11,0.15), rgba(30,39,97,0.2)); border-left-color: var(--orange); }
    .story-label {
      font-size: 0.7rem;
      font-weight: 700;
      letter-spacing: 0.1em;
      color: var(--red);
      margin-bottom: 0.4rem;
      text-transform: uppercase;
    }
    .story-box.success .story-label { color: var(--green); }
    .story-box.warning .story-label { color: var(--orange); }
    .story-text { font-size: 0.95rem; line-height: 1.6; }

    /* Epic Story Box */
    .story-box.epic {
      background: linear-gradient(135deg, rgba(20,27,61,0.95), rgba(0,0,0,0.9));
      border-left: 4px solid var(--gold);
      border-top: 1px solid rgba(212,175,55,0.3);
      border-right: 1px solid rgba(212,175,55,0.2);
      border-bottom: 1px solid rgba(212,175,55,0.2);
      padding: 1.5rem;
      position: relative;
    }
    .story-box.epic::before {
      content: '';
      position: absolute;
      top: 0;
      left: 0;
      right: 0;
      height: 2px;
      background: linear-gradient(90deg, var(--gold), transparent);
    }
    .story-box.epic .story-label { color: var(--gold); font-size: 0.65rem; letter-spacing: 0.15em; }
    .story-box.epic .story-text { font-family: 'Cormorant Garamond', Georgia, serif; font-size: 1.05rem; line-height: 1.7; }

    /* GRADE Certainty Colors */
    .grade-high { background: linear-gradient(135deg, rgba(34,197,94,0.2), rgba(30,39,97,0.2)); border-color: var(--green); }
    .grade-moderate { background: linear-gradient(135deg, rgba(59,130,246,0.2), rgba(30,39,97,0.2)); border-color: #3b82f6; }
    .grade-low { background: linear-gradient(135deg, rgba(245,158,11,0.2), rgba(30,39,97,0.2)); border-color: var(--orange); }
    .grade-very-low { background: linear-gradient(135deg, rgba(197,48,48,0.2), rgba(30,39,97,0.2)); border-color: var(--red); }

    .grade-badge {
      display: inline-block;
      padding: 0.25rem 0.75rem;
      border-radius: 4px;
      font-size: 0.75rem;
      font-weight: 700;
      text-transform: uppercase;
      letter-spacing: 0.05em;
    }
    .grade-badge.high { background: var(--green); color: white; }
    .grade-badge.moderate { background: #3b82f6; color: white; }
    .grade-badge.low { background: var(--orange); color: white; }
    .grade-badge.very-low { background: var(--red); color: white; }

    /* Stats */
    .stats-grid {
      display: flex;
      gap: 0.75rem;
      margin: 1rem 0;
      flex-wrap: wrap;
      justify-content: center;
    }
    .stat-box {
      background: var(--navy);
      color: var(--cream);
      padding: 1rem 1.25rem;
      text-align: center;
      min-width: 120px;
      border-radius: 8px;
    }
    .stat-box.light { background: var(--light-cream); color: var(--navy); border: 1px solid var(--gold); }
    .stat-value {
      font-family: 'Cormorant Garamond', serif;
      font-size: clamp(1.3rem, 2.5vw, 2rem);
      font-weight: 700;
    }
    .stat-value.gold { color: var(--gold); }
    .stat-value.red { color: var(--red); }
    .stat-value.green { color: var(--green); }
    .stat-label { font-size: 0.75rem; opacity: 0.8; margin-top: 0.2rem; }

    /* Timeline */
    .timeline { display: flex; flex-direction: column; gap: 0.4rem; width: 100%; max-width: 650px; }
    .timeline-item {
      display: flex;
      align-items: center;
      gap: 0.75rem;
      padding: 0.6rem 0.75rem;
      background: rgba(255,255,255,0.05);
      border-radius: 6px;
      border-left: 4px solid var(--gold);
    }
    .timeline-days { font-weight: 700; font-size: 0.8rem; min-width: 70px; color: var(--gold); }
    .timeline-content { flex: 1; }
    .timeline-title { font-weight: 600; font-size: 0.9rem; }
    .timeline-desc { font-size: 0.75rem; opacity: 0.7; }

    /* Checklist */
    .checklist { display: flex; flex-direction: column; gap: 0.4rem; width: 100%; max-width: 650px; }
    .checklist-item {
      display: flex;
      align-items: flex-start;
      gap: 0.6rem;
      padding: 0.6rem 0.75rem;
      background: rgba(255,255,255,0.05);
      border-radius: 6px;
      border: 1px solid rgba(255,255,255,0.1);
    }
    .check-icon {
      width: 22px;
      height: 22px;
      background: var(--gold);
      color: var(--navy);
      border-radius: 4px;
      display: flex;
      align-items: center;
      justify-content: center;
      font-weight: 700;
      font-size: 0.75rem;
      flex-shrink: 0;
    }
    .checklist-text { font-size: 0.9rem; line-height: 1.4; }

    /* Lessons */
    .lesson-item { display: flex; align-items: flex-start; gap: 0.75rem; margin: 0.5rem 0; max-width: 700px; }
    .lesson-number {
      background: var(--gold);
      color: var(--navy);
      width: 28px;
      height: 28px;
      border-radius: 50%;
      display: flex;
      align-items: center;
      justify-content: center;
      font-weight: 700;
      font-size: 0.85rem;
      flex-shrink: 0;
    }
    .lesson-content h4 { font-size: 1rem; font-weight: 700; margin-bottom: 0.2rem; }
    .lesson-content p { font-size: 0.85rem; opacity: 0.8; }

    /* ====== DECISION TREE ====== */
    .decision-tree {
      width: 100%;
      max-width: 700px;
      background: linear-gradient(135deg, rgba(124,58,237,0.15), rgba(30,39,97,0.25));
      border: 2px solid var(--purple);
      border-radius: 12px;
      padding: 1.5rem;
      margin: 0.75rem 0;
    }
    .decision-header {
      display: flex;
      align-items: center;
      gap: 0.75rem;
      margin-bottom: 1rem;
    }
    .decision-icon {
      width: 40px;
      height: 40px;
      background: var(--purple);
      border-radius: 50%;
      display: flex;
      align-items: center;
      justify-content: center;
      font-size: 1.25rem;
    }
    .decision-title {
      font-family: 'Cormorant Garamond', serif;
      font-size: 1.2rem;
      font-weight: 700;
    }
    .decision-xp {
      margin-left: auto;
      background: rgba(212,175,55,0.2);
      padding: 0.25rem 0.75rem;
      border-radius: 12px;
      font-size: 0.75rem;
      color: var(--gold);
      font-weight: 600;
    }
    .decision-scenario {
      background: rgba(0,0,0,0.2);
      padding: 1rem;
      border-radius: 8px;
      margin-bottom: 1rem;
      font-size: 0.95rem;
      line-height: 1.6;
    }
    .decision-question {
      font-weight: 600;
      color: var(--gold);
      margin-bottom: 0.75rem;
      font-size: 1rem;
    }
    .decision-options { display: flex; flex-direction: column; gap: 0.5rem; }
    .decision-option {
      display: flex;
      align-items: flex-start;
      gap: 0.75rem;
      padding: 0.75rem 1rem;
      background: rgba(255,255,255,0.05);
      border: 2px solid rgba(255,255,255,0.15);
      border-radius: 8px;
      cursor: pointer;
      transition: all 0.2s;
    }
    .decision-option:hover { background: rgba(124,58,237,0.2); border-color: var(--purple); }
    .decision-option.selected { background: rgba(124,58,237,0.3); border-color: var(--purple); }
    .decision-option.correct { background: rgba(34,197,94,0.2); border-color: var(--green); }
    .decision-option.incorrect { background: rgba(239,68,68,0.15); border-color: var(--red); }
    .decision-option.disabled { pointer-events: none; opacity: 0.7; }
    .decision-option:focus-visible { outline: 3px solid var(--gold); outline-offset: 2px; }
    .option-letter {
      width: 24px;
      height: 24px;
      background: rgba(255,255,255,0.1);
      border-radius: 50%;
      display: flex;
      align-items: center;
      justify-content: center;
      font-weight: 700;
      font-size: 0.8rem;
      flex-shrink: 0;
    }
    .decision-option.correct .option-letter { background: var(--green); color: white; }
    .decision-option.incorrect .option-letter { background: var(--red); color: white; }
    .option-text { font-size: 0.9rem; }
    .decision-feedback {
      margin-top: 1rem;
      padding: 1rem;
      border-radius: 8px;
      display: none;
    }
    .decision-feedback.show { display: block; }
    .decision-feedback.correct { background: rgba(34,197,94,0.2); border: 1px solid var(--green); }
    .decision-feedback.incorrect { background: rgba(239,68,68,0.15); border: 1px solid var(--red); }
    .feedback-title { font-weight: 700; margin-bottom: 0.5rem; display: flex; align-items: center; gap: 0.5rem; }
    .feedback-text { font-size: 0.9rem; line-height: 1.5; }

    /* ====== QUIZ ====== */
    .quiz-container { width: 100%; max-width: 650px; }
    .quiz-question {
      font-family: 'Cormorant Garamond', serif;
      font-size: 1.2rem;
      margin-bottom: 1.25rem;
      text-align: center;
    }
    .quiz-options { display: flex; flex-direction: column; gap: 0.5rem; }
    .quiz-option {
      padding: 0.75rem 1rem;
      background: rgba(255,255,255,0.05);
      border: 2px solid rgba(255,255,255,0.2);
      border-radius: 8px;
      cursor: pointer;
      transition: all 0.2s;
      text-align: left;
      font-size: 0.9rem;
    }
    .quiz-option:hover { background: rgba(212,175,55,0.15); border-color: var(--gold); }
    .quiz-option.correct { background: rgba(34,197,94,0.2); border-color: var(--green); }
    .quiz-option.incorrect { background: rgba(239,68,68,0.15); border-color: var(--red); }
    .quiz-option.disabled { pointer-events: none; }
    .quiz-option:focus-visible { outline: 3px solid var(--gold); outline-offset: 2px; }
    .quiz-feedback {
      margin-top: 1rem;
      padding: 1rem;
      border-radius: 8px;
      display: none;
      font-size: 0.9rem;
    }
    .quiz-feedback.show { display: block; }
    .quiz-feedback.correct { background: rgba(34,197,94,0.2); border: 1px solid var(--green); }
    .quiz-feedback.incorrect { background: rgba(239,68,68,0.15); border: 1px solid var(--red); }

    /* Learning Objectives */
    .objectives-box {
      background: linear-gradient(135deg, rgba(59,130,246,0.15), rgba(30,39,97,0.25));
      border: 2px solid #3b82f6;
      border-radius: 12px;
      padding: 1.25rem;
      margin: 0.75rem 0;
      max-width: 700px;
      width: 100%;
    }
    .objectives-header {
      display: flex;
      align-items: center;
      gap: 0.75rem;
      margin-bottom: 0.75rem;
    }
    .objectives-icon {
      width: 36px;
      height: 36px;
      background: #3b82f6;
      border-radius: 50%;
      display: flex;
      align-items: center;
      justify-content: center;
      font-size: 1.1rem;
    }
    .objectives-title {
      font-family: 'Cormorant Garamond', serif;
      font-size: 1.1rem;
      font-weight: 700;
      color: #60a5fa;
    }
    .objectives-list { list-style: none; padding: 0; }
    .objectives-list li {
      display: flex;
      align-items: flex-start;
      gap: 0.5rem;
      padding: 0.4rem 0;
      font-size: 0.9rem;
    }
    .objectives-list li::before { content: '‚óã'; color: #3b82f6; font-weight: bold; }

    /* Animation */
    .slide.active .animate { animation: fadeUp 0.5s ease-out forwards; }
    .slide.active .animate.delay-1 { animation-delay: 0.1s; }
    .slide.active .animate.delay-2 { animation-delay: 0.2s; }
    .slide.active .animate.delay-3 { animation-delay: 0.3s; }
    @keyframes fadeUp {
      from { opacity: 0; transform: translateY(15px); }
      to { opacity: 1; transform: translateY(0); }
    }
    .animate { opacity: 0; }

    /* XP Popup */
    .xp-popup {
      position: fixed;
      top: 50%;
      left: 50%;
      transform: translate(-50%, -50%) scale(0);
      background: linear-gradient(135deg, var(--gold), #f0c040);
      color: var(--navy);
      padding: 1.5rem 2.5rem;
      border-radius: 12px;
      font-family: 'Cormorant Garamond', serif;
      font-size: 2rem;
      font-weight: 700;
      z-index: 1000;
      box-shadow: 0 10px 40px rgba(0,0,0,0.5);
      transition: transform 0.3s ease;
    }
    .xp-popup.show { transform: translate(-50%, -50%) scale(1); }
    .xp-popup .xp-amount { font-size: 3rem; display: block; }

    /* Badge Earned Modal */
    .badge-modal {
      position: fixed;
      top: 0; left: 0; right: 0; bottom: 0;
      background: rgba(0,0,0,0.85);
      display: none;
      justify-content: center;
      align-items: center;
      z-index: 1001;
    }
    .badge-modal.show { display: flex; }
    .badge-modal-content {
      background: linear-gradient(135deg, var(--deep-navy), #0a0f1a);
      border: 2px solid var(--gold);
      border-radius: 16px;
      padding: 2rem;
      text-align: center;
      max-width: 350px;
    }
    .badge-modal-icon { font-size: 4rem; margin-bottom: 1rem; }
    .badge-modal-title {
      font-family: 'Cormorant Garamond', serif;
      font-size: 1.5rem;
      color: var(--gold);
      margin-bottom: 0.5rem;
    }
    .badge-modal-desc { font-size: 0.9rem; opacity: 0.8; margin-bottom: 1rem; }
    .badge-modal-close {
      padding: 0.5rem 1.5rem;
      background: var(--gold);
      color: var(--navy);
      border: none;
      border-radius: 6px;
      font-weight: 600;
      cursor: pointer;
    }

    /* Confetti */
    .confetti-container {
      position: fixed;
      top: 0; left: 0;
      width: 100%; height: 100%;
      pointer-events: none;
      z-index: 999;
      overflow: hidden;
    }
    .confetti {
      position: absolute;
      width: 10px; height: 10px;
      opacity: 0;
      animation: confetti-fall 3s ease-out forwards;
    }
    @keyframes confetti-fall {
      0% { transform: translateY(-100px) rotate(0deg); opacity: 1; }
      100% { transform: translateY(100vh) rotate(720deg); opacity: 0; }
    }
    @media (prefers-reduced-motion: reduce) {
      .confetti { animation: none; display: none; }
      .xp-popup { transition: none; }
      .slide { transition: none; }
    }

    /* Nav */
    .slide-nav {
      position: absolute;
      bottom: 0; left: 0; right: 0;
      display: flex;
      justify-content: space-between;
      align-items: flex-end;
      padding: 0.75rem 1rem 1.25rem;
      z-index: 100;
      pointer-events: none;
    }
    .nav-btn {
      background: rgba(0,0,0,0.5);
      border: 1px solid rgba(255,255,255,0.2);
      color: white;
      font-size: 1.1rem;
      cursor: pointer;
      opacity: 0.6;
      transition: all 0.2s;
      padding: 0.4rem 0.6rem;
      border-radius: 6px;
      pointer-events: auto;
    }
    .nav-btn:hover { opacity: 1; background: rgba(0,0,0,0.7); border-color: var(--gold); }
    .nav-btn:disabled { opacity: 0.2; cursor: not-allowed; }
    .nav-btn:focus-visible { outline: 3px solid var(--gold); outline-offset: 2px; }
    .nav-center { display: flex; flex-direction: column; align-items: center; gap: 0.2rem; pointer-events: auto; }
    .slide-counter { font-size: 0.7rem; opacity: 0.5; }
    .progress-dots { display: flex; gap: 3px; flex-wrap: wrap; max-width: 220px; justify-content: center; }
    .progress-dot {
      width: 44px;
      height: 44px;
      display: flex;
      align-items: center;
      justify-content: center;
      cursor: pointer;
      background: none;
      border: none;
      padding: 0;
    }
    .progress-dot::after {
      content: '';
      width: 12px;
      height: 12px;
      border-radius: 50%;
      background: var(--text-muted, rgba(255,255,255,0.25));
      transition: all 0.2s ease;
    }
    .progress-dot.active::after,
    .progress-dot.completed::after {
      background: var(--gold);
      width: 14px;
      height: 14px;
    }

    /* Mobile */
    @media (max-width: 768px) {
      .sidebar {
        position: fixed;
        left: -300px;
        top: 0;
        bottom: 0;
        z-index: 1000;
        transition: left 0.3s ease;
      }
      .sidebar.open { left: 0; }
      .sidebar-toggle {
        display: flex;
        position: fixed;
        top: 10px;
        left: 10px;
        z-index: 1001;
        width: 40px;
        height: 40px;
        background: var(--gold);
        color: var(--navy);
        border: none;
        border-radius: 8px;
        align-items: center;
        justify-content: center;
        font-size: 1.2rem;
        cursor: pointer;
      }
      .sidebar-overlay {
        display: none;
        position: fixed;
        top: 0; left: 0; right: 0; bottom: 0;
        background: rgba(0,0,0,0.5);
        z-index: 999;
      }
      .sidebar-overlay.show { display: block; }
    }
    @media (min-width: 769px) {
      .sidebar-toggle { display: none; }
      .sidebar-overlay { display: none !important; }
    }

    /* Combo Counter */
    .combo-display {
      position: fixed;
      top: 80px;
      right: 20px;
      background: linear-gradient(135deg, var(--orange), #ef4444);
      color: white;
      padding: 0.5rem 1rem;
      border-radius: 20px;
      font-weight: 700;
      font-size: 0.9rem;
      z-index: 500;
      transform: scale(0);
      transition: transform 0.3s ease;
      box-shadow: 0 4px 15px rgba(239,68,68,0.4);
    }
    .combo-display.show { transform: scale(1); }
  </style>
</head>
<body>
<a class="skip-link" href="#main-content">Skip to main content</a>
<div class="course-container">
<!-- Sidebar -->
<nav aria-label="Kursnavigation" class="sidebar" role="navigation">
<div class="sidebar-header">
<a href="index.html" onmouseout="this.style.color='rgba(212,175,55,0.7)'" onmouseover="this.style.color='#D4AF37'" style="display:block;font-size:0.7rem;color:rgba(212,175,55,0.7);text-decoration:none;margin-bottom:0.5rem;">‚Üê Course Library</a>
<h1>GRADE Mastery</h1>
<p>Die Kunst, Beweise zu beurteilen</p>
</div>
<div class="stats-panel">
<div class="level-display">
<div class="level-badge" id="levelIcon">üìä</div>
<div class="level-info">
<div class="level-title" id="levelTitle">Novice Appraiser</div>
<div class="level-subtitle">Level <span id="levelNum">1</span></div>
</div>
</div>
<div class="xp-bar"><div class="xp-fill" id="xpFill" style="width: 0%"></div></div>
<div class="xp-text"><span id="xpCurrent">0</span> / <span id="xpNeeded">100</span> XP</div>
<div class="quick-stats">
<div class="quick-stat">
<div class="quick-stat-value" id="correctCount">0</div>
<div class="quick-stat-label">Correct</div>
</div>
<div class="quick-stat">
<div class="quick-stat-value" id="decisionCount">0</div>
<div class="quick-stat-label">Decisions</div>
</div>
<div class="quick-stat">
<div class="quick-stat-value" id="gradesCount">0</div>
<div class="quick-stat-label">Graded</div>
</div>
</div>
</div>
<div class="course-progress">
<div class="course-progress-label">
<span>Course Progress</span>
<span id="courseProgressPct">0%</span>
</div>
<div class="course-progress-bar">
<div class="course-progress-fill" id="courseProgressFill" style="width: 0%"></div>
</div>
</div>
<div class="module-list" id="moduleList"></div>
<div class="badges-panel">
<div class="badges-title">Achievements</div>
<div class="badges-grid" id="badgesGrid"></div>
</div>
</nav>
<!-- Main Content -->
<main class="main-content" id="main-content">
<header class="content-header">
<div class="breadcrumb">GRADE Mastery / <span id="currentModule">Module 1</span></div>
<div class="header-actions">
<div class="streak-display" id="streakDisplay">
<span class="streak-flame">üî•</span>
<span class="streak-count" id="streakCount">0</span>
<span>day streak</span>
</div>
<button class="btn" onclick="resetProgress()">Reset</button>
</div>
</header>
<div class="content-body">
<div class="slides-container" id="slidesContainer"></div>
</div>
</main>
</div>
<!-- XP Popup -->
<div aria-atomic="true" aria-live="polite" class="xp-popup" id="xpPopup" role="status">
<span class="xp-amount" id="xpAmount">+25</span>
    XP
  </div>
<!-- Badge Modal -->
<div aria-labelledby="badgeModalTitle" aria-modal="true" class="badge-modal" id="badgeModal" role="dialog">
<div class="badge-modal-content">
<div class="badge-modal-icon" id="badgeModalIcon">üèÜ</div>
<div class="badge-modal-title" id="badgeModalTitle">Badge Earned!</div>
<div class="badge-modal-desc" id="badgeModalDesc">Sie haben einen neuen Erfolg freigeschaltet</div>
<button class="badge-modal-close" onclick="closeBadgeModal()">Awesome!</button>
</div>
</div>
<!-- Confetti Container -->
<div class="confetti-container" id="confettiContainer"></div>
<!-- Combo Counter -->
<div aria-live="polite" class="combo-display" id="comboDisplay" role="status">üî• <span id="comboCount">0</span>x Combo!</div>
<!-- Mobile Sidebar Toggle -->
<button aria-expanded="false" aria-label="Toggle menu" class="sidebar-toggle" onclick="toggleSidebar()">‚ò∞</button>
<div class="sidebar-overlay" id="sidebarOverlay" onclick="toggleSidebar()"></div>
<script>
// ===== GAMIFICATION STATE =====
const DEFAULT_STATE = {
  xp: 0,
  level: 1,
  streak: 0,
  lastActive: null,
  correctAnswers: 0,
  decisionsCompleted: 0,
  gradesAssigned: 0,
  badges: [],
  completedModules: [],
  answeredQuestions: {},
  consecutiveCorrect: 0
};

function safeGetStorage(key, fallback) {
  try {
    const item = localStorage.getItem(key);
    return item ? JSON.parse(item) : fallback;
  } catch (e) {
    return fallback;
  }
}

function safeSetStorage(key, value) {
  try {
    localStorage.setItem(key, JSON.stringify(value));
  } catch (e) {}
}

// Migration from old storage key to versioned key
(function migrateStorage() {
  try {
    const oldData = localStorage.getItem('gradeGame');
    if (oldData && !localStorage.getItem('gradeGame_v1')) {
      localStorage.setItem('gradeGame_v1', oldData);
      localStorage.removeItem('gradeGame');
    }
  } catch (e) {}
})();

let gameState = safeGetStorage('gradeGame_v1', DEFAULT_STATE);

const LEVELS = [
  { level: 1, title: "Novice Appraiser", icon: "üìä", xp: 0 },
  { level: 2, title: "Bias Spotter", icon: "üîç", xp: 100 },
  { level: 3, title: "Certainty Seeker", icon: "‚öñÔ∏è", xp: 250 },
  { level: 4, title: "Evidence Evaluator", icon: "üìã", xp: 450 },
  { level: 5, title: "GRADE Apprentice", icon: "üéì", xp: 700 },
  { level: 6, title: "Certainty Guardian", icon: "üõ°Ô∏è", xp: 1000 },
  { level: 7, title: "Evidence Master", icon: "üèÜ", xp: 1400 },
  { level: 8, title: "GRADE Sage", icon: "üëë", xp: 1900 }
];

const BADGES = [
  { id: "first_grade", icon: "üìä", name: "First Rating", desc: "Assign your first GRADE rating" },
  { id: "bias_hunter", icon: "üîç", name: "Bias Hunter", desc: "Schlie√üen Sie das Modul ‚ÄûRisk of Bias‚Äú ab" },
  { id: "precision_master", icon: "üéØ", name: "Precision Master", desc: "Schlie√üen Sie das Modul ‚ÄûUngenauigkeit‚Äú ab" },
  { id: "consistency_king", icon: "üîó", name: "Consistency King", desc: "Schlie√üen Sie das Modul ‚ÄûInkonsistenz‚Äú ab" },
  { id: "directness_detective", icon: "üé™", name: "Directness Detective", desc: "Schlie√üen Sie das Modul ‚ÄûIndirektheit‚Äú ab" },
  { id: "publication_sleuth", icon: "üì∞", name: "Publication Sleuth", desc: "Komplettes Modul ‚ÄûPublication Bias‚Äú." },
  { id: "upgrader", icon: "‚¨ÜÔ∏è", name: "The Upgrader", desc: "Learn all upgrading factors" },
  { id: "perfect_5", icon: "‚≠ê", name: "Five Star", desc: "Get 5 correct answers in a row" },
  { id: "decision_maker", icon: "‚öñÔ∏è", name: "Decision Maker", desc: "Schlie√üe 15 Entscheidungsb√§ume ab" },
  { id: "finisher", icon: "üèÅ", name: "Course Complete", desc: "Beenden Sie den gesamten Kurs" },
  { id: "streak_3", icon: "üî•", name: "On Fire", desc: "Maintain a 3-day streak" },
  { id: "streak_7", icon: "üí´", name: "Weekly Warrior", desc: "Maintain a 7-day streak" },
  { id: "grade_master", icon: "üëë", name: "GRADE Master", desc: "Schlie√üen Sie die Abschlussbewertung ab" }
];

// ===== MODULES DATA =====
const MODULES = [
  {
    id: 1, title: "Why Certainty Matters", subtitle: "When confidence kills", xp: 150,
    slides: [
      { type: "title", theme: "dark", content: { title: "Why Certainty Matters", subtitle: "When overconfidence in evidence kills patients" }},
      { type: "objectives", theme: "dark", content: {
        objectives: [
          "Understand why evidence certainty determines patient outcomes",
          "Lernen Sie aus Richtlinien, die get√∂tet wurden, weil die Gewissheit falsch eingesch√§tzt wurde",
          "Erkennen Sie den Unterschied zwischen ‚ÄûBeweise liegen vor‚Äú und ‚ÄûBeweise sind vertrauensw√ºrdig‚Äú",
          "Understand what GRADE provides that traditional reviews don't"
        ],
        tip: "Dieses Modul zeigt, warum eine falsche Gewissheit echte Konsequenzen hat."
      }},
      { type: "story", theme: "red-bg", content: {
        label: "Die Betablocker-Katastrophe", title: "Guidelines Based on a Liar",
        text: "For two decades, clinical guidelines worldwide recommended <strong>beta-blockers before non-cardiac surgery</strong> to prevent heart attacks. The recommendation was rated 'strong'‚Äîhigh certainty of benefit. Millions of patients received the drugs before operations. The evidence came largely from one man: <strong>Don Poldermans</strong>, who contributed 15 studies showing dramatic benefits.",
        followup: "In 2011, Poldermans was found guilty of research misconduct. His data was fabricated. When his studies were removed from meta-analyses, the math reversed: beta-blockers didn't prevent heart attacks‚Äîthey caused them. Researchers calculated the cost: following guidelines based on this fraudulent 'high certainty' evidence may have <strong>killed 800,000 patients</strong> over a decade. The certainty rating was wrong. The patients paid with their lives."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "‚ö†Ô∏è", title: "Szenario: Die starke Empfehlung",
        xp: 25,
        scenario: "Ein Leitliniengremium bewertet die Evidenz als ‚Äûhohe Sicherheit‚Äú und spricht eine ‚Äûstarke Empfehlung‚Äú f√ºr eine vorbeugende Behandlung aus. Sie stellen fest, dass 60 % der Beweise von einer einzelnen Forschungsgruppe stammen, deren Ergebnisse nie unabh√§ngig reproduziert wurden.",
        question: "Welche Bedenken sollten Sie hinsichtlich der Sicherheitsbewertung √§u√üern?",
        options: [
          { letter: "A", text: "Keine ‚Äì peer-reviewte Studien sind vertrauensw√ºrdig", correct: false },
          { letter: "B", text: "Die Sicherheit sollte aufgrund des Risikos einer Verzerrung und mangelnder Replikation herabgestuft werden", correct: true },
          { letter: "C", text: "Fordern Sie zur Best√§tigung weitere Studien derselben Gruppe an", correct: false },
          { letter: "D", text: "Die starke Empfehlung gleicht etwaige Unsicherheiten aus", correct: false }
        ],
        feedback: {
          correct: "Richtig! Die nicht reproduzierten Ergebnisse von Poldermans wurden trotz der Abh√§ngigkeit von einer Quelle als ‚Äûhohe Sicherheit‚Äú eingestuft. GRADE erfordert eine Herabstufung, wenn die Beweise stark von potenziell voreingenommenen Quellen abh√§ngen, denen eine unabh√§ngige Best√§tigung fehlt.",
          incorrect: "800.000 Todesf√§lle resultierten aus dem Vertrauen auf nicht reproduzierte Beweise aus einer einzigen Quelle. Hohe Sicherheit erfordert unabh√§ngige Replikation. Die Konzentration auf eine Forschungsgruppe stellt ein kritisches Risiko einer Verzerrung dar."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "Die Hormonumkehr", title: "Two Million Women Betrayed",
        text: "For forty years, doctors prescribed <strong>hormone replacement therapy (HRT)</strong> to prevent heart disease in menopausal women. The evidence seemed overwhelming: observational studies showed <strong>50% fewer heart attacks</strong>. Experts were certain. Guidelines were strong. Two million American women took HRT specifically for heart protection.",
        followup: "In 2002, the Women's Health Initiative RCT delivered a verdict that shattered decades of certainty. HRT didn't prevent heart disease‚Äîit <strong>increased heart attacks by 29%</strong>, strokes by 41%, and breast cancer by 26%. The observational evidence had been confounded: healthy women chose HRT, creating an illusion of benefit. The certainty had been based on the wrong type of evidence. Two million women had taken a drug that harmed them, prescribed by doctors who were certain they were helping."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üìä", title: "Scenario: Observational vs. RCT",
        xp: 25,
        scenario: "Zwanzig gro√üe Beobachtungsstudien zeigen, dass eine Behandlung die kardiovaskul√§ren Todesf√§lle um 45 % reduziert. Zwei kleine RCTs zeigen keine Wirkung. Ein Leitliniengremium muss die Evidenzsicherheit f√ºr den Nutzen bewerten.",
        question: "What certainty rating is appropriate?",
        options: [
          { letter: "A", text: "Hoch ‚Äì 20 Studien √ºberwiegen 2 Studien", correct: false },
          { letter: "B", text: "Moderate‚Äîmixed evidence requires caution", correct: false },
          { letter: "C", text: "Low‚ÄîRCTs trump observational studies; confounding likely explains the discrepancy", correct: true },
          { letter: "D", text: "Very Low‚Äîno conclusion is possible", correct: false }
        ],
        feedback: {
          correct: "Richtig! Die HRT-Katastrophe hat uns genau diese Lektion gelehrt. Beobachtungsstudien, die einen Nutzen von 50 % zeigten, wurden von RCTs √ºbertrumpft, die einen Schaden zeigten. Wenn RCTs im Widerspruch zu Beobachtungsdaten stehen, ist Confounding die wahrscheinliche Erkl√§rung. GRADE startet RCTs auf einem hohen Niveau, Beobachtungsstudien auf einem niedrigen Niveau.",
          incorrect: "HRT observational studies showed 50% benefit; the RCT showed 29% harm. The discrepancy was confounding‚Äîhealthy women chose HRT. RCT evidence, even from smaller studies, provides higher certainty than observational evidence for causal questions."
        }
      }},
      { type: "stats", theme: "dark", content: {
        title: "Der Preis falscher Gewissheit",
        stats: [
          { value: "800K", label: "Todesf√§lle durch Poldermans-Betrug" },
          { value: "2M", label: "Women harmed by HRT" },
          { value: "50K", label: "CAST drug deaths" },
          { value: "83K", label: "Avandia heart attacks" }
        ],
        caption: "Bei jeder Katastrophe handelte es sich um Richtlinien, die aufgrund fehlerhafter Beweisw√ºrdigung ‚Äûsicher‚Äú waren."
      }},
      { type: "story", theme: "red-bg", content: {
        label: "Die intensive Glukosekatastrophe", title: "ACCORD: When Tight Control Killed",
        text: "Diabetes doctors were certain: if high blood sugar caused complications, then tighter glucose control must prevent them. The logic seemed irrefutable. Guidelines recommended <strong>aggressive targets</strong>. The ACCORD trial enrolled 10,251 patients to prove what everyone already 'knew'‚Äîintensive glucose control saves lives.",
        followup: "In February 2008, the trial was stopped early. Not for benefit‚Äî<strong>for harm</strong>. Intensive glucose control increased deaths by 22%. The certainty had been based on biological plausibility, not actual outcome data. The surrogate outcome (glucose levels) improved while the patient-important outcome (survival) worsened. 257 excess deaths occurred in the intensive group. The guidelines had been confident. The confidence was misplaced."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üéØ", title: "Szenario: Die logische Behandlung",
        xp: 25,
        scenario: "Eine Behandlung verbessert einen Biomarker (Laborwert), von dem bekannt ist, dass er Krankheiten verursacht, erheblich. Bisher wurden in keiner Studie tats√§chliche klinische Ergebnisse wie Tod oder Krankenhausaufenthalt gemessen. Ein Kollege argumentiert, dass die Gewissheit des Nutzens ‚Äûhoch‚Äú sei, weil der Mechanismus gut verstanden sei.",
        question: "What certainty rating should apply?",
        options: [
          { letter: "A", text: "High‚Äîclear mechanism implies clear benefit", correct: false },
          { letter: "B", text: "Moderate‚Äîmechanism is supportive but not definitive", correct: false },
          { letter: "C", text: "Low or Very Low‚Äîsurrogate outcomes don't guarantee patient-important benefits", correct: true },
          { letter: "D", text: "Eine Bewertung ist erst m√∂glich, wenn die Tests abgeschlossen sind", correct: false }
        ],
        feedback: {
          correct: "Richtig! ACCORD, CAST und unz√§hlige andere Katastrophen folgten dem Irrtum des ‚Äûlogischen Mechanismus‚Äú. Eine Verbesserung der Leihm√ºtter kann die Ergebnisse verschlechtern. GRADE erfordert eine Herabstufung wegen Indirektheit, wenn nur Ersatzergebnisse gemessen werden.",
          incorrect: "Die ACCORD-Intensivtherapie verbesserte den Blutzuckerspiegel perfekt und t√∂tete gleichzeitig Patienten. CAST-Medikamente reparierten EKGs und verdreifachten gleichzeitig die Zahl der Todesf√§lle. Biologische Plausibilit√§t ist kein klinischer Beweis. F√ºr eine hohe Sicherheit sind patientenrelevante Ergebnisse erforderlich."
        }
      }},
      { type: "concept", theme: "dark", content: {
        title: "What GRADE Provides",
        subtitle: "Ein systematischer Rahmen f√ºr Gewissheit",
        text: "GRADE (Grading of Recommendations Assessment, Development and Evaluation) bietet eine strukturierte, transparente Methode zur Bewertung, wie viel Vertrauen wir in Beweise setzen sollten. Es trennt ‚ÄûBeweise liegen vor‚Äú und ‚ÄûBeweise sind vertrauensw√ºrdig‚Äú.",
        highlight: "GRADE fragt: ‚ÄûWie sicher sind wir, dass der wahre Effekt nahe am gesch√§tzten Effekt liegt?‚Äú"
      }},
      { type: "story", theme: "dark", content: {
        label: "Die Offenbarung der Arthroskopie", title: "A Billion-Dollar Placebo",
        text: "Knee arthroscopy for osteoarthritis was one of the most common orthopedic procedures in the world. <strong>700,000 Americans</strong> underwent it annually at a cost of $3 billion. Surgeons were certain it worked‚Äîthey saw patients improve. Insurance covered it. Guidelines recommended it.",
        followup: "Then came the sham surgery trials. Patients were randomized to real arthroscopy or fake surgery (incisions but no actual procedure). The result: <strong>no difference</strong>. Patients improved equally whether they received real surgery or placebo. Decades of certainty, billions of dollars, millions of surgeries‚Äîall based on the placebo effect that surgeons couldn't see. The certainty had been based on uncontrolled observations. Controlled trials revealed the truth."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üî¨", title: "Szenario: Der erfahrene Chirurg",
        xp: 25,
        scenario: "Eine leitende Chirurgin argumentiert, dass ein Eingriff ‚Äûdefinitiv funktioniert‚Äú, weil sie ihn 2.000 Mal durchgef√ºhrt und ‚Äûgesehen hat, wie es den Patienten besser geht‚Äú. Es liegen keine randomisierten Studien vor. Sie m√∂chte, dass die Leitlinie die Sicherheit basierend auf der klinischen Erfahrung als ‚Äûm√§√üig‚Äú einstuft.",
        question: "What certainty rating is appropriate?",
        options: [
          { letter: "A", text: "Moderate‚Äî2,000 cases is substantial experience", correct: false },
          { letter: "B", text: "Low‚Äîuncontrolled observations can't distinguish treatment effect from placebo", correct: true },
          { letter: "C", text: "Hoch ‚Äì Expertenerfahrung ist die h√∂chste Beweisform", correct: false },
          { letter: "D", text: "Sehr niedrig ‚Äì Anekdoten sind kein Beweis", correct: false }
        ],
        feedback: {
          correct: "Richtig! Kniearthroskopie-Chirurgen ‚Äûsahen‚Äú jahrzehntelang, wie es den Patienten besser ging ‚Äì dann zeigten Versuche mit Scheinoperationen, dass es sich um ein Placebo handelte. Expertenerfahrungen k√∂nnen keine Placebo-Effekte erkennen. GRADE bewertet unkontrollierte Beobachtungen mit sehr geringer Sicherheit.",
          incorrect: "Chirurgen f√ºhrten j√§hrlich 700.000 Arthroskopien durch und ‚Äûsahen‚Äú einen Nutzen ‚Äì das war v√∂llig Placebo. Klinische Erfahrungen, egal wie umfangreich, k√∂nnen Behandlungseffekte nicht von nat√ºrlicher Verbesserung oder Placebo unterscheiden. RCTs sind unerl√§sslich."
        }
      }},
      { type: "refrain", theme: "black", content: { text: "Bei der Gewissheit kommt es nicht darauf an, wie viele Beweise vorhanden sind. Es geht darum, wie sehr wir ihm vertrauen sollten." }},
      { type: "quiz", theme: "dark", content: {
        question: "Warum haben die HRT-Beobachtungsstudien √Ñrzte 40 Jahre lang in die Irre gef√ºhrt?",
        options: [
          { text: "Die Studien wurden erfunden", correct: false },
          { text: "Healthy women were more likely to choose HRT, creating confounding", correct: true },
          { text: "The RCTs used different doses", correct: false },
          { text: "Heart disease definitions changed over time", correct: false }
        ],
        xp: 20,
        feedback: {
          correct: "Genau. Die Verwirrung durch die Indikation ‚Äì gesunde Frauen entschieden sich f√ºr eine HRT ‚Äì erzeugte die Illusion eines Nutzens. Aus diesem Grund bewertet GRADE Beobachtungsstudien bei kausalen Fragen schlechter als RCTs.",
          incorrect: "Die Studien waren real, aber verwirrend. Bei gesunden Frauen war die Wahrscheinlichkeit einer HRT h√∂her, was den Eindruck erweckte, dass dies vorteilhaft sei. RCTs beseitigen diese Verwirrung zuf√§llig und enth√ºllen so den wahren Effekt."
        }
      }}
    ]
  },
  {
    id: 2, title: "Das GRADE-Framework", subtitle: "Von hoch bis sehr niedrig", xp: 120,
    slides: [
      { type: "title", theme: "dark", content: { title: "Das GRADE-Framework", subtitle: "Four levels of certainty, five reasons to doubt" }},
      { type: "objectives", theme: "dark", content: {
        objectives: [
          "Lernen Sie die vier GRADE-Sicherheitsstufen und ihre Bedeutung kennen",
          "Understand starting points: RCTs vs observational studies",
          "Kennen Sie die f√ºnf Bereiche zur Herabstufung der Sicherheit",
          "Kennen Sie die drei Faktoren zur Verbesserung der Beobachtungsbeweise"
        ],
        tip: "Dieses Modul stellt den Rahmen bereit, den Sie w√§hrend des gesamten Kurses anwenden werden."
      }},
      { type: "stats", theme: "dark", content: {
        title: "Die vier Sicherheitsstufen",
        stats: [
          { value: "‚äï‚äï‚äï‚äï", label: "HIGH" },
          { value: "‚äï‚äï‚äï‚óã", label: "MODERATE" },
          { value: "‚äï‚äï‚óã‚óã", label: "LOW" },
          { value: "‚äï‚óã‚óã‚óã", label: "VERY LOW" }
        ],
        caption: "Auf jeder Ebene erfahren Entscheidungstr√§ger, wie viel Vertrauen sie in die Beweise setzen sollen."
      }},
      { type: "concept", theme: "dark", content: {
        title: "What Each Level Means",
        subtitle: "Practical interpretation",
        checkpoints: [
          { day: "HIGH", event: "Sehr zuversichtlich, dass der tats√§chliche Effekt nahe an der Sch√§tzung liegt" },
          { day: "MODERATE", event: "Moderately confident; true effect likely close but may differ" },
          { day: "LOW", event: "Limited confidence; true effect may be substantially different" },
          { day: "VERY LOW", event: "Very little confidence; true effect likely substantially different" }
        ]
      }},
      { type: "story", theme: "dark", content: {
        label: "Das Ausgangspunktprinzip", title: "Why RCTs Begin Higher",
        text: "In 1747, James Lind conducted what many consider the first controlled trial. Twelve sailors with scurvy were divided into six pairs, each receiving a different treatment. <strong>Only the two who received citrus fruits recovered.</strong> This simple comparison‚Äîtreated vs. untreated under similar conditions‚Äîrevealed truth that centuries of observation had missed.",
        followup: "Randomization is the great equalizer. It balances known and unknown confounders between groups. When patients are randomized, differences in outcomes can be attributed to the treatment, not to differences between patients. This is why GRADE starts RCT evidence at <strong>HIGH</strong> certainty and observational evidence at <strong>LOW</strong>‚Äîthe study design itself determines how much confounding might distort results."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üé≤", title: "Szenario: Der Ausgangspunkt",
        xp: 25,
        scenario: "You're rating evidence for a new drug. You have three RCTs (total n=1,200) and five cohort studies (total n=45,000). A colleague argues the cohort studies should start at the same certainty level because they have more patients.",
        question: "Was ist der richtige Ausgangspunkt f√ºr jeden Beweistyp?",
        options: [
          { letter: "A", text: "Both start at HIGH‚Äîsample size determines certainty", correct: false },
          { letter: "B", text: "RCTs start HIGH, cohorts start LOW‚Äîdesign determines starting point", correct: true },
          { letter: "C", text: "Cohorts start MODERATE because of large sample size", correct: false },
          { letter: "D", text: "Beide beginnen bei MODERATE und passen sich von dort aus an", correct: false }
        ],
        feedback: {
          correct: "Richtig! GRADE-Anfangspunkte basieren auf dem Studiendesign und nicht auf der Stichprobengr√∂√üe. RCTs beginnen HOCH, weil die Randomisierung die Verwirrung kontrolliert. Beobachtungsstudien beginnen NIEDRIG, da St√∂rfaktoren unabh√§ngig von der Gr√∂√üe nicht beseitigt werden k√∂nnen.",
          incorrect: "Sample size affects precision, not confounding. The HRT cohort studies had millions of patients but were still wrong because of confounding. RCTs start HIGH; observational studies start LOW."
        }
      }},
      { type: "checklist", theme: "dark", content: {
        title: "F√ºnf Domains zum Downgrade",
        items: [
          "Verzerrungsrisiko ‚Äì Besteht bei den Studien ein hohes Verzerrungsrisiko?",
          "Inkonsistenz ‚Äì Variieren die Ergebnisse zwischen den Studien auf unerkl√§rliche Weise?",
          "Indirektheit ‚Äì Gehen Beweise direkt auf unsere Frage ein?",
          "Imprecision ‚Äî Is the effect estimate precise enough?",
          "Publikationsbias ‚Äì Fehlen Studien in der Evidenzbasis?"
        ]
      }},
      { type: "story", theme: "red-bg", content: {
        label: "Die Tamiflu-Saga", title: "When All Five Domains Failed",
        text: "In 2009, governments stockpiled Tamiflu for pandemic flu. The UK spent <strong>¬£473 million</strong>. The evidence looked solid: published trials showed reduced complications. But Cochrane reviewers noticed problems in every GRADE domain.",
        followup: "<strong>Risk of bias:</strong> Trials were industry-funded with unclear methods. <strong>Inconsistency:</strong> Results varied between published and unpublished studies. <strong>Indirectness:</strong> 'Complications' were poorly defined. <strong>Imprecision:</strong> Confidence intervals were wide. <strong>Publication bias:</strong> 60% of patient data was never published. When Roche finally released the raw data after five years, the truth emerged: Tamiflu reduced symptom duration by less than a day and had no proven effect on hospitalizations or complications. Half a billion pounds spent on evidence that should have been rated VERY LOW."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üìâ", title: "Szenario: Das Multi-Domain-Problem",
        xp: 25,
        scenario: "You're rating evidence from 5 RCTs. You find: unclear allocation concealment (risk of bias), I¬≤ = 75% with no explanation (inconsistency), and half the trials never published (publication bias). The trials themselves are precise and direct.",
        question: "Um wie viele Stufen sollten Sie von HIGH herabstufen?",
        options: [
          { letter: "A", text: "One level‚Äîmultiple minor concerns equal one downgrade", correct: false },
          { letter: "B", text: "Two levels‚Äîserious concerns in two domains", correct: false },
          { letter: "C", text: "Three levels‚Äîserious concerns in three domains (to VERY LOW)", correct: true },
          { letter: "D", text: "Cannot downgrade RCTs‚Äîthey're always HIGH", correct: false }
        ],
        feedback: {
          correct: "Correct! Serious concerns in each domain typically warrant one downgrade each. Risk of bias (‚àí1), inconsistency (‚àí1), and publication bias (‚àí1) would take HIGH to VERY LOW. Multiple domains can compound.",
          incorrect: "Each domain with serious concerns typically warrants one downgrade. Three serious domain concerns = three downgrades. HIGH ‚àí 3 = VERY LOW. GRADE is cumulative."
        }
      }},
      { type: "checklist", theme: "dark", content: {
        title: "Three Factors for Upgrading (Observational Only)",
        items: [
          "Large Effect ‚Äî Very large magnitude of effect (RR > 2 or < 0.5)",
          "Dose-Response ‚Äî Clear gradient between exposure and outcome",
          "Confounding ‚Äî All plausible confounding would reduce the effect"
        ]
      }},
      { type: "story", theme: "green-bg", content: {
        label: "Der Beweis f√ºr das Rauchen", title: "When Observation Earned Certainty",
        text: "In the 1950s, Richard Doll and Austin Bradford Hill published observational studies linking cigarettes to lung cancer. No RCTs existed‚Äîyou cannot randomize people to smoke. Yet the evidence became <strong>HIGH certainty</strong>. Why?",
        followup: "Every upgrading criterion was met. <strong>Large effect:</strong> Smokers had 10-30x higher lung cancer rates‚Äîan effect size that confounding alone cannot explain. <strong>Dose-response:</strong> More cigarettes = more cancer in a clear gradient. <strong>Confounding direction:</strong> Any unmeasured confounder that caused both smoking and cancer would have to be implausibly powerful to explain the effect. When observational evidence meets all three upgrading criteria, it can achieve certainty that rivals RCTs."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "‚¨ÜÔ∏è", title: "Szenario: Die Upgrade-Frage",
        xp: 25,
        scenario: "An observational study shows a treatment increases survival with RR = 1.3 (30% relative increase). The association is statistically significant with narrow confidence intervals. The authors argue this should be upgraded from LOW to MODERATE.",
        question: "Sollten diese Beweise aufgewertet werden?",
        options: [
          { letter: "A", text: "Yes‚Äîstatistical significance warrants upgrading", correct: false },
          { letter: "B", text: "Yes‚Äînarrow confidence intervals warrant upgrading", correct: false },
          { letter: "C", text: "No‚ÄîRR 1.3 is not large enough; confounding could easily explain it", correct: true },
          { letter: "D", text: "No‚Äîobservational evidence can never be upgraded", correct: false }
        ],
        feedback: {
          correct: "Correct! RR 1.3 is well within the range that confounding can produce. Large effect upgrading typically requires RR > 2 or < 0.5‚Äîeffects so large that confounding alone is an implausible explanation. Statistical significance and precision are not upgrading criteria.",
          incorrect: "A 30% relative increase (RR 1.3) can easily result from modest confounding. The HRT studies showed RR 0.5 for heart protection‚Äîentirely due to confounding. Large effect upgrading requires effects that confounding cannot plausibly explain (typically RR > 2 or < 0.5)."
        }
      }},
      { type: "concept", theme: "dark", content: {
        title: "Die GRADE-Mnemonik: RIIPP",
        subtitle: "Denken Sie an die 5 Downgrade-Domains",
        text: "<strong style='color:var(--gold);font-size:1.5rem'>R</strong>isk of bias ‚Äî Can we trust the studies?<br><br><strong style='color:var(--gold);font-size:1.5rem'>I</strong>nconsistency ‚Äî Do studies agree?<br><br><strong style='color:var(--gold);font-size:1.5rem'>I</strong>ndirectness ‚Äî Does evidence match our question?<br><br><strong style='color:var(--gold);font-size:1.5rem'>I</strong>mprecision ‚Äî Is the estimate precise?<br><br><strong style='color:var(--gold);font-size:1.5rem'>P</strong>ublication bias ‚Äî Is evidence missing?",
        highlight: "RIIPP ‚Äì Denken Sie daran: ‚ÄûRCT-Beweise k√∂nnen RIIPP auseinandernehmen, wenn diese Bereiche ernsthafte Probleme haben.‚Äú"
      }},
      { type: "quiz", theme: "dark", content: {
        question: "Why do observational studies start at LOW certainty in GRADE?",
        options: [
          { text: "They usually have smaller sample sizes", correct: false },
          { text: "They cannot control for unmeasured confounding", correct: true },
          { text: "They are more often industry-funded", correct: false },
          { text: "Die Fertigstellung dauert l√§nger", correct: false }
        ],
        xp: 20,
        feedback: {
          correct: "Genau. Durch Randomisierung werden St√∂rfaktoren zwischen Gruppen ausgeglichen. Ohne sie k√∂nnten Unterschiede in den Ergebnissen auf Unterschiede bei den Patienten und nicht auf Behandlungseffekte zur√ºckzuf√ºhren sein. HRT-Studien mit Millionen von Patienten waren wegen der Verwirrung immer noch falsch.",
          incorrect: "Das Problem ist die Verwirrung, nicht die Stichprobengr√∂√üe. Beobachtungsstudien k√∂nnen unbekannte St√∂rfaktoren nicht so ausgleichen wie die Randomisierung. Diese grundlegende Einschr√§nkung bestimmt den Ausgangspunkt."
        }
      }}
    ]
  },
  {
    id: 3, title: "Risk of Bias", subtitle: "Wenn Studien l√ºgen", xp: 180,
    slides: [
      { type: "title", theme: "purple-bg", content: { title: "Risk of Bias", subtitle: "Der erste Bereich: K√∂nnen wir diesen Studien vertrauen?" }},
      { type: "objectives", theme: "dark", content: {
        objectives: [
          "Identifizieren Sie wichtige Bias-Dom√§nen in RCTs und Beobachtungsstudien",
          "Recognize how bias inflates or deflates treatment effects",
          "Apply risk of bias assessment to real examples",
          "Decide when to downgrade certainty for bias"
        ],
        tip: "Schlie√üen Sie alle Entscheidungsszenarien ab, um den Bias Hunter zu erhalten Abzeichen!"
      }},
      { type: "story", theme: "red-bg", content: {
        label: "Die VIGOR-T√§uschung", title: "When Merck Chose the Cutoff",
        text: "In 2000, Merck published the VIGOR trial comparing Vioxx to naproxen. The New England Journal of Medicine reported a 4-fold increase in heart attacks with Vioxx. But the published paper hid something: <strong>three additional heart attacks</strong> occurred in the Vioxx group after the data cutoff date. Merck scientists knew about them.",
        followup: "Those three heart attacks mattered. Including them would have changed the risk ratio from 'concerning' to 'alarming.' Instead, Merck's chosen cutoff date‚Äîa methodological decision made after seeing the data‚Äîobscured the true risk. The NEJM later published an 'expression of concern,' calling the paper 'inaccurate and incomplete.' By then, tens of thousands had suffered heart attacks from a drug whose danger had been hidden by selective reporting. The bias wasn't in the trial design‚Äîit was in how the data was analyzed and presented."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "‚úÇÔ∏è", title: "Szenario: Der gleitende Grenzwert",
        xp: 30,
        scenario: "Sie bewerten eine Studie, deren prim√§rer Analysezeitpunkt nach Studienbeginn ge√§ndert wurde ‚Äì von 12 Monaten auf 6 Monate. Die 6-Monats-Ergebnisse sprechen f√ºr die Behandlung. Die Autoren geben an, dass die √Ñnderung aus ‚Äûadministrativen Gr√ºnden‚Äú vorgenommen wurde, die nichts mit den Ergebnissen zu tun haben.",
        question: "Wie sollte sich dies auf Ihre Risikobewertung f√ºr Verzerrungen auswirken?",
        options: [
          { letter: "A", text: "No concern‚Äîadministrative changes happen", correct: false },
          { letter: "B", text: "Hohes Risiko f√ºr Verzerrungen bei selektiver Berichterstattung ‚Äì Zeitpunkt√§nderungen nach Sichtung der Daten sind verd√§chtig.", correct: true },
          { letter: "C", text: "Geringes Risiko, wenn die 12-Monats-Daten ebenfalls verd√§chtig sind gemeldet", correct: false },
          { letter: "D", text: "Unclear risk‚Äîwe cannot know their true motivation", correct: false }
        ],
        feedback: {
          correct: "Richtig! Post-hoc-√Ñnderungen von Analysepl√§nen stellen ein hohes Risiko f√ºr die selektive Berichterstattung dar. Die Datensperre von VIGOR war eine ‚Äûmethodische Entscheidung‚Äú, die drei Herzinfarkte verbarg. Wenn sich die Zeitpunkte √§ndern, nachdem sich Daten angesammelt haben, gehen Sie vom Schlimmsten aus.",
          incorrect: "Mercks ‚Äûmethodischer‚Äú Stichtag verbarg t√∂dliche Herzinfarkte. Post-hoc-Analyse√§nderungen ‚Äì insbesondere wenn die Ergebnisse eine Behandlung beg√ºnstigen ‚Äì sind klassische selektive Berichte. GRADE erfordert Skepsis gegen√ºber Post-hoc-√Ñnderungen."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "Das Open-Label-Problem", title: "When Knowing Changes Everything",
        text: "The ASCOT-LLA trial compared atorvastatin to placebo for cardiovascular prevention. The primary endpoint was non-fatal MI plus fatal CHD‚Äî<strong>objective outcomes</strong> that shouldn't depend on whether doctors knew which treatment patients received.",
        followup: "But doctors did know. The trial was stopped early when the Data Safety Monitoring Board saw benefit. The problem: some outcomes were adjudicated by committees who were <strong>not blinded</strong> to treatment assignment. Did knowing a patient was on statin affect how borderline MIs were classified? Studies comparing blinded vs. unblinded assessment show systematic differences. Open-label designs can inflate apparent benefits by 10-20% even for 'objective' outcomes. ASCOT-LLA was rated down for risk of bias despite being an RCT."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üëÅÔ∏è", title: "Szenario: Die unverblindeten Gutachter",
        xp: 25,
        scenario: "Ein RCT eines chirurgischen Eingriffs berichtet √ºber eine 30-prozentige Reduzierung ‚Äûschwerer kardiovaskul√§rer Ereignisse‚Äú. Die Studie war notwendigerweise entblindet (die Patienten wussten, ob sie operiert wurden). Die Ergebnispr√ºfer waren ebenfalls nicht verblindet. Die Ereignisse wurden von einem Ausschuss beurteilt, der die Behandlungszuweisungen kannte.",
        question: "Wie hoch ist das Risiko einer Verzerrung aufgrund einer Erkennungsverzerrung?",
        options: [
          { letter: "A", text: "Low‚Äîcardiovascular events are objective", correct: false },
          { letter: "B", text: "High‚Äîunblinded assessment of cardiovascular events inflates effects", correct: true },
          { letter: "C", text: "Unklar ‚Äì wir ben√∂tigen weitere Informationen √ºber den Ausschuss", correct: false },
          { letter: "D", text: "Not applicable‚Äîsurgical trials cannot be blinded", correct: false }
        ],
        feedback: {
          correct: "Correct! Even 'objective' outcomes like MI involve judgment calls (borderline troponins, ECG interpretations). Studies show unblinded assessment inflates effects 10-20%. Outcome assessors should always be blinded when possible, regardless of intervention blinding.",
          incorrect: "Cardiovascular events require interpretation‚Äîborderline troponin elevations, ECG changes, symptom classification. Unblinded assessors systematically favor the intervention. Outcome assessment should be blinded even when intervention blinding is impossible."
        }
      }},
      { type: "story", theme: "red-bg", content: {
        label: "Die ITT-Verletzung", title: "Roche's Missing Patients",
        text: "In Tamiflu trials, Roche excluded patients from analysis after randomization. Some were excluded for 'protocol violations'‚Äîbut the violations often occurred <strong>after</strong> patients had taken the drug and experienced side effects. Patients who developed complications were retroactively deemed 'protocol violators' and removed.",
        followup: "Intention-to-treat (ITT) analysis exists precisely to prevent this. Once randomized, always analyzed‚Äîregardless of what happens afterward. Excluding patients after randomization destroys the balance that randomization created. Roche's selective exclusions removed patients who had adverse outcomes, making Tamiflu appear safer and more effective than it was. The Cochrane review downgraded certainty specifically for these ITT violations."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üö™", title: "Szenario: Die Post-Randomisierung Ausschl√ºsse",
        xp: 25,
        scenario: "A trial randomizes 500 patients per arm. The paper reports results for 420 vs. 380 patients, with 80 and 120 exclusions respectively. Reasons include: 'withdrew consent,' 'lost to follow-up,' and 'protocol deviation.' More patients were excluded from the control arm.",
        question: "What risk of bias concern does this raise?",
        options: [
          { letter: "A", text: "No concern‚Äîexclusions happen in every trial", correct: false },
          { letter: "B", text: "High risk of attrition bias‚Äîdifferential exclusions destroy randomization balance", correct: true },
          { letter: "C", text: "Low risk if reasons are documented", correct: false },
          { letter: "D", text: "Unclear‚Äîwe need to know why controls were excluded more", correct: false }
        ],
        feedback: {
          correct: "Richtig! Die unterschiedliche Fluktuation (120 vs. 80 Ausschl√ºsse) deutet darauf hin, dass die Gruppen nicht mehr vergleichbar sind. Wenn die Kontrollpatienten, bei denen sich keine Besserung zeigte, eher dazu neigten, die Studie abzubrechen, sahen die verbleibenden Kontrollpatienten ges√ºnder aus, als sie sollten. Dadurch wird der offensichtliche Behandlungsnutzen erh√∂ht.",
          incorrect: "Differenzielle Ausschl√ºsse (120 vs. 80) unterbrechen die Randomisierung. Die √ºbrigen Gruppen sind nicht mehr ausgeglichen. Wenn erkrankte Kontrollpatienten die Studie abbrachen, erscheint die Kontrollgruppe k√ºnstlich gesund. GRADE erfordert eine Herabstufung wegen erheblicher Differenzabwanderung."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "Die Registrierungsl√ºcke", title: "Die Ergebnisse, die verschwunden sind",
        text: "A systematic review of trial registration found that <strong>31% of trials</strong> changed their primary outcome between registration and publication. The changes weren't random‚Äîthey systematically favored positive results. Outcomes that showed benefit were promoted to primary; outcomes showing no effect were demoted or disappeared.",
        followup: "Selective outcome reporting is invisible without registration comparison. A trial might register five outcomes, find benefit in one, and publish only that one as the 'primary' outcome. The reader sees a positive trial. The reality: 4 of 5 outcomes showed nothing. PROSPERO registration for systematic reviews and ClinicalTrials.gov for trials exist specifically to combat this. When assessing risk of bias, always compare published outcomes to registered protocols."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üìã", title: "Scenario: The Primary Outcome Switch",
        xp: 25,
        scenario: "Sie vergleichen eine ver√∂ffentlichte Studie mit ihrer Registrierung. In der Registrierung wird ‚Äûkardiovaskul√§rer Tod‚Äú als prim√§rer Wert aufgef√ºhrt. In der Ver√∂ffentlichung wird ‚ÄûZusammensetzung aus kardiovaskul√§rem Tod, Myokardinfarkt oder Schlaganfall‚Äú als prim√§r aufgef√ºhrt und als signifikant angegeben. Der kardiovaskul√§re Tod allein wird in einer Tabelle vergraben und zeigt keinen signifikanten Unterschied.",
        question: "What risk of bias rating is appropriate?",
        options: [
          { letter: "A", text: "Low‚Äîcomposite endpoints are clinically reasonable", correct: false },
          { letter: "B", text: "High‚Äîthis is outcome switching to achieve significance", correct: true },
          { letter: "C", text: "Unclear‚Äîthe authors may have had good reasons", correct: false },
          { letter: "D", text: "Niedrig, wenn die Kombination im Protokoll vorab festgelegt wurde", correct: false }
        ],
        feedback: {
          correct: "Richtig! Der Wechsel von einem engen Ergebnis (CV-Tod) zu einem breiteren kombinierten Ergebnis (CV-Tod/MI/Schlaganfall), nachdem festgestellt wurde, dass das enge Ergebnis fehlgeschlagen ist, ist ein Ergebniswechsel wie aus dem Lehrbuch. Die 31 % der Studien, die dies tun, √ºbertreiben die positiven Ergebnisse systematisch.",
          incorrect: "Dabei handelt es sich um eine Ergebnisumschaltung ‚Äì die registrierte prim√§re L√∂sung ist fehlgeschlagen, daher wurde eine breitere Kombination gef√∂rdert. Die zusammengesetzte Bedeutung kann vollst√§ndig von den weniger wichtigen Komponenten bestimmt werden. Vergleichen Sie jede Ver√∂ffentlichung mit ihrer Registrierung."
        }
      }},
      { type: "story", theme: "red-bg", content: {
        label: "Das Avandia-Audit", title: "38,000 Heart Attacks Exposed by One Cardiologist",
        text: "In 2007, Dr. Steven Nissen at the Cleveland Clinic did what regulators hadn't: he pooled all available rosiglitazone (Avandia) data. <strong>42 trials, 27,847 patients</strong>. The FDA had approved Avandia based on surrogate outcomes‚Äîit lowered blood sugar beautifully. But Nissen asked a different question: what about hearts?",
        followup: "His meta-analysis revealed the truth: Avandia increased heart attacks by <strong>43%</strong> (OR 1.43, 95% CI 1.03-1.98). GSK had conducted these trials. GSK had the data. But the data on cardiovascular events had been scattered across trials, buried in adverse event tables, never pooled. When Nissen pooled it, the pattern became undeniable. The FDA estimated <strong>83,000 excess heart attacks</strong> between 1999-2007. The bias wasn't in study conduct‚Äîit was in how results were analyzed and presented. Selective synthesis can be as dangerous as selective reporting."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üìë", title: "Szenario: Die verstreuten Sicherheitsdaten",
        xp: 25,
        scenario: "A drug has been studied in 30 trials for various conditions. Each trial reports a few adverse cardiac events in supplementary tables, but no single trial was powered for cardiac outcomes. A meta-analysis combining cardiac events across all 30 trials shows RR 1.35 (95% CI 1.10-1.65) for heart attacks.",
        question: "How should this post-hoc safety signal affect certainty?",
        options: [
          { letter: "A", text: "Ignore it‚Äîtrials weren't designed for cardiac outcomes", correct: false },
          { letter: "B", text: "Nehmen Sie es ernst ‚Äì gepoolte unerw√ºnschte Ereignisse k√∂nnen selbst aus einer Post-hoc-Analyse echte Signale offenbaren", correct: true },
          { letter: "C", text: "Dismiss it‚Äîmeta-analysis of adverse events is unreliable", correct: false },
          { letter: "D", text: "Wait for a dedicated cardiac outcome trial before acting", correct: false }
        ],
        feedback: {
          correct: "Richtig! Nissens Avandia-Analyse war eine ‚ÄûPost-hoc‚Äú-Zusammenfassung vereinzelter unerw√ºnschter Ereignisse ‚Äì und sie ergab 83.000 zus√§tzliche Herzinfarkte. Post-hoc-Sicherheitssignale aus Metaanalysen k√∂nnen real sein. Das Fehlen vorher festgelegter kardialer Folgen bedeutet nicht, dass keine kardialen Ereignisse aufgetreten sind.",
          incorrect: "Der Avandia-Fall hat gezeigt, dass eine nachtr√§gliche Zusammenfassung unerw√ºnschter Ereignisse echte Sch√§den aufdecken kann. Es w√§re unzumutbar gewesen, auf einen speziellen Prozess zu warten, w√§hrend sich 83.000 Herzinfarkte angesammelt haben. Sicherheitssignale aus der Metaanalyse unerw√ºnschter Ereignisse verdienen ernsthafte Beachtung."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "Die ENHANCE-T√§uschung", title: "When Merck Hid What They Found",
        text: "Im Jahr 2006 schloss Merck die ENHANCE-Studie mit Vytorin (Ezetimib + Simvastatin) gegen Arteriosklerose ab. In der Studie wurde die Dicke der Halsschlagader gemessen ‚Äì ein Ersatz f√ºr Herz-Kreislauf-Erkrankungen. Die Ergebnisse sollten Anfang 2007 vorliegen. Merck k√ºndigte eine ‚ÄûVerz√∂gerung‚Äú f√ºr ‚Äûzus√§tzliche Analysen‚Äú an.",
        followup: "The 'additional analyses' took <strong>two years</strong>. When finally released in 2008, ENHANCE showed <strong>no benefit</strong>‚ÄîVytorin didn't reduce artery thickness despite lowering LDL cholesterol. During those two years of concealment, Vytorin sales exceeded <strong>$5 billion</strong>. Congressional investigations revealed internal documents showing Merck knew the results were negative in 2006. The delay wasn't for analysis‚Äîit was for commercial protection. Publication delay is a form of selective reporting: timing becomes a bias tool."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "‚è∞", title: "Szenario: Die verd√§chtige Verz√∂gerung",
        xp: 25,
        scenario: "Eine mit Spannung erwartete Studie zu einem Blockbuster-Medikament sollte vor 18 Monaten Ergebnisse ver√∂ffentlichen. Das Unternehmen f√ºhrt ‚Äûlaufende Analysen‚Äú und ‚ÄûDatenqualit√§tsprobleme‚Äú an. Unterdessen verkauft sich das Medikament weiterhin j√§hrlich in Milliardenh√∂he. Studien von Mitbewerbern haben bereits berichtet.",
        question: "Was sollten Sie √ºber die nicht gemeldeten Ergebnisse vermuten?",
        options: [
          { letter: "A", text: "Nothing‚Äîdata quality takes time", correct: false },
          { letter: "B", text: "Likely negative or harmful‚Äîcompanies delay bad news, not good news", correct: true },
          { letter: "C", text: "Likely positive‚Äîthey're waiting for regulatory approval", correct: false },
          { letter: "D", text: "Cannot infer anything from publication timing", correct: false }
        ],
        feedback: {
          correct: "Correct! The ENHANCE delay taught us: companies don't delay good news for two years. Unexplained publication delays, especially for products still generating revenue, are strong evidence of unfavorable results. Consider delayed trials as potentially biased against the intervention.",
          incorrect: "Der Zeitpunkt der Ver√∂ffentlichung ist aufschlussreich. Unternehmen beschleunigen die Ver√∂ffentlichung positiver Ergebnisse (Aktienkurs, Marketing) und verz√∂gern negative (weitere Verk√§ufe). Eine 18-monatige Verz√∂gerung bei einem Blockbuster-Medikament deutet stark darauf hin, dass die Ergebnisse den fortgesetzten Konsum nicht unterst√ºtzen."
        }
      }},
      { type: "checklist", theme: "dark", content: {
        title: "Risk of Bias Domains (RCTs)",
        items: [
          "Random sequence generation ‚Äî Was randomization truly random?",
          "Allocation concealment ‚Äî Could anyone predict assignments?",
          "Blinding of participants/personnel ‚Äî Did they know treatment?",
          "Blinding of outcome assessment ‚Äî Did assessors know treatment?",
          "Unvollst√§ndige Ergebnisdaten ‚Äì Wurden die Fluktuationen ausgeglichen und erkl√§rt?",
          "Selective reporting ‚Äî Are registered outcomes all reported?",
          "Other bias ‚Äî Baseline imbalances, early stopping, etc."
        ]
      }},
      { type: "quiz", theme: "dark", content: {
        question: "Why does GRADE downgrade for open-label outcome assessment even when outcomes seem 'objective'?",
        options: [
          { text: "Open-label trials are always lower quality", correct: false },
          { text: "Even objective outcomes involve judgment calls affected by knowledge of treatment", correct: true },
          { text: "Regulations require blinded assessment", correct: false },
          { text: "Es handelt sich um eine konservative Konvention, die nicht auf Beweisen basiert", correct: false }
        ],
        xp: 20,
        feedback: {
          correct: "Richtig! Borderline-MI, unsichere Schlaganfallsymptome, umstrittene EKG-Ver√§nderungen ‚Äì alles erfordert Interpretation. Studien zeigen, dass eine unverblindete Beurteilung die bekannte Behandlung systematisch um 10‚Äì20 % beg√ºnstigt, selbst bei ‚Äûharten‚Äú Endpunkten.",
          incorrect: "Untersuchungen zeigen, dass eine unverblindete Beurteilung die Wirkung sogar bei Ergebnissen verst√§rkt, die objektiv erscheinen. Grenzf√§lle werden zugunsten der erwarteten Wirkung interpretiert. Das ist Erkennungsverzerrung."
        }
      }}
    ]
  },
  {
    id: 4, title: "Inconsistency", subtitle: "Wenn Studien nicht √ºbereinstimmen", xp: 160,
    slides: [
      { type: "title", theme: "orange-bg", content: { title: "Inconsistency", subtitle: "Der zweite Bereich: Was tun wir, wenn Studien nicht √ºbereinstimmen?" }},
      { type: "objectives", theme: "dark", content: {
        objectives: [
          "Verstehen, warum Studienergebnisse variieren und wann Abweichungen von Belang sind",
          "I¬≤- und Tau¬≤-Statistiken auf Heterogenit√§t interpretieren",
          "Distinguish explainable from unexplainable inconsistency",
          "Decide when to downgrade certainty for inconsistency"
        ],
        tip: "Real disagreement between studies tells us something important."
      }},
      { type: "story", theme: "red-bg", content: {
        label: "Das Vitamin D Widerspruch", title: "Wenn 200 Studien nicht √ºbereinstimmen konnten",
        text: "By 2019, over <strong>200 randomized trials</strong> had studied vitamin D supplementation. The results were chaos. Some showed vitamin D prevented cancer (RR 0.77). Others showed no effect (RR 1.02). Some showed harm (RR 1.15). Meta-analyses pooled them all and proclaimed 'statistically significant benefit.' But the I¬≤ was <strong>78%</strong>‚Äîmassive heterogeneity that the summary estimate concealed.",
        followup: "The largest trial, VITAL (25,871 participants), finally brought clarity. It showed <strong>no benefit</strong> for cancer or cardiovascular disease. The smaller positive studies had methodological problems: inadequate randomization, post-hoc analyses, selected populations. The pooled estimate had hidden a crucial truth: when studies wildly disagree, the average may represent no one's truth. GRADE requires downgrading for this kind of inconsistency, regardless of what the pooled estimate shows."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üìä", title: "Szenario: Die heterogene Metaanalyse",
        xp: 25,
        scenario: "A meta-analysis of 15 trials shows pooled benefit (OR 0.75, p<0.001). However, I¬≤ = 82%, tau¬≤ is large, and the prediction interval crosses 1.0. Six trials show harm, nine show benefit. The authors conclude 'significant benefit with moderate heterogeneity.'",
        question: "How should inconsistency affect the certainty rating?",
        options: [
          { letter: "A", text: "No downgrade‚Äîthe pooled estimate is statistically significant", correct: false },
          { letter: "B", text: "Downgrade one level‚ÄîI¬≤ > 75% is substantial heterogeneity", correct: false },
          { letter: "C", text: "Downgrade one or two levels‚Äîprediction interval crossing 1.0 means future studies might show harm", correct: true },
          { letter: "D", text: "Cannot rate‚Äîinconsistent evidence is uninterpretable", correct: false }
        ],
        feedback: {
          correct: "Correct! The prediction interval is key. When it crosses the null, we're saying: 'If we did another study, it might show the opposite effect.' That's profound uncertainty. I¬≤ = 82% with a prediction interval crossing 1.0 warrants serious downgrading.",
          incorrect: "I¬≤ von 82 % ist eine starke Heterogenit√§t, aber das Vorhersageintervall ist informativer. Wenn der Wert 1,0 √ºberschreitet, bedeutet dies, dass zuk√ºnftige Studien einen Schaden nachweisen k√∂nnten ‚Äì der zusammengefasste ‚ÄûNutzen‚Äú gilt m√∂glicherweise nicht f√ºr den n√§chsten Patienten. Die statistische Signifikanz der gepoolten Sch√§tzung rettet inkonsistente Beweise nicht."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "Das Schlaganfall-R√§tsel", title: "Aspirin's Vanishing Benefit",
        text: "In 1988, the ISIS-2 trial proved aspirin reduced death after heart attack by <strong>23%</strong>. The evidence was bulletproof‚Äî17,187 patients, clear benefit, minimal heterogeneity when pooled with similar trials. Aspirin became standard care.",
        followup: "But stroke prevention was different. Meta-analyses of aspirin for primary prevention showed <strong>wildly inconsistent results</strong>. Some trials showed 15% reduction in stroke. Others showed 10% increase. The I¬≤ exceeded 60%. The explanation emerged slowly: aspirin prevents <strong>ischemic</strong> stroke but causes <strong>hemorrhagic</strong> stroke. When trials measured 'all stroke,' results depended on the baseline mix of stroke types in each population. The inconsistency wasn't noise‚Äîit was biology. Understanding <em>why</em> studies differ changes interpretation entirely."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üîç", title: "Szenario: Die erkl√§rbare Inkonsistenz",
        xp: 25,
        scenario: "A meta-analysis shows I¬≤ = 70%. However, subgroup analysis reveals: trials in high-risk patients show consistent benefit (I¬≤ = 15%, OR 0.60), while trials in low-risk patients show consistent null effects (I¬≤ = 20%, OR 1.02). The high I¬≤ is entirely explained by mixing these populations.",
        question: "Sollten Sie wegen Inkonsistenz herabstufen?",
        options: [
          { letter: "A", text: "Yes‚ÄîI¬≤ = 70% always requires downgrading", correct: false },
          { letter: "B", text: "No‚Äîinconsistency is fully explained by a pre-specified, biologically plausible subgroup", correct: true },
          { letter: "C", text: "Partially‚Äîdowngrade one level despite the explanation", correct: false },
          { letter: "D", text: "Report two separate certainty ratings for each subgroup", correct: false }
        ],
        feedback: {
          correct: "Richtig! GRADE unterscheidet unerkl√§rliche Heterogenit√§t (Herabstufung) von Heterogenit√§t, die vollst√§ndig durch glaubw√ºrdige Untergruppeneffekte erkl√§rt wird (keine Herabstufung wegen Inkonsistenz). Die Erkl√§rung muss vorab spezifiziert und biologisch plausibel sein ‚Äì nicht nachtr√§gliches Ausbaggern von Daten.",
          incorrect: "When heterogeneity is fully explained by a pre-specified, credible subgroup effect, the 'inconsistency' actually tells us something useful: treatment works differently in different populations. This informs clinical practice rather than undermining certainty."
        }
      }},
      { type: "story", theme: "red-bg", content: {
        label: "Das Albumin-Paradoxon", title: "28 Trials, Zero Answers",
        text: "Should critically ill patients receive albumin for fluid resuscitation? By 1998, the Cochrane Injuries Group had pooled <strong>28 trials</strong>. Their conclusion: albumin <strong>increases mortality by 68%</strong> (RR 1.68). Headlines screamed. NHS considered banning albumin. The evidence seemed damning.",
        followup: "But look closer at those 28 trials. I¬≤ was <strong>0%</strong>‚Äîno heterogeneity. A different problem lurked: the trials were tiny (many with <50 patients), measured different populations (burns, trauma, surgery), and many were decades old. The <strong>SAFE trial</strong> (6,997 patients, 2004) finally answered the question: albumin was <strong>equivalent to saline</strong>‚Äîno benefit, no harm. The pooled estimate from 28 small, disparate trials had been an artifact of random variation in underpowered studies, not a real signal. Consistency (low I¬≤) doesn't guarantee truth."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "‚öñÔ∏è", title: "Szenario: Die konsistenten, aber besorgniserregenden Beweise",
        xp: 25,
        scenario: "A meta-analysis pools 12 small trials (total n=400) with I¬≤ = 5%‚Äîvery low heterogeneity. The pooled effect is OR 0.50 (dramatic benefit), statistically significant. A colleague argues this deserves HIGH certainty because results are 'beautifully consistent.'",
        question: "What concern should you raise?",
        options: [
          { letter: "A", text: "None‚Äîlow I¬≤ means high certainty for inconsistency", correct: false },
          { letter: "B", text: "Low I¬≤ in small trials may reflect consistent bias, not consistent truth", correct: true },
          { letter: "C", text: "I¬≤ = 5% is too low and suggests publication bias", correct: false },
          { letter: "D", text: "The pooled estimate is too dramatic to be real", correct: false }
        ],
        feedback: {
          correct: "Richtig! Kleine Studien mit durchweg dramatischen Ergebnissen sollten Verdacht erregen. M√∂glicherweise teilen sie die gleichen Vorurteile (Publikationsbias, √§hnliche fehlerhafte Methoden). Die Albumin-Metaanalyse ergab in 28 Studien einen I¬≤-Wert nahe 0 % ‚Äì die gro√üe SAFE-Studie zeigte jedoch keinen Effekt. Konsistenz in kleinen Versuchen ‚â† Wahrheit.",
          incorrect: "Low heterogeneity among small, potentially biased trials can be misleading. If all trials share similar biases (publication bias, poor methods), they'll show consistently biased results. The albumin case proves this: I¬≤ was low, but the effect was an artifact."
        }
      }},
      { type: "stats", theme: "dark", content: {
        title: "Understanding I¬≤ Thresholds",
        stats: [
          { value: "0-25%", label: "Low heterogeneity" },
          { value: "25-50%", label: "Moderate" },
          { value: "50-75%", label: "Substantial" },
          { value: ">75%", label: "Considerable" }
        ],
        caption: "Aber I¬≤ allein bestimmt nicht die Herabstufung ‚Äì das Vorhersageintervall und die klinische Bedeutung sind wichtiger."
      }},
      { type: "checklist", theme: "dark", content: {
        title: "Inconsistency Assessment Checklist",
        items: [
          "Calculate I¬≤ and tau¬≤ ‚Äî but don't stop there",
          "Examine prediction interval ‚Äî does it cross clinically important thresholds?",
          "Suchen Sie nach √ºberlappenden Konfidenzintervallen zwischen Studien",
          "Check if heterogeneity can be explained by credible subgroups",
          "Consider if small trials are driving inconsistency (vs. large trial disagreement)"
        ]
      }},
      { type: "quiz", theme: "dark", content: {
        question: "Warum ist das Vorhersageintervall f√ºr die GRADE-Inkonsistenzbewertung wichtiger als I¬≤?",
        options: [
          { text: "Prediction intervals are easier to calculate", correct: false },
          { text: "Prediction intervals tell us what effect a future study might show", correct: true },
          { text: "I¬≤ is only valid for large meta-analyses", correct: false },
          { text: "Prediction intervals account for publication bias", correct: false }
        ],
        xp: 20,
        feedback: {
          correct: "Exactly. The prediction interval says: 'The next study from this distribution of effects will probably fall in this range.' If that range includes harm while the pooled estimate shows benefit, we're deeply uncertain about what will happen to the next patient.",
          incorrect: "The prediction interval captures uncertainty about what future studies (or the next patient) might experience. I¬≤ tells us whether heterogeneity exists; the prediction interval tells us whether it matters clinically."
        }
      }}
    ]
  },
  {
    id: 5, title: "Indirectness", subtitle: "Falsche Frage, falsche Antwort", xp: 170,
    slides: [
      { type: "title", theme: "purple-bg", content: { title: "Indirectness", subtitle: "Der dritte Bereich: Beantwortet dieser Beweis unsere eigentliche Frage?" }},
      { type: "objectives", theme: "dark", content: {
        objectives: [
          "Recognize four types of indirectness: population, intervention, comparator, outcome",
          "Understand why surrogate outcomes mislead",
          "Apply indirectness assessment to real scenarios",
          "Decide when evidence is too indirect to trust"
        ],
        tip: "Der beste Beweis f√ºr die falsche Frage ist immer noch die falsche Antwort."
      }},
      { type: "story", theme: "red-bg", content: {
        label: "Die CAST-Katastrophe", title: "50.000 Tote durch eine logische Behandlung",
        text: "After a heart attack, arrhythmias predict death. <strong>Encainide and flecainide</strong> suppressed arrhythmias on ECG beautifully‚Äî85% reduction in premature ventricular contractions. The FDA approved them. Cardiologists prescribed them to hundreds of thousands of post-MI patients. The logic was irresistible: dangerous arrhythmias ‚Üí sudden death; suppress arrhythmias ‚Üí prevent death.",
        followup: "The CAST trial was designed to confirm what everyone already 'knew.' Instead, it delivered a verdict that stunned cardiology. Patients on anti-arrhythmic drugs died at <strong>3.6 times the rate</strong> of placebo. The trials were stopped early for harm. An estimated <strong>50,000 Americans died</strong> from drugs that perfectly fixed the surrogate (ECG) while causing the outcome (death). The evidence for arrhythmia suppression was HIGH certainty‚Äîbut it was indirect evidence for mortality. That indirectness killed 50,000 people."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üìà", title: "Szenario: Der perfekte Ersatz",
        xp: 25,
        scenario: "Ein neues Diabetes-Medikament zeigt eine dramatische Senkung des HbA1c (Verbesserung um 1,5 % gegen√ºber Placebo). Da HbA1c ein ‚Äûvalidierter Ersatz‚Äú f√ºr kardiovaskul√§re Ergebnisse sei, argumentiert das Unternehmen, dass die Gewissheit des kardiovaskul√§ren Nutzens als M√§√üig eingestuft werden sollte. Es gibt noch keine CV-Outcome-Studien.",
        question: "Wie ist die Sicherheit f√ºr den kardiovaskul√§ren Nutzen zu bewerten?",
        options: [
          { letter: "A", text: "MODERATE‚ÄîHbA1c is a validated surrogate", correct: false },
          { letter: "B", text: "HIGH‚Äî1.5% reduction is clinically meaningful", correct: false },
          { letter: "C", text: "LOW or VERY LOW‚Äîdowngrade for indirectness (surrogate outcome)", correct: true },
          { letter: "D", text: "Cannot rate until CV trials are conducted", correct: false }
        ],
        feedback: {
          correct: "Correct! ACCORD showed intensive HbA1c lowering <em>increased</em> deaths. Rosiglitazone lowered HbA1c while increasing heart attacks. Surrogate outcomes require downgrading for indirectness, no matter how 'validated' they seem. Patient-important outcomes are required for high certainty.",
          incorrect: "CAST drugs fixed ECGs while tripling deaths. ACCORD lowered HbA1c while increasing mortality. 'Validated surrogates' have repeatedly failed. GRADE requires downgrading one or two levels when only surrogate outcomes are measured."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "Der Verrat an der Knochendichte", title: "When Stronger Bones Broke More",
        text: "Sodium fluoride increased bone mineral density dramatically‚Äî<strong>8% improvement per year</strong>. For osteoporosis, this seemed like a miracle. Bone density was the accepted surrogate for fracture risk. Higher density = fewer fractures. The math seemed inescapable.",
        followup: "Then came the trials measuring actual fractures. Sodium fluoride <strong>increased</strong> fracture rates despite improving bone density. The explanation: fluoride created dense but brittle bone‚Äîlike adding quantity without quality. The surrogate (density) moved in the right direction while the patient-important outcome (fractures) moved in the wrong direction. This case became a landmark in surrogate outcome skepticism."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ü¶¥", title: "Scenario: The Bone Drug Decision",
        xp: 25,
        scenario: "A new osteoporosis drug shows 4% improvement in bone mineral density at 2 years. The company presents evidence of reduced fractures, but the fracture trials used a different formulation and dose than the one being approved. The FDA asks you to rate certainty of fracture benefit for the approved formulation.",
        question: "What indirectness concern applies?",
        options: [
          { letter: "A", text: "No concern‚Äîbone density is a validated surrogate", correct: false },
          { letter: "B", text: "Indirekt zur Intervention ‚Äì es wurde eine andere Formulierung/Dosis getestet", correct: true },
          { letter: "C", text: "Indirect for population‚Äîfracture trials may have different patients", correct: false },
          { letter: "D", text: "Indirekt f√ºr das Ergebnis ‚Äì Frakturen sind f√ºr den Patienten nicht wichtig", correct: false }
        ],
        feedback: {
          correct: "Richtig! Indirektheit kann sich auf Intervention, Population, Vergleichsgr√∂√üe oder Ergebnis beziehen. Dabei weicht die bei Frakturen gepr√ºfte Rezeptur/Dosis von der zugelassenen ab. Wir k√∂nnen keine Gleichwertigkeit annehmen. Dies erfordert eine Herabstufung f√ºr indirekte Eingriffe.",
          incorrect: "Der Bruchbeweis ergibt sich aus einer anderen Formulierung und Dosierung. Wir extrapolieren von Medikament A bei Dosis"
        }
      }},
      { type: "story", theme: "red-bg", content: {
        label: "Die Rosiglitazon-Abrechnung", title: "FDA's 2.5 Million Patient Gamble",
        text: "In 2007, cardiologist Steven Nissen published a meta-analysis showing rosiglitazone (Avandia) increased heart attacks by <strong>43%</strong>. The drug had been prescribed to millions based on glucose control. But no large outcome trial had ever been required.",
        followup: "The FDA's logic had been: diabetes causes heart disease ‚Üí better glucose control should prevent it. That's <strong>indirectness</strong>‚Äîassuming a chain of causation without testing the final link. The FDA estimated rosiglitazone caused <strong>83,000 excess heart attacks</strong> before restrictions were imposed. The European Medicines Agency suspended it entirely. A drug approved on indirect evidence had harmed more patients than it helped."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üíä", title: "Szenario: Die Kopf-an-Kopf-Kluft",
        xp: 25,
        scenario: "F√ºr Ihre Leitlinie m√ºssen Sie Medikament A mit Medikament B vergleichen. Es gibt keine direkten Vergleiche. Sie haben: Medikament A vs. Placebo (RR 0,70) und Medikament B vs. Placebo (RR 0,65) aus separaten Studien in verschiedenen Populationen, die im Abstand von 10 Jahren durchgef√ºhrt wurden.",
        question: "What type of indirectness applies?",
        options: [
          { letter: "A", text: "No indirectness‚Äîwe can compare the two placebo-controlled estimates", correct: false },
          { letter: "B", text: "Indirect comparisons require downgrading‚Äîdifferent trials break randomization", correct: true },
          { letter: "C", text: "Nur indirekt f√ºr die Bev√∂lkerung, nicht zum Vergleich", correct: false },
          { letter: "D", text: "Network meta-analysis solves this indirectness", correct: false }
        ],
        feedback: {
          correct: "Correct! Comparing across trials breaks randomization. Drug A's trial may have sicker patients, different background care, different outcome definitions. The RR difference (0.70 vs. 0.65) may reflect trial differences, not drug differences. GRADE calls this 'indirect comparison' and requires downgrading.",
          incorrect: "Indirekte Vergleiche unterscheiden sich grundlegend von direkten Vergleichen. Wenn wir Medikament A vs. Placebo (Versuch 1) mit Medikament B vs. Placebo (Versuch 2) vergleichen, wird jeder Unterschied zwischen den Studien zu einem St√∂rfaktor. Die Netzwerk-Metaanalyse hilft, beseitigt diese Indirektheit aber nicht."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "Die Oseltamivir-Extrapolation", title: "Vom Labor √ºber die Klinik zur L√ºge",
        text: "Tamiflu (oseltamivir) was approved based on trials showing it reduced <strong>symptom duration by 21 hours</strong> in otherwise healthy adults. When pandemic flu threatened, governments extrapolated: if it shortens symptoms, it must prevent complications. If it works in healthy adults, it must work in high-risk patients.",
        followup: "Neither extrapolation was supported. Trials in <strong>high-risk patients</strong> (the ones who actually need protection) showed no benefit. Trials measuring <strong>hospitalizations and complications</strong> (the outcomes that matter) were never conducted‚Äîor never published. The ¬£473 million UK stockpile was based on indirect evidence: wrong population (healthy, not high-risk), wrong outcome (symptoms, not complications). The Cochrane review downgraded certainty for both types of indirectness."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üè•", title: "Szenario: Die Bev√∂lkerungsextrapolation",
        xp: 25,
        scenario: "Eine Behandlung zeigt in Studien mit Patienten im Alter von 18 bis 65 Jahren ohne Komorbidit√§ten einen Nutzen. Ihre Leitlinie richtet sich an √§ltere Pflegeheimbewohner mit mehreren Komorbidit√§ten. Es gibt biologisch plausible Gr√ºnde daf√ºr, dass die Behandlung bei √§lteren Menschen anders wirkt (ver√§nderter Stoffwechsel, Arzneimittelwechselwirkungen).",
        question: "Sollten Sie wegen Indirektheit ein Downgrade durchf√ºhren?",
        options: [
          { letter: "A", text: "No‚Äîage alone doesn't require downgrading", correct: false },
          { letter: "B", text: "Yes‚Äîbiological reasons for different effects in target population require downgrading", correct: true },
          { letter: "C", text: "Only if the elderly show different baseline risk", correct: false },
          { letter: "D", text: "Verwenden Sie stattdessen die Subgruppenanalyse aus den Originalversuchen", correct: false }
        ],
        feedback: {
          correct: "Correct! When there are biological reasons to expect different effects in the target population, downgrade for indirectness. Tamiflu worked in healthy adults but the question was about sick elderly patients‚Äîa population with very different biology. Extrapolation across populations with different biology requires downgrading.",
          incorrect: "Population indirectness applies when the trial population differs meaningfully from the guideline population, especially when there are biological reasons to expect different effects. Elderly with comorbidities may metabolize drugs differently, have drug interactions, and have different risk-benefit profiles."
        }
      }},
      { type: "story", theme: "red-bg", content: {
        label: "Die Torcetrapib-Trag√∂die", title: "$800 Million Buried in 82 Days",
        text: "Pfizer's torcetrapib was the most expensive drug development in history‚Äî<strong>$800 million</strong> over 15 years. It dramatically raised HDL cholesterol (the 'good' cholesterol) by 72%. The logic was irresistible: low HDL causes heart disease ‚Üí raising HDL should prevent it. Phase 2 trials showed perfect surrogate outcomes. Pfizer began building manufacturing plants before Phase 3 completed.",
        followup: "The ILLUMINATE trial enrolled <strong>15,067 patients</strong>. After just 82 days, the Data Safety Monitoring Board stopped the trial. Torcetrapib increased death by <strong>58%</strong> and cardiovascular events by 25%. The drug that perfectly improved HDL was killing patients. Pfizer's stock dropped $21 billion in one day. The entire HDL-raising hypothesis‚Äîbuilt on decades of surrogate evidence‚Äîcollapsed. No HDL-raising drug has ever prevented cardiovascular events. Surrogate perfection masked clinical catastrophe."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üíî", title: "Szenario: Der perfekte Ersatz",
        xp: 25,
        scenario: "Ein neues Medikament erh√∂ht den HDL-Cholesterinspiegel um 80 % ‚Äì mehr als jeder bisherige Wirkstoff. Das Unternehmen argumentiert: ‚ÄûWir haben nachgewiesen, dass HDL urs√§chlich vor Herzerkrankungen sch√ºtzt.‚Äú ‚ÄûDieses Medikament wird Millionen von Leben retten.‚Äú Sie beantragen eine beschleunigte Zulassung allein aufgrund der HDL-Verbesserung.",
        question: "Based on the torcetrapib experience, what certainty applies to cardiovascular benefit?",
        options: [
          { letter: "A", text: "HIGH‚ÄîHDL is a validated causal risk factor", correct: false },
          { letter: "B", text: "MODERATE‚Äîstrong mechanistic support warrants some confidence", correct: false },
          { letter: "C", text: "LOW to VERY LOW‚ÄîHDL-raising has consistently failed to translate to outcomes", correct: true },
          { letter: "D", text: "Cannot rate until mechanism is fully understood", correct: false }
        ],
        feedback: {
          correct: "Correct! Torcetrapib, dalcetrapib, evacetrapib‚Äîevery HDL-raising drug has failed to prevent cardiovascular events despite dramatic surrogate improvement. The entire drug class teaches us: manipulating a surrogate doesn't guarantee clinical benefit. Evidence from this class requires serious downgrading for indirectness.",
          incorrect: "Mehrere HDL-erh√∂hende Medikamente zeigten eine dramatische Ersatzverbesserung ohne kardiovaskul√§ren Nutzen (oder tats√§chlichen Schaden). Diese Medikamentenklasse hat definitiv bewiesen, dass HDL-Manipulation keine Folgen hat. Die Ersatzbeziehung gilt nicht, wenn sie pharmakologisch manipuliert wird."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "Die Erythropoetin-Umkehr", title: "When Better Blood Was Worse",
        text: "Krebspatienten mit An√§mie f√ºhlen sich schrecklich ‚Äì M√ºdigkeit, Schw√§che, Kurzatmigkeit. Erythropoetin-stimulierende Wirkstoffe (ESAs) erh√∂hten den H√§moglobinspiegel und sorgten daf√ºr, dass sich die Patienten besser f√ºhlten. Die Lebensqualit√§t hat sich verbessert. Die FDA hat ESAs f√ºr krebsbedingte An√§mie zugelassen. Onkologen haben sie h√§ufig verschrieben.",
        followup: "Then meta-analyses examining <strong>mortality</strong> emerged. Despite improving hemoglobin (surrogate) and quality of life, ESAs increased <strong>death by 10%</strong> and thromboembolic events by 57%. Patients felt better while dying faster. The FDA added a black box warning. ESA use plummeted. The lesson: even quality-of-life improvements can coexist with mortality harm. Surrogates that patients can feel aren't necessarily safer surrogates."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ü©∏", title: "Scenario: The Quality of Life Surrogate",
        xp: 25,
        scenario: "Eine Behandlung verbessert ein Ersatzsymptom dramatisch ‚Äì Patienten f√ºhlen sich viel besser, die Energie verbessert sich, die t√§glichen Funktionen nehmen zu. Die Lebensqualit√§t verbessert sich um 40 %. Es liegen keine Mortalit√§tsdaten vor. Das Unternehmen argumentiert, dass es sich hierbei um ‚Äûpatientenzentrierte Beweise‚Äú handele, die eine hohe Sicherheit erhalten sollten.",
        question: "What certainty applies to net clinical benefit?",
        options: [
          { letter: "A", text: "HIGH‚Äîpatient-reported outcomes matter most", correct: false },
          { letter: "B", text: "MODERATE‚Äîquality of life is a valid outcome", correct: false },
          { letter: "C", text: "LOW‚Äîimproved symptoms can coexist with mortality harm; need outcome data", correct: true },
          { letter: "D", text: "H√§ngt von der spezifischen Erkrankung ab", correct: false }
        ],
        feedback: {
          correct: "Richtig! ESAs verbesserten die Lebensqualit√§t und erh√∂hten gleichzeitig die Zahl der Todesf√§lle um 10 %. Sich besser zu f√ºhlen ist nicht dasselbe wie besser zu sein. Eine Verbesserung der Symptome kann einen √úberlebensschaden verschleiern. GRADE erfordert eine Herabstufung wegen Indirektheit, wenn keine Daten zu Mortalit√§t/schweren Sch√§den vorliegen, selbst bei positiven Symptomergebnissen.",
          incorrect: "Die ESA-Erfahrung beweist, dass sich Patienten deutlich besser f√ºhlen k√∂nnen und gleichzeitig schneller sterben. Eine Verbesserung der Lebensqualit√§t ist real, garantiert jedoch keinen Nettovorteil. Ohne Daten zur Mortalit√§t und zu schwerwiegenden unerw√ºnschten Ereignissen muss die Gewissheit unabh√§ngig von der Verbesserung der Symptome niedrig bleiben."
        }
      }},
      { type: "checklist", theme: "dark", content: {
        title: "Four Types of Indirectness",
        items: [
          "Population ‚Äî Trial patients differ from guideline patients",
          "Intervention ‚Äî Trial intervention differs from recommendation",
          "Komparator ‚Äì Studienvergleich weicht von klinischer Frage ab",
          "Outcome ‚Äî Trial measures surrogates instead of patient-important outcomes"
        ]
      }},
      { type: "quiz", theme: "dark", content: {
        question: "Warum t√∂teten die CAST-Antiarrhythmika 50.000 Menschen trotz perfekter Beweise f√ºr die Unterdr√ºckung von Arrhythmien?",
        options: [
          { text: "Die Studien waren betr√ºgerisch", correct: false },
          { text: "Der Ersatz (Unterdr√ºckung von Arrhythmien) hat das Ergebnis (Tod) nicht vorhergesagt", correct: true },
          { text: "Doctors used the drugs incorrectly", correct: false },
          { text: "Die Patientenpopulation unterschied sich von den Studien", correct: false }
        ],
        xp: 20,
        feedback: {
          correct: "Exactly. The evidence for arrhythmia suppression was impeccable. The drugs did exactly what they were supposed to do on ECG. But suppressing arrhythmias didn't prevent death‚Äîit caused it through different mechanisms. This is indirectness for outcome: measuring surrogates instead of patient-important endpoints.",
          incorrect: "The trials were well-conducted. The drugs worked perfectly for their intended purpose (suppressing arrhythmias). The problem was indirectness: arrhythmia suppression (the measured outcome) didn't predict mortality (the outcome that matters). Surrogate outcomes can mislead even when evidence is methodologically perfect."
        }
      }}
    ]
  },
  {
    id: 6, title: "Imprecision", subtitle: "Nicht gen√ºgend Daten", xp: 150,
    slides: [
      { type: "title", theme: "dark", content: { title: "Imprecision", subtitle: "Der vierte Bereich: Haben wir genug? Daten?" }},
      { type: "objectives", theme: "dark", content: {
        objectives: [
          "Understand why wide confidence intervals undermine certainty",
          "Apply the 'Optimal Information Size' concept",
          "Recognize when 95% CIs cross clinical decision thresholds",
          "Decide when to downgrade for imprecision"
        ],
        tip: "Statistical significance is not enough‚Äîconfidence intervals must be clinically narrow."
      }},
      { type: "story", theme: "red-bg", content: {
        label: "Das PROWESS Mirage", title: "When 1,690 Deaths Weren't Enough",
        text: "In 2001, Eli Lilly's drotrecogin alfa (Xigris) was approved for severe sepsis based on the PROWESS trial. The trial showed <strong>6.1% absolute mortality reduction</strong>‚Äîfrom 30.8% to 24.7%. The FDA approved it despite concerns. Cost: $6,800 per treatment. Lilly projected billions in revenue.",
        followup: "Then came the confidence interval analysis. The 95% CI for mortality reduction ranged from <strong>1.9% to 10.4%</strong>. The benefit might be huge (10.4%) or clinically marginal (1.9%). With a drug this expensive and risky (increased bleeding), that uncertainty mattered. Subsequent trials failed to replicate PROWESS. The ADDRESS trial in less severe sepsis showed <strong>no benefit</strong>. The PROWESS-SHOCK trial confirmed <strong>no mortality benefit</strong> even in severe sepsis. In 2011, Lilly withdrew Xigris worldwide. A decade of use, billions spent, and the imprecision had warned us from the start."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üìê", title: "Scenario: The Wide Confidence Interval",
        xp: 25,
        scenario: "A trial shows a new treatment reduces mortality from 20% to 14%‚Äîa 6% absolute reduction (RR 0.70, p=0.04). However, the 95% CI for absolute risk reduction is 0.5% to 11.5%. The lower bound (0.5%) is below your minimum clinically important difference of 2%.",
        question: "Sollten Sie wegen Ungenauigkeit herabstufen?",
        options: [
          { letter: "A", text: "Nein ‚Äì das Ergebnis ist statistisch signifikant", correct: false },
          { letter: "B", text: "No‚Äîthe point estimate shows clinically meaningful benefit", correct: false },
          { letter: "C", text: "Yes‚Äîthe CI includes clinically unimportant effects", correct: true },
          { letter: "D", text: "Ja ‚Äì das CI umfasst Schaden", correct: false }
        ],
        feedback: {
          correct: "Richtig! Statistische Signifikanz garantiert keine klinische Pr√§zision. Wenn der tats√§chliche Effekt nur 0,5 % betragen k√∂nnte (unter Ihrem minimalen wichtigen Unterschied), k√∂nnen Sie die Behandlung nicht mit gutem Gewissen empfehlen. GRADE erfordert eine Herabstufung, wenn die CIs klinische Entscheidungsschwellen √ºberschreiten, nicht nur den Nullwert.",
          incorrect: "Die Untergrenze des CI (0,5 %) f√§llt unter die minimale klinisch wichtige Differenz (2 %). Dies bedeutet, dass die tats√§chliche Wirkung m√∂glicherweise zu gering ist, um die Behandlungskosten/-risiken zu rechtfertigen. Statistische Signifikanz reicht nicht aus ‚Äì CIs m√ºssen klinisch unwichtige Effekte ausschlie√üen, um eine hohe Sicherheit zu gew√§hrleisten."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "Die optimale Informationsgr√∂√üe", title: "Why Sample Size Matters for Certainty",
        text: "Consider a simple thought experiment: You flip a coin 4 times and get 3 heads (75%). Would you bet your house that the coin is biased? Now flip 1,000 times and get 750 heads. Same proportion‚Äîbut utterly different certainty.",
        followup: "GRADE uses the <strong>Optimal Information Size (OIS)</strong> concept. This asks: 'How many events would a single adequately-powered trial need to reliably detect this effect?' If your meta-analysis has fewer events than the OIS, you're in the position of the person who flipped 4 coins‚Äîthe proportion might be right, but you don't have enough data to be confident. For mortality outcomes, OIS is typically <strong>200-400 events</strong>. Many celebrated meta-analyses have far fewer."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üî¢", title: "Szenario: Die kleine Metaanalyse",
        xp: 25,
        scenario: "A meta-analysis of 8 RCTs (total n=1,200) shows a treatment prevents death with RR 0.65 (95% CI 0.45-0.95). The total number of deaths across all trials is 87. The pooled estimate is statistically significant. Your OIS calculation suggests 300 events would be needed.",
        question: "Sollten Sie wegen Ungenauigkeit herabstufen?",
        options: [
          { letter: "A", text: "No‚Äîstatistical significance means adequate precision", correct: false },
          { letter: "B", text: "No‚Äî8 RCTs provide adequate power through meta-analysis", correct: false },
          { letter: "C", text: "Yes‚Äî87 events is well below the OIS of 300", correct: true },
          { letter: "D", text: "Nur wenn das CI kreuzt 1.0", correct: false }
        ],
        feedback: {
          correct: "Richtig! 87 Ereignisse im Vergleich zu einem OIS von 300 bedeuten, dass wir √ºber weniger als 30 % der ben√∂tigten Informationen verf√ºgen. Die Sch√§tzung mag richtig sein, aber wir befinden uns im Bereich der ‚Äûkleinen Stichproben‚Äú, in dem zuf√§llige Variationen dramatisch aussehende, aber unzuverl√§ssige Effekte hervorrufen k√∂nnen. GRADE erfordert eine Herabstufung, wenn Ereignisse weit unter OIS liegen.",
          incorrect: "Meta-Analyse erzeugt keine Informationen auf magische Weise. 8 kleine Pr√ºfungen mit insgesamt 87 Veranstaltungen entsprechen nicht einer gro√üen Pr√ºfung mit 300 Veranstaltungen. Die statistische Signifikanz ist wahrscheinlich fragil ‚Äì ein paar Ereignisse w√ºrden die Schlussfolgerung √§ndern. OIS bietet eine Realit√§tspr√ºfung der Probenad√§quanz."
        }
      }},
      { type: "story", theme: "red-bg", content: {
        label: "Die Hydroxyethylst√§rke-Umkehrung", title: "When 10,000 Patients Weren't Enough... Then Were",
        text: "Hydroxyethyl starch (HES) fluids were used for decades in critically ill patients. Early meta-analyses with few events showed possible benefit. Then came the large trials: <strong>6S trial (798 patients)</strong>, <strong>CHEST trial (7,000 patients)</strong>, <strong>CRISTAL trial (2,857 patients)</strong>.",
        followup: "The large trials showed HES <strong>increased mortality and kidney failure</strong>. The earlier 'positive' evidence had been imprecise‚Äîconfidence intervals that allowed for benefit also allowed for the substantial harm that large trials eventually detected. The European Medicines Agency suspended HES for critical illness. Imprecise evidence had allowed a harmful intervention to persist for years."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "‚ö†Ô∏è", title: "Scenario: The Borderline Mortality Signal",
        xp: 25,
        scenario: "Eine Metaanalyse zeigt ein RR f√ºr den Tod von 1,25 (95 %-KI 0,98‚Äì1,60) bei einer Behandlung. Das Ergebnis tendiert zum Schaden, ist aber statistisch nicht signifikant. Ihre Leitlinie muss entscheiden, ob diese Behandlung f√ºr eine nicht t√∂dliche Erkrankung empfohlen wird, f√ºr die es Alternativen gibt.",
        question: "How should imprecision affect your recommendation?",
        options: [
          { letter: "A", text: "Die Behandlung ist sicher ‚Äì CI umfasst 1,0", correct: false },
          { letter: "B", text: "The treatment is harmful‚Äîpoint estimate shows 25% increase", correct: false },
          { letter: "C", text: "Erhebliche Unsicherheit hinsichtlich des Schadens ‚Äì CI steht im Einklang mit einem Anstieg der Sterblichkeit um bis zu 60 %", correct: true },
          { letter: "D", text: "Need more trials before any conclusion", correct: false }
        ],
        feedback: {
          correct: "Correct! The upper bound (1.60) represents a 60% mortality increase. For a non-fatal condition with alternatives, that possibility should drive decision-making. 'Not statistically significant' doesn't mean safe‚Äîit means we can't rule out substantial harm. GRADE incorporates the entire CI, not just p-values.",
          incorrect: "Die Obergrenze des CI von 1,60 bedeutet, dass wir Eine um 60 % erh√∂hte Sterblichkeit kann nicht ausgeschlossen werden. Bei einer Behandlung einer nicht t√∂dlichen Erkrankung, f√ºr die es Alternativen gibt, sollte diese Ungewissheit √ºber einen schwerwiegenden Schaden die Entscheidung dominieren. Statistische Nicht-Signifikanz ‚â† Sicherheit."
        }
      }},
      { type: "concept", theme: "dark", content: {
        title: "Der Fragilit√§tsindex",
        subtitle: "How stable is statistical significance?",
        text: "The fragility index asks: 'How many patients would need to have had a different outcome to make this result non-significant?' A fragility index of 3 means if just 3 patients had different outcomes, the p-value would cross 0.05. Many published 'significant' findings have fragility indices under 10.",
        highlight: "Eine Studie mit einem Fragilit√§tsindex von 5 bedeutet, dass das ‚Äûsignifikante‚Äú Ergebnis von weniger Patienten abh√§ngt, als in Ihrem B√ºro-Wartezimmer sitzen."
      }},
      { type: "story", theme: "dark", content: {
        label: "Die Tranexams√§ure Triumph", title: "When Precision Demanded 20,000 Patients",
        text: "Could tranexamic acid (TXA) reduce death from bleeding in trauma? Early trials were suggestive but imprecise. The <strong>CRASH-2 trial</strong> took a different approach: enroll enough patients to get a precise answer.",
        followup: "<strong>20,211 patients</strong> across 274 hospitals in 40 countries. Result: TXA reduced death from bleeding from 5.7% to 4.9%‚Äîa 0.8% absolute reduction. The 95% CI was <strong>0.3% to 1.3%</strong>. Finally, precision: the entire CI showed clinically meaningful benefit. The WHO added TXA to its Essential Medicines List. The precision wasn't just scientific‚Äîit changed global policy because decision-makers could trust the narrow bounds."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "‚úì", title: "Scenario: The Precise But Small Effect",
        xp: 25,
        scenario: "A mega-trial (n=40,000) shows a treatment reduces mortality with RR 0.95 (95% CI 0.91-0.99). The result is statistically significant and the CI is narrow. However, the absolute risk reduction is 0.3% (NNT = 333). Your minimum clinically important difference for this outcome is 0.2%.",
        question: "Sollten Sie wegen Ungenauigkeit herabstufen?",
        options: [
          { letter: "A", text: "Yes‚Äîthe effect is too small to matter clinically", correct: false },
          { letter: "B", text: "No‚Äîthe narrow CI excludes clinically unimportant effects", correct: true },
          { letter: "C", text: "Yes‚ÄîNNT of 333 suggests imprecision", correct: false },
          { letter: "D", text: "Cannot determine without knowing the OIS", correct: false }
        ],
        feedback: {
          correct: "Correct! The entire CI (0.91-0.99) lies below 1.0, and the corresponding absolute effects (0.1%-0.5%) are all above your minimum important difference of 0.2%. Small but precise effects that meet the clinical threshold don't require downgrading for imprecision. The issue is clinical judgment about whether the effect justifies intervention.",
          incorrect: "Bei der Ungenauigkeit geht es um Konfidenzintervalle, nicht um die Effektgr√∂√üe. Ein kleiner, aber genau abgesch√§tzter Effekt, der klinisch unwichtige Werte ausschlie√üt, ist nicht ungenau ‚Äì er ist nur gering. Ob eine absolute Reduzierung um 0,3 % eine Behandlung rechtfertigt, ist ein Werteurteil und keine Frage der Pr√§zision."
        }
      }},
      { type: "story", theme: "red-bg", content: {
        label: "Die JUPITER-Kontroverse", title: "When 17,802 Patients Still Weren't Enough",
        text: "The JUPITER trial enrolled <strong>17,802 patients</strong> to test rosuvastatin for primary prevention. After just 1.9 years (planned: 5 years), it was stopped early for 'overwhelming benefit.' Heart attacks were reduced by 54%! Headlines celebrated. Rosuvastatin prescriptions soared.",
        followup: "But critics noticed problems. Only <strong>68 heart attacks</strong> total across both groups‚Äîfragility index of just 4. The wide confidence intervals (0.29-0.73) reflected genuine uncertainty. Early stopping inflates effect sizes by 30% on average. And absolute risk reduction was just <strong>0.35%</strong> over 1.9 years‚ÄîNNT of 286. A 'landmark' trial with thousands of patients still had imprecision concerns because it was stopped before enough events accumulated. Large n doesn't guarantee precision when event rates are low."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "‚èπÔ∏è", title: "Szenario: Der vorzeitig abgebrochene Prozess",
        xp: 25,
        scenario: "A large trial (n=10,000) is stopped early after 2 years (planned: 5) for 'overwhelming efficacy.' The treatment shows 50% relative risk reduction. However, only 45 total events occurred, and the original planned stopping boundary was crossed by just 2 events.",
        question: "How should early stopping affect certainty assessment?",
        options: [
          { letter: "A", text: "No concern‚Äîlarge sample size ensures precision", correct: false },
          { letter: "B", text: "Herabstufung wegen Ungenauigkeit ‚Äì fr√ºhes Anhalten verst√§rkt die Wirkung und erzeugt Fragilit√§t Ergebnisse", correct: true },
          { letter: "C", text: "Upgrade certainty‚Äîstopping early proves the effect is large", correct: false },
          { letter: "D", text: "Neutral‚Äîmonitoring rules are pre-specified", correct: false }
        ],
        feedback: {
          correct: "Correct! Early stopping typically inflates effect sizes by 30%. With only 45 events and crossing the boundary by 2, this finding is extremely fragile. Large n doesn't help when event rates are low‚Äîyou need enough events, not just patients. GRADE recommends downgrading for trials stopped early with few events.",
          incorrect: "Fr√ºh abgebrochene Studien √ºbersch√§tzen die Auswirkungen systematisch. Bei 45 Ereignissen und einem Fragilit√§tsindex von ~2 w√ºrde die Reduzierung um 50 % verschwinden, wenn nur zwei Patienten unterschiedliche Ergebnisse h√§tten. Die gro√üe Stichprobe ist irrelevant ‚Äì es sind Ereignisse, die die Pr√§zision vorantreiben."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "Die ISIS-4-Lektion", title: "Als 58.000 Patienten die Frage beantworteten",
        text: "After GISSI-2 suggested magnesium might reduce mortality in heart attack patients, smaller trials showed inconsistent results. The <strong>ISIS-4</strong> trial was designed to end the debate: <strong>58,050 patients</strong>, the largest heart attack trial ever. If magnesium worked, this trial would prove it.",
        followup: "Result: magnesium showed <strong>no benefit</strong> (mortality 7.64% vs. 7.24%, NS). The pooled meta-analysis before ISIS-4 had shown significant benefit‚Äîbut was driven by small trials with imprecise estimates. When finally tested with adequate precision, the effect vanished. This pattern‚Äîdramatic effects in small trials, null effects in large trials‚Äîis so common it has a name: 'the winner's curse.' Small trials select for extreme results; large trials reveal reality."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üé≤", title: "Scenario: Small Trial Meta-Analysis vs. Large Trial",
        xp: 25,
        scenario: "A meta-analysis of 15 small trials (total n=2,000, 180 events) shows significant mortality benefit (RR 0.65, p=0.001). A single large trial (n=15,000, 2,100 events) shows no benefit (RR 0.98, p=0.61). The meta-analysis was published first.",
        question: "Wie sollten Sie diese widerspr√ºchlichen Ergebnisse gewichten?",
        options: [
          { letter: "A", text: "Average them‚Äîmore trials means more evidence", correct: false },
          { letter: "B", text: "Prefer the meta-analysis‚Äî15 trials beat 1 trial", correct: false },
          { letter: "C", text: "Bevorzugen Sie die gro√üe Studie ‚Äì sie hat 10x mehr Ereignisse und Pr√§zision", correct: true },
          { letter: "D", text: "Beweise f√ºr nicht schl√ºssig erkl√§ren", correct: false }
        ],
        feedback: {
          correct: "Richtig! 2.100 Ereignisse im Vergleich zu 180 Ereignissen bedeuten, dass die gro√üe Studie etwa 12-mal mehr Informationen enth√§lt. Metaanalysen kleiner Studien sind anf√§llig f√ºr Publikationsbias und den Fluch des Gewinners. Wenn eine gro√üe, ausreichend aussagekr√§ftige Studie im Widerspruch zu Metaanalysen kleiner Studien steht, bringt die gro√üe Studie normalerweise die Wahrheit ans Licht.",
          incorrect: "ISIS-4 taught this lesson. Small trials showed magnesium benefit; the 58,000-patient trial showed nothing. Events determine precision, not number of trials. Publication bias and random variation create false signals in small trial meta-analyses that large trials correct."
        }
      }},
      { type: "checklist", theme: "dark", content: {
        title: "Imprecision Assessment Checklist",
        items: [
          "Does the 95% CI cross clinically important thresholds?",
          "Kreuzt das CI sowohl Nutzen als auch Schaden?",
          "Liegt die Gesamtzahl der Ereignisse unter der optimalen Informationsgr√∂√üe?",
          "Was ist der Fragilit√§tsindex f√ºr Schl√ºsselergebnisse?",
          "Would the upper or lower bound change clinical decision-making?"
        ]
      }},
      { type: "quiz", theme: "dark", content: {
        question: "Why does GRADE require downgrading when confidence intervals cross 'clinical decision thresholds' even if statistically significant?",
        options: [
          { text: "Statistische Konventionen sind willk√ºrlich", correct: false },
          { text: "The true effect might be too small (or too harmful) to justify treatment", correct: true },
          { text: "P-values don't account for sample size", correct: false },
          { text: "Confidence intervals are more accurate than p-values", correct: false }
        ],
        xp: 20,
        feedback: {
          correct: "Genau. Wenn eine Behandlung die Sterblichkeit ‚Äûerheblich‚Äú senkt, das KI jedoch zu geringe Auswirkungen aufweist, um die Kosten/das Risiko zu rechtfertigen ‚Äì oder erhebliche Sch√§den mit sich bringt ‚Äì k√∂nnen wir sie nicht mit gutem Gewissen empfehlen. GRADE beurteilt die Pr√§zision anhand klinischer Schwellenwerte und nicht anhand statistischer Konventionen.",
          incorrect: "Klinische Entscheidungen erfordern die Kenntnis, ob der tats√§chliche Effekt gro√ü genug ist, um von Bedeutung zu sein. Ein statistisch signifikantes Ergebnis mit einem KI-Bereich von ‚Äûgeringf√ºgig hilfreich‚Äú bis ‚Äûerheblich sch√§dlich‚Äú gibt keinen Hinweis auf die Behandlung. GRADE verwendet klinische Schwellenwerte, weil diese Entscheidungen erfordern."
        }
      }}
    ]
  },
  {
    id: 7, title: "Publication Bias", subtitle: "Die unsichtbaren Beweise", xp: 160,
    slides: [
      { type: "title", theme: "red-bg", content: { title: "Publication Bias", subtitle: "Der f√ºnfte Bereich: Welche Beweise haben uns nie erreicht?" }},
      { type: "objectives", theme: "dark", content: {
        objectives: [
          "Verstehen Sie, wie negative Studien aus der Literatur verschwinden",
          "Interpret funnel plots and their limitations",
          "Recognize when publication bias likely distorts evidence",
          "Decide when to downgrade certainty for publication bias"
        ],
        tip: "Die gef√§hrlichsten Beweise sind Beweise, die Sie nie erhalten siehe."
      }},
      { type: "story", theme: "red-bg", content: {
        label: "Die Paroxetin-T√§uschung", title: "GlaxoSmithKline's Hidden Children",
        text: "In the early 2000s, GSK marketed paroxetine (Paxil) for adolescent depression. The published evidence looked convincing. Study 329, published in the <em>Journal of the American Academy of Child and Adolescent Psychiatry</em>, reported paroxetine was <strong>'generally well tolerated and effective.'</strong> Thousands of teenagers were prescribed the drug.",
        followup: "Then lawsuits forced GSK to release internal documents. Study 329 had actually shown paroxetine was <strong>no better than placebo</strong> and increased suicidal behavior. GSK had conducted other trials‚Äîalso negative‚Äîthat were never published. The published paper had been ghost-written by a medical communications company. When all studies were combined, the truth emerged: paroxetine didn't work for teen depression and was dangerous. The published literature had been systematically manipulated. Publication bias wasn't passive‚Äîit was manufactured."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üìö", title: "Szenario: Die alles positive Literatur",
        xp: 25,
        scenario: "Eine Metaanalyse umfasst 12 von der Industrie finanzierte Studien zu einem neuen Antidepressivum ‚Äì alle zeigen einen Nutzen. Das Trichterdiagramm erscheint symmetrisch. Ein Kollege stellt fest, dass aus den Aufzeichnungen der FDA hervorgeht, dass das Unternehmen acht weitere Studien durchgef√ºhrt hat, die nie ver√∂ffentlicht wurden. Sie k√∂nnen nicht auf die unver√∂ffentlichten Daten zugreifen.",
        question: "Sollten Sie ein Downgrade wegen Publikationsbias durchf√ºhren?",
        options: [
          { letter: "A", text: "Nein ‚Äì das Trichterdiagramm ist symmetrisch", correct: false },
          { letter: "B", text: "Nein ‚Äì wir k√∂nnen nur vorhandene Beweise beurteilen", correct: false },
          { letter: "C", text: "Yes‚Äîdocumented unpublished trials suggest selective reporting", correct: true },
          { letter: "D", text: "Fordern Sie die Daten an, bevor Sie eine Entscheidung treffen", correct: false }
        ],
        feedback: {
          correct: "Correct! The funnel plot only shows published studies‚Äîit can't detect missing studies. Knowing that 8 unpublished trials exist is strong evidence of publication bias. Paroxetine's symmetric funnel plot concealed hidden negative trials. GRADE downgrades when there's direct evidence of unpublished studies.",
          incorrect: "Trichterdiagramme zeigen nur, was ver√∂ffentlicht wurde. Wenn negative Studien systematisch unterdr√ºckt werden (wie bei Paroxetin), kann der Trichter perfekt erscheinen, w√§hrend wichtige Beweise verborgen bleiben. FDA-Aufzeichnungen, die unver√∂ffentlichte Studien zeigen, sind ein direkter Beweis f√ºr Publikationsbias."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "Die Oseltamivir-Blockade", title: "Five Years to See the Truth",
        text: "The Cochrane Collaboration spent <strong>five years</strong> fighting Roche for Tamiflu (oseltamivir) data. Published trials showed reduced complications. Governments stockpiled billions of dollars worth of the drug. But Cochrane noticed discrepancies: study reports didn't match clinical study reports.",
        followup: "When Roche finally released the data in 2013, the missing <strong>60% of patient data</strong> revealed the truth. Published trials had reported 'complications' without proper definitions. Unpublished data showed adverse events were underreported. The updated Cochrane review: Tamiflu reduced symptoms by less than a day and had <strong>no proven effect on hospitalization or complications</strong>. Five years. Billions of dollars. And the published literature had been a carefully curated selection."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üìä", title: "Szenario: Der asymmetrische Trichter",
        xp: 25,
        scenario: "A funnel plot shows clear asymmetry‚Äîsmall studies cluster toward positive effects while negative small studies are absent. Egger's test is statistically significant (p=0.01). The meta-analysis includes 25 trials with a pooled OR of 0.65 (significant benefit).",
        question: "Wie sollte sich dies auf Ihre Sicherheitsbewertung auswirken?",
        options: [
          { letter: "A", text: "No effect‚ÄîEgger's test has poor specificity", correct: false },
          { letter: "B", text: "Downgrade one level‚Äîasymmetry suggests missing negative small studies", correct: true },
          { letter: "C", text: "Schlie√üen Sie kleine Studien aus und Analysieren Sie erneut", correct: false },
          { letter: "D", text: "Asymmetry could be small-study effects, not publication bias", correct: false }
        ],
        feedback: {
          correct: "Correct! Significant funnel asymmetry with missing negative small studies is classic publication bias. Small negative studies are less likely to be published than small positive ones. Egger's test p=0.01 supports genuine asymmetry. GRADE requires downgrading when funnel asymmetry is clearly present.",
          incorrect: "While asymmetry has multiple causes, missing negative small studies is the most common pattern. The scenario describes classic publication bias: small positive studies published, small negative studies missing. This requires downgrading even if the exact cause is uncertain."
        }
      }},
      { type: "story", theme: "red-bg", content: {
        label: "Der Reboxetin-Skandal", title: "74% of Data Hidden",
        text: "Reboxetine, an antidepressant approved in Europe, had <strong>74% of patient data</strong> from clinical trials never published. The published literature showed the drug worked. Regulatory agencies approved it. Doctors prescribed it to thousands of patients.",
        followup: "German researchers obtained the unpublished data through freedom of information requests. When all data was combined, reboxetine was <strong>no better than placebo</strong> and caused more side effects than other antidepressants. The published literature‚Äîbased on only 26% of the data‚Äîhad created a complete fiction. A drug that didn't work and caused harm had been sold for years because three-quarters of the evidence was invisible."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üóÉÔ∏è", title: "Szenario: Die L√ºcke im Register",
        xp: 25,
        scenario: "Sie beurteilen Studien zu einem Krebsmedikament. ClinicalTrials.gov zeigt, dass zwischen 2010 und 2018 15 Studien registriert und abgeschlossen wurden. Ihre systematische Suche findet nur 9 ver√∂ffentlichte Artikel. Die 6 unver√∂ffentlichten Studien waren alle kleiner als die ver√∂ffentlichten.",
        question: "Was sollten Sie zum Publikationsbias sagen?",
        options: [
          { letter: "A", text: "Kein Bias ‚Äì kleinere Studien sind oft Pilotstudien", correct: false },
          { letter: "B", text: "Unklar ‚Äì wir kennen die Ergebnisse unver√∂ffentlichter Studien nicht Studien", correct: false },
          { letter: "C", text: "High likelihood of bias‚Äî40% of completed trials unpublished, all smaller ones", correct: true },
          { letter: "D", text: "Request unpublished results before rating", correct: false }
        ],
        feedback: {
          correct: "Correct! 40% unpublished rate‚Äîand specifically the smaller trials‚Äîis a red flag. Small trials showing positive results get published; small trials showing nothing often don't. This pattern inflates pooled estimates. GRADE recognizes registry-publication gaps as strong evidence of publication bias.",
          incorrect: "Sechs von 15 abgeschlossenen Studien (40 %) wurden nie ver√∂ffentlicht ‚Äì und alle waren kleinere Studien. Dies ist genau das Muster, das Metaanalysen aufbl√§ht: Kleine negative Studien verschwinden. Wir k√∂nnen nicht ewig auf unver√∂ffentlichte Daten warten ‚Äì wir m√ºssen anerkennen, dass es eine Verzerrung gibt."
        }
      }},
      { type: "stats", theme: "dark", content: {
        title: "Das Ausma√ü der verborgenen Beweise",
        stats: [
          { value: "50%", label: "Trials never published" },
          { value: "74%", label: "Reboxetine-Daten verborgen" },
          { value: "60%", label: "Tamiflu-Daten unver√∂ffentlicht" },
          { value: "31%", label: "Outcomes switched" }
        ],
        caption: "Die ver√∂ffentlichte Literatur stellt eine kuratierte Auswahl dar. keine vollst√§ndige Evidenz."
      }},
      { type: "concept", theme: "dark", content: {
        title: "Why Funnel Plots Aren't Enough",
        subtitle: "Erkennen des Nichtnachweisbaren",
        text: "Funnel plots can only show what's published. They cannot detect:<br>‚Ä¢ Entire drugs that failed in trials and were never developed further<br>‚Ä¢ Studies with outcome switching (positive outcomes published, negative ones hidden)<br>‚Ä¢ Industry studies kept confidential<br>‚Ä¢ Studies published in inaccessible journals",
        highlight: "When publication bias is well-executed, it leaves no visible trace in the published literature."
      }},
      { type: "checklist", theme: "dark", content: {
        title: "Publication Bias Red Flags",
        items: [
          "All or most trials industry-funded",
          "Trial registries show unpublished completed trials",
          "Funnel-Plot-Asymmetrie mit fehlenden negativen kleinen Studien",
          "Outcomes in publications differ from registered protocols",
          "Large effects in meta-analysis contradicted by single large trial"
        ]
      }},
      { type: "quiz", theme: "dark", content: {
        question: "Warum blieb der Publikationsbias mit Paroxetin bei Depressionen bei Jugendlichen jahrelang unentdeckt?",
        options: [
          { text: "Die Studien waren gut durchgef√ºhrt", correct: false },
          { text: "Negative Studien wurden ausgeblendet und die positive Studie wurde von einem Ghostwriter geschrieben, um die Ergebnisse falsch darzustellen", correct: true },
          { text: "The drug genuinely worked in some patients", correct: false },
          { text: "Regulierungsbeh√∂rden haben die Daten nicht √ºberpr√ºft", correct: false }
        ],
        xp: 20,
        feedback: {
          correct: "Genau. GSK verheimlichte negative Studien und beauftragte ein medizinisches Kommunikationsunternehmen damit, die Studie 329 so zu verfassen, dass Paroxetin wirksam wirkte. Die Ver√∂ffentlichungsvoreingenommenheit war bewusst und systematisch ‚Äì sichtbar nur, wenn Klagen eine Offenlegung erzwangen.",
          incorrect: "Die T√§uschung war aktiv, nicht passiv. GSK wusste, dass Paroxetin bei Depressionen und erh√∂htem Selbstmordverhalten bei Teenagern nicht wirkte. Sie begruben negative Prozesse und stellten den einzigen ver√∂ffentlichten Prozess falsch dar. Herk√∂mmliche Erkennungsmethoden konnten nicht finden, was absichtlich verborgen war."
        }
      }},
      { type: "story", theme: "red-bg", content: {
        label: "Die antidepressive Illusion", title: "Turner's 94 Trial Revelation",
        text: "In 2008, Dr. Erick Turner at the FDA did something unprecedented: he compared <strong>74 FDA-registered antidepressant trials</strong> to what was actually published. The FDA had seen all trials‚Äîpositive and negative. The literature had seen a carefully curated selection.",
        followup: "The results were damning. Of 38 positive trials, <strong>37 were published</strong>. Of 36 negative or questionable trials, only <strong>3 were published as negative</strong>‚Äî22 were never published, and 11 were published but 'spun' to appear positive. The published literature showed antidepressants were effective in 94% of trials. The FDA data showed 51%. Effect sizes in publications were <strong>32% larger</strong> than reality. An entire drug class had its efficacy inflated by systematic publication bias."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üíä", title: "Szenario: Die selektive Literatur",
        xp: 25,
        scenario: "You're assessing antidepressants for a guideline. The published literature shows 12 of 15 trials are positive. However, you discover FDA databases listing 8 additional completed trials that were never published. The published effect size is d=0.50.",
        question: "Wie sollten Sie Ihre Sicherheitsbewertung anpassen?",
        options: [
          { letter: "A", text: "Use only published trials‚Äîunpublished data isn't peer-reviewed", correct: false },
          { letter: "B", text: "Downgrade significantly‚Äî8 unpublished trials likely changes the effect size substantially", correct: true },
          { letter: "C", text: "Assume unpublished trials showed similar results", correct: false },
          { letter: "D", text: "Request unpublished data before making any assessment", correct: false }
        ],
        feedback: {
          correct: "Richtig! Die Analyse von Turner ergab, dass die ver√∂ffentlichten Effektgr√∂√üen um 32 % √ºberh√∂ht waren. Acht unver√∂ffentlichte Studien von insgesamt 23 (35 % verborgen) bedeuten, dass Ihre Wirkungssch√§tzung wahrscheinlich erheblich verzerrt ist. Herabstufung wegen Publikationsbias und beachten Sie, dass der tats√§chliche Effekt wahrscheinlich geringer ist als ver√∂ffentlichte Sch√§tzungen.",
          incorrect: "Die Antidepressiva-Literatur zeigte 94 % positive Studien in Ver√∂ffentlichungen gegen√ºber 51 % in FDA-Daten. Unver√∂ffentlichte Studien fallen systematisch negativ aus. Die Annahme, dass sie ver√∂ffentlichten Studien √§hneln, widerspricht den jahrzehntelangen Beweisen zu Publikationsverzerrungsmustern."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "Das RECORD-Desaster", title: "When a Safety Study Hid Safety Signals",
        text: "After Avandia's cardiovascular concerns emerged, GSK designed RECORD‚Äîa 'cardiovascular safety study' of rosiglitazone. The study enrolled <strong>4,447 patients</strong> and ran for 5+ years. It was specifically designed to assess cardiovascular safety. The published conclusion: 'Rosiglitazone did not significantly increase cardiovascular risk.'",
        followup: "An FDA re-analysis told a different story. RECORD had serious adjudication problems‚Äî<strong>35% of potential cardiovascular events weren't properly evaluated</strong>. Some patients' events were classified as 'non-cardiac' when records suggested otherwise. The study designed to answer the safety question had been conducted in ways that systematically underdetected the very events it was supposed to measure. The publication bias wasn't in what studies were published‚Äîit was in how the study itself was designed and analyzed to produce a publishable 'negative' safety finding."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üîç", title: "Szenario: Die ‚Äûberuhigende‚Äú Sicherheitsstudie",
        xp: 25,
        scenario: "A drug with suspected harm has a 'definitive' safety study published showing no increased risk. However, you notice: outcomes were adjudicated by company employees, 30% of potential events were excluded as 'protocol deviations,' and the comparison group had higher baseline risk.",
        question: "Wie sollten sich diese methodischen Merkmale auf Ihre Interpretation auswirken?",
        options: [
          { letter: "A", text: "Akzeptieren Sie die Beruhigung ‚Äì die Studie wurde speziell f√ºr die Sicherheit konzipiert", correct: false },
          { letter: "B", text: "Be skeptical‚Äîsystematic bias in outcome ascertainment can hide real signals", correct: true },
          { letter: "C", text: "Partially reassured‚Äîsome bias doesn't eliminate all value", correct: false },
          { letter: "D", text: "Ignorieren und auf unabh√§ngige Replikation warten", correct: false }
        ],
        feedback: {
          correct: "Richtig! RECORD hat uns gelehrt, dass ‚ÄûSicherheitsstudien‚Äú so gestaltet werden k√∂nnen, dass kein Schaden festgestellt wird. Unternehmensurteile, selektive Ausschl√ºsse und g√ºnstige Vergleiche k√∂nnen dazu f√ºhren, dass unerw√ºnschte Ereignisse systematisch nicht erkannt werden. Eine ‚Äûnegative‚Äú Sicherheitsstudie mit diesen Merkmalen vermittelt eine falsche Sicherheit.",
          incorrect: "Eine Sicherheitsstudie, die von dem Unternehmen mit dem verd√§chtigen Produkt entworfen und beurteilt wurde, weist offensichtliche Konflikte auf. Die Nichtauswertungsquote von RECORD von 35 % bedeutete, dass Ereignisse nicht ordnungsgem√§√ü gez√§hlt wurden. ‚ÄûAuf Sicherheit ausgelegt‚Äú ist bedeutungslos, wenn das Design zul√§sst, dass Sch√§den nicht entdeckt werden."
        }
      }}
    ]
  },
  {
    id: 8, title: "Upgrading Factors", subtitle: "When observational evidence earns trust", xp: 140,
    slides: [
      { type: "title", theme: "green-bg", content: { title: "Upgrading Factors", subtitle: "When observation rivals randomization" }},
      { type: "objectives", theme: "dark", content: {
        objectives: [
          "Understand the three GRADE upgrading factors",
          "Learn when large effects can overcome confounding",
          "Recognize dose-response gradients as evidence of causation",
          "Apply 'all plausible confounders' reasoning"
        ],
        tip: "Upgrading is rare‚Äîbut sometimes observational evidence is unassailable."
      }},
      { type: "story", theme: "green-bg", content: {
        label: "Der Raucherbeweis", title: "How 30x Risk Silenced Doubt",
        text: "In 1950, Richard Doll and Austin Bradford Hill published their case-control study: smokers had <strong>30 times higher lung cancer rates</strong> than non-smokers. The tobacco industry demanded RCTs‚Äîknowing they were impossible. 'Correlation isn't causation,' they insisted. 'Where's the randomized evidence?'",
        followup: "But the effect size spoke for itself. For confounding to explain a 30-fold increase, some unmeasured factor would need to cause both smoking and lung cancer with extraordinary strength‚Äîand be distributed perfectly across populations, generations, and geographies. No such confounder has ever been found. The evidence was upgraded from LOW to HIGH. GRADE recognizes that some effects are too large for confounding to explain."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üìà", title: "Szenario: Der gro√üe Effekt",
        xp: 25,
        scenario: "Eine Beobachtungsstudie zeigt, dass ein chirurgischer Eingriff die Sterblichkeit von 80 % auf 10 % reduziert ‚Äì ein relatives Risiko von 0,125 (87,5 % relativ). Reduzierung). Es gibt keine RCTs, da das Zur√ºckhalten einer Behandlung angesichts des dramatischen beobachteten Nutzens unethisch w√§re.",
        question: "Sollten diese Beweise f√ºr eine gro√üe Wirkung aktualisiert werden?",
        options: [
          { letter: "A", text: "Nein ‚Äì Beobachtungsnachweise k√∂nnen nicht aktualisiert werden", correct: false },
          { letter: "B", text: "Yes‚ÄîRR 0.125 is so large that confounding alone is implausible", correct: true },
          { letter: "C", text: "Nur wenn die Studie dies tut Gut gestaltet", correct: false },
          { letter: "D", text: "Only if dose-response is also present", correct: false }
        ],
        feedback: {
          correct: "Correct! RR 0.125 (or 8-fold relative reduction) is in the range where confounding alone is implausible. No unmeasured confounder could realistically reduce mortality from 80% to 10%. GRADE upgrades for large effects when RR < 0.5 or > 2, with additional upgrading for very large effects (RR < 0.2 or > 5).",
          incorrect: "Effekte dieser Gr√∂√üe sind im Wesentlichen RCT-sicher. Kein St√∂rfaktor konnte eine relative Reduzierung um 87,5 % plausibel erkl√§ren. Fallschirme wurden noch nie in RCTs getestet, aber wir bezweifeln nicht, dass sie funktionieren ‚Äì die Gr√∂√üe des Effekts ist offensichtlich. GRADE erm√∂glicht die Hochstufung von Effekten, die zu gro√ü sind, als dass sie durch Verwirrung erkl√§rt werden k√∂nnten."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "Die Folat-Entdeckung", title: "Neural Tube Defects Prevented",
        text: "In den 1980er Jahren deuteten Beobachtungsstudien darauf hin, dass eine Folat-Supplementierung Neuralrohrdefekte (NTDs) wie Spina bifida verhinderte. Aber wie konnte jemand sicher sein? Die Verwirrung schien unvermeidlich ‚Äì Frauen, die Vitamine einnehmen, sind wahrscheinlich in vielerlei Hinsicht ges√ºnder.",
        followup: "Three upgrading factors came together. <strong>Large effect:</strong> Folate reduced NTDs by 70-80%. <strong>Dose-response:</strong> Higher folate levels correlated with lower NTD risk in a clear gradient. <strong>Confounding direction:</strong> Women who take supplements tend to be healthier‚Äîwhich would make folate look beneficial even if it weren't. But folate's effect persisted after adjusting for socioeconomic factors. When an effect survives adjustment for confounders that should bias toward it, the effect is likely real. The MRC RCT eventually confirmed 72% reduction‚Äîthe observational data had been right."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üìâ", title: "Szenario: Die Dosis-Wirkungs-Frage",
        xp: 25,
        scenario: "A series of cohort studies shows alcohol consumption and liver cirrhosis. Results: 1-2 drinks/day (RR 1.2), 3-4 drinks/day (RR 2.1), 5-6 drinks/day (RR 4.5), 7+ drinks/day (RR 9.3). The gradient is consistent across studies and populations.",
        question: "Does this dose-response pattern support upgrading?",
        options: [
          { letter: "A", text: "Nein ‚Äì alle Effekte stammen aus Beobachtungsstudien", correct: false },
          { letter: "B", text: "Yes‚Äîa consistent dose-response gradient across studies suggests causation", correct: true },
          { letter: "C", text: "Only if RR exceeds 2 at all dose levels", correct: false },
          { letter: "D", text: "Only if confounders show the same gradient", correct: false }
        ],
        feedback: {
          correct: "Richtig! Ein klarer Dosis-Wirkungs-Gradient (1,2 ‚Üí 2,1 ‚Üí 4,5 ‚Üí 9,3) l√§sst sich nur schwer durch Verwechslung erkl√§ren. Ein Confounder m√ºsste den Alkoholkonsum auf jeder Ebene in verschiedenen Bev√∂lkerungsgruppen perfekt verfolgen. Dieser biologische Gradient unterst√ºtzt die Kausalit√§t und rechtfertigt eine Aktualisierung.",
          incorrect: "Dosis-Wirkungs-Beziehungen liefern starke Beweise f√ºr die Kausalit√§t. Damit Confounding dieses Muster erzeugt, m√ºsste ein unbekannter Faktor in jeder Studie und Population im perfekten Verh√§ltnis zum Alkoholkonsum zunehmen. Das ist unglaubw√ºrdig ‚Äì der Gradient deutet auf einen Kausalzusammenhang hin."
        }
      }},
      { type: "story", theme: "green-bg", content: {
        label: "Das verwirrende Paradoxon", title: "When Bias Proves the Case",
        text: "Man bedenke die Beobachtung, dass Motorradhelme die Zahl der Todesf√§lle durch Kopfverletzungen senken. Kritiker k√∂nnten einwenden: ‚ÄûVielleicht sind Helmtr√§ger vorsichtigere Autofahrer.‚Äú Das ist verwirrend ‚Äì und es ist wahrscheinlich wahr. Vorsichtige Fahrer tragen wahrscheinlich h√§ufiger Helme.",
        followup: "But here's the paradox: if cautious driving confounds the relationship, it should bias <em>toward</em> helmets looking beneficial. Cautious drivers have fewer crashes and thus fewer head injuries. If helmets still show dramatic benefit <em>despite</em> this confounding working in their favor, the true effect might be even larger. When all plausible confounders bias in one direction and the effect persists (or is opposite), causation becomes more credible. This 'all plausible confounders' reasoning is GRADE's third upgrading criterion."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üîÑ", title: "Szenario: Die verwirrende Richtung",
        xp: 25,
        scenario: "Eine Registerstudie zeigt, dass eine neue Operationstechnik Komplikationen reduziert (RR 0,60). Sie vermuten eine Verwechslung: Wahrscheinlich erhalten ges√ºndere Patienten die neue Technik. Ges√ºndere Patienten h√§tten ohnehin weniger Komplikationen. Diese Verwirrung sollte die Ergebnisse dahingehend verzerren, dass sie einen Nutzen zeigen.",
        question: "Does this confounding pattern support or undermine causation?",
        options: [
          { letter: "A", text: "Undermines‚Äîconfounding invalidates observational studies", correct: false },
          { letter: "B", text: "Supports‚Äîif benefit persists despite confounding that favors treatment, true benefit may exist", correct: true },
          { letter: "C", text: "Neutral‚Äîwe cannot determine confounding direction", correct: false },
          { letter: "D", text: "Undermines‚Äîwe need propensity score matching", correct: false }
        ],
        feedback: {
          correct: "Correct! If healthier patients get the new technique AND the technique still shows benefit, the true benefit might be real (or even underestimated). When confounding should bias toward benefit but benefit still appears after adjustment, that's evidence for causation. GRADE upgrades when 'all plausible confounders' would bias in the observed direction.",
          incorrect: "Think about the direction: healthy patient confounding should make the new technique look good. If the technique still shows benefit after adjusting for health status, the true effect is supported. The confounding direction helps interpret the finding."
        }
      }},
      { type: "concept", theme: "dark", content: {
        title: "Die Zusammenfassung der Upgrade-Kriterien",
        subtitle: "Three paths to higher certainty",
        checkpoints: [
          { day: "LARGE", event: "RR > 2 or < 0.5 (upgrade 1); RR > 5 or < 0.2 (upgrade 2)" },
          { day: "DOSE", event: "Clear gradient between exposure and outcome" },
          { day: "CONFOUND", event: "All plausible confounders would reduce observed effect" }
        ]
      }},
      { type: "story", theme: "dark", content: {
        label: "Der Schilddr√ºsensturm", title: "When 96% Survival Speaks for Itself",
        text: "Before propylthiouracil (PTU), thyroid storm had <strong>nearly 100% mortality</strong>. With PTU, mortality dropped to around <strong>4%</strong>. No RCT was ever conducted‚Äîit would have required letting patients die in the control arm.",
        followup: "This is the paradigm case for large effect upgrading. A treatment that changes survival from ~0% to ~96% doesn't need an RCT. No confounder could explain turning certain death into reliable survival. The evidence quality was upgraded to HIGH despite being entirely observational. Some effects are simply too dramatic to doubt."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "‚ö†Ô∏è", title: "Szenario: Der m√§√üige Effekt",
        xp: 25,
        scenario: "Eine Kohortenstudie zeigt, dass eine Lebensstilintervention Herzerkrankungen mit einem RR von 0,75 reduziert (25 % relative Reduzierung). Die Studie ist gro√ü, gut konzipiert und liefert konsistente Ergebnisse. Ein Kollege argumentiert, dass dies aufgrund einer gro√üen Wirkung eine Aktualisierung verdient.",
        question: "Sollten Sie eine Aktualisierung durchf√ºhren?",
        options: [
          { letter: "A", text: "Yes‚Äî25% reduction is clinically important", correct: false },
          { letter: "B", text: "No‚ÄîRR 0.75 is well within the range confounding can produce", correct: true },
          { letter: "C", text: "Yes‚Äîlarge sample size warrants upgrading", correct: false },
          { letter: "D", text: "Only if dose-response is also present", correct: false }
        ],
        feedback: {
          correct: "Correct! RR 0.75 is exactly the range where confounding thrives. The HRT disaster showed RR 0.50 for heart protection‚Äîentirely due to confounding. Large effect upgrading requires RR > 2 or < 0.5 (some use even stricter thresholds). Clinical importance ‚â† causal certainty.",
          incorrect: "RR 0.75 is modest and easily explained by healthy user bias, unmeasured confounders, or selection effects. HRT's observational RR of 0.50 was entirely confounded. Only effects so large that confounding is implausible (RR > 2 or < 0.5) qualify for upgrading."
        }
      }},
      { type: "checklist", theme: "dark", content: {
        title: "Upgrading Criteria Checklist",
        items: [
          "Large effect: RR > 2 or < 0.5 (very large: > 5 or < 0.2)",
          "Dose-response: Clear gradient across exposure levels",
          "Confounding: All plausible confounders would reduce the effect",
          "Upgrading is rare‚Äîmost observational evidence remains LOW",
          "Multiple upgrading factors can be applied if clearly present"
        ]
      }},
      { type: "quiz", theme: "dark", content: {
        question: "Warum erreichten die Beobachtungsnachweise f√ºr Rauchen und Lungenkrebs trotz fehlender RCTs HOHE Sicherheit?",
        options: [
          { text: "Die Studien waren methodisch perfekt.", correct: false },
          { text: "Large effect (30x risk) + dose-response + no plausible confounders could explain it", correct: true },
          { text: "Der biologische Mechanismus war gut verstanden", correct: false },
          { text: "Mehrere Studiendesigns vereinbart", correct: false }
        ],
        xp: 20,
        feedback: {
          correct: "Exactly. A 30-fold risk increase is beyond what confounding can explain. The clear dose-response (more cigarettes = more cancer) added evidence. And no unmeasured confounder has ever been found that could explain the effect. All three upgrading criteria were met.",
          incorrect: "The combination was powerful: an effect so large confounding couldn't explain it, a dose-response gradient supporting causation, and the direction of any conceivable confounding wouldn't diminish the finding. All three upgrading factors pushed the evidence to HIGH certainty."
        }
      }}
    ]
  },
  {
    id: 9, title: "Putting It Together", subtitle: "Real guideline decisions", xp: 200,
    slides: [
      { type: "title", theme: "dark", content: { title: "Putting It Together", subtitle: "Applying all five domains to real guideline decisions" }},
      { type: "objectives", theme: "dark", content: {
        objectives: [
          "Apply all GRADE domains to complex real-world evidence",
          "√úben Sie das Erstellen von Beweiszusammenfassungen",
          "Make defensible certainty judgments",
          "Translate certainty to recommendation strength"
        ],
        tip: "In diesem Modul werden vollst√§ndige F√§lle vorgestellt ‚Äì Sie wenden alles an, was Sie gelernt haben."
      }},
      { type: "story", theme: "red-bg", content: {
        label: "Fall 1: Die Statin-Kontroverse", title: "Statine f√ºr die Prim√§rpr√§vention",
        text: "In 2016, a Lancet review claimed statins for primary prevention were supported by <strong>'overwhelming evidence.'</strong> The meta-analysis showed 25% relative reduction in major vascular events. Industry-funded trials dominated. Patient advocates and independent researchers disagreed vehemently.",
        followup: "Let's assess this systematically. <strong>Risk of bias:</strong> Most trials industry-funded with concerns about selective reporting. <strong>Inconsistency:</strong> Effects varied by baseline risk‚Äîbenefit clear in high-risk, uncertain in low-risk. <strong>Indirectness:</strong> Many trials included patients with existing disease (secondary prevention). <strong>Imprecision:</strong> For low-risk primary prevention, confidence intervals crossed clinical thresholds. <strong>Publication bias:</strong> Industry sponsorship raised concerns about selective publication."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üíä", title: "Szenario: Bewertung des Statin-Nachweises",
        xp: 30,
        scenario: "For statins in LOW-RISK primary prevention (10-year CVD risk <10%), you have: industry-funded RCTs, some risk of bias concerns, heterogeneous results by risk level, outcomes measured may include secondary prevention patients, and modest absolute benefits (NNT ~200-500 to prevent one event over 5 years).",
        question: "Welche Sicherheitsbewertung ist am besten geeignet? Reduzierung von CV-Ereignissen in dieser Population?",
        options: [
          { letter: "A", text: "HIGH ‚Äì die Metaanalyse ist umfangreich und zeigt einen signifikanten Nutzen", correct: false },
          { letter: "B", text: "MODERATE‚Äîdowngrade one level for indirectness (mixed populations)", correct: false },
          { letter: "C", text: "NIEDRIG ‚Äì Herabstufung wegen Indirektheit UND Ungenauigkeit f√ºr diese spezifische Population", correct: true },
          { letter: "D", text: "VERY LOW‚Äîmultiple serious concerns across domains", correct: false }
        ],
        feedback: {
          correct: "Correct! For low-risk primary prevention specifically: indirectness (trials mixed with higher-risk patients) and imprecision (modest absolute benefits, NNT 200-500) both warrant downgrading. The certainty differs by population‚Äîwhat's HIGH for secondary prevention may be LOW for low-risk primary prevention.",
          incorrect: "Die Frage bezieht sich speziell auf die Prim√§rpr√§vention mit niedrigem Risiko. Die gesamte Metaanalyse umfasst Bev√∂lkerungsgruppen mit h√∂herem Risiko, bei denen der Nutzen klarer ist. F√ºr die spezifische Population in der Frage gelten sowohl Indirektheit als auch Ungenauigkeit. GRADE ist bev√∂lkerungsspezifisch."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "Fall 2: Die Hydroxychloroquin-Saga", title: "COVID-19 und vorzeitige Gewissheit",
        text: "In March 2020, a French study of <strong>36 patients</strong> claimed hydroxychloroquine cleared COVID-19 viral load. The study was open-label, non-randomized, with selective exclusion of patients who died or went to ICU. Despite this, world leaders promoted it and millions of doses were prescribed.",
        followup: "Systematic GRADE assessment would have revealed: <strong>Risk of bias:</strong> CRITICAL (non-randomized, open-label, selective exclusion). <strong>Imprecision:</strong> SERIOUS (36 patients, 6 in treatment arm). <strong>Indirectness:</strong> SERIOUS (viral load, not clinical outcomes). Certainty: <strong>VERY LOW</strong>. Subsequent RCTs (RECOVERY, WHO Solidarity) showed no benefit. The pandemic revealed what happens when certainty assessment is bypassed."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ü¶†", title: "Szenario: Bewertung von Pandemiebeweisen",
        xp: 30,
        scenario: "Ein neues Atemwegsvirus tritt auf. Eine monozentrische Studie mit 80 Patienten (nicht randomisiert, offen) zeigt, dass ein umfunktioniertes Medikament die Zahl der Intensivpatienten von 25 % auf 12 % reduziert. Die Ergebnisse werden als ‚Äûvielversprechend‚Äú beworben und erzeugen eine enorme √∂ffentliche Nachfrage.",
        question: "Wie soll diese Evidenz bewertet und kommuniziert werden?",
        options: [
          { letter: "A", text: "M√ÑSSIG ‚Äì die Effektgr√∂√üe ist gro√ü und klinisch bedeutsam", correct: false },
          { letter: "B", text: "NIEDRIG ‚Äì Beobachtungsstudie mit gravierenden Einschr√§nkungen", correct: false },
          { letter: "C", text: "VERY LOW‚Äîcritical risk of bias, serious imprecision; communicate uncertainty clearly", correct: true },
          { letter: "D", text: "Cannot rate‚Äîmore studies needed before any assessment", correct: false }
        ],
        feedback: {
          correct: "Correct! Non-randomized, open-label, single-center, n=80: VERY LOW certainty. The effect might be real, might be selection bias, might be confounding. Communicating this uncertainty‚Äînot dismissing the evidence, but properly contextualizing it‚Äîis essential for informed decision-making.",
          incorrect: "Dieses Szenario spiegelt Hydroxychloroquin wider. Das kritische Risiko einer Verzerrung (nicht randomisiert, offen) plus schwerwiegende Ungenauigkeiten (80 Patienten) f√ºhrt zu SEHR GERINGER Sicherheit. Das bedeutet nicht, es zu ignorieren ‚Äì es bedeutet, die tiefe Unsicherheit zu kommunizieren und gleichzeitig auf bessere Beweise zu warten."
        }
      }},
      { type: "story", theme: "green-bg", content: {
        label: "Case 3: The Insulin Pump Victory", title: "When Certainty Builds Slowly",
        text: "Kontinuierliche subkutane Insulininfusion (Pumpentherapie) bei Typ-1-Diabetes hat √ºber Jahrzehnte hinweg Beweise gesammelt. Die ersten Versuche waren klein. Die Ergebnisse waren unterschiedlich. Kein einzelner Versuch war endg√ºltig. Aber mit der Zeit f√ºgte sich das Mosaik zusammen.",
        followup: "By 2010, meta-analyses showed: consistent HbA1c improvement (~0.3%), reduced severe hypoglycemia, improved quality of life. <strong>Risk of bias:</strong> Some concerns but improving over time. <strong>Inconsistency:</strong> Low for HbA1c, moderate for hypoglycemia (likely explainable by patient selection). <strong>Indirectness:</strong> None‚Äîdirect outcomes in target population. <strong>Imprecision:</strong> Resolved with cumulative trials. <strong>Publication bias:</strong> Low concern with trials in multiple settings. Final rating: <strong>MODERATE to HIGH</strong> for HbA1c improvement, with appropriate nuance for other outcomes."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üìã", title: "Szenario: Die sich entwickelnde Beweisbasis",
        xp: 25,
        scenario: "You're updating a guideline. Five years ago, certainty was LOW for a treatment. Since then: 3 new large RCTs with low risk of bias, consistent results (I¬≤=18%), direct population and outcomes, total events now exceed OIS, no evidence of publication bias.",
        question: "What certainty rating is now appropriate?",
        options: [
          { letter: "A", text: "Remains LOW‚Äîinitial rating shouldn't change dramatically", correct: false },
          { letter: "B", text: "MODERATE‚Äînew evidence improves but doesn't transform certainty", correct: false },
          { letter: "C", text: "HIGH‚Äînew RCTs with no serious concerns across domains", correct: true },
          { letter: "D", text: "Requires independent replication before upgrading", correct: false }
        ],
        feedback: {
          correct: "Correct! GRADE ratings should evolve as evidence evolves. Starting HIGH (RCTs), no downgrading needed: low risk of bias, consistent (I¬≤=18%), direct outcomes, adequate precision (exceeds OIS), no publication bias concern. The evidence now supports HIGH certainty.",
          incorrect: "GRADE ist ein lebendiges Framework. Da sich Beweise h√§ufen und fr√ºhere Bedenken ausr√§umen, sollte die Gewissheit neu bewertet werden. Drei gro√üe RCTs mit geringer Voreingenommenheit und konsistenten Ergebnissen in allen Bereichen k√∂nnen die Sicherheit absolut von NIEDRIG auf HOCH erh√∂hen."
        }
      }},
      { type: "story", theme: "red-bg", content: {
        label: "Case 4: The Arthroscopy Lesson Revisited", title: "When Guidelines Persist Despite Evidence",
        text: "Bis 2008 hatten zwei RCTs mit Scheinoperationen gezeigt, dass die Kniearthroskopie bei Osteoarthritis nicht besser war als Placebo. Die Evidenz war HOHE Sicherheit ‚Äì gut konzipierte RCTs, konsistente Ergebnisse, direkte Ergebnisse. Doch es dauerte Jahre, bis sich die Richtlinien √§nderten, und das Verfahren wurde fortgesetzt.",
        followup: "This reveals GRADE's limitation: certainty ratings inform decisions but don't make them. Surgeons argued: 'My patients improve.' Patients wanted the procedure. Systems had invested in it. A HIGH certainty of 'no benefit' should have ended the practice‚Äîbut implementation requires more than evidence rating. GRADE tells us what the evidence says; behavior change requires understanding why evidence gets ignored."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üî¨", title: "Szenario: Die Kluft zwischen Evidenz und Praxis",
        xp: 25,
        scenario: "Ihr Leitliniengremium bewertet die Evidenz als HOHE Gewissheit, dass ein gemeinsames Verfahren nicht besser ist als ein Placebo. Das Verfahren ist lukrativ, wird h√§ufig durchgef√ºhrt und die Patienten berichten von Zufriedenheit. Die Gremiumsmitglieder sind sich √ºber die St√§rke der Empfehlung nicht einig.",
        question: "What recommendation strength is appropriate given HIGH certainty of no benefit?",
        options: [
          { letter: "A", text: "Strong recommendation AGAINST‚Äîhigh certainty of no benefit demands strong action", correct: true },
          { letter: "B", text: "Conditional recommendation against‚Äîpatient preferences matter", correct: false },
          { letter: "C", text: "No recommendation‚Äîpractice patterns should determine guidelines", correct: false },
          { letter: "D", text: "Conditional recommendation for‚Äîpatients report benefit", correct: false }
        ],
        feedback: {
          correct: "Correct! HIGH certainty that a procedure provides no benefit over placebo justifies a STRONG recommendation against. Patient-reported benefit in unblinded settings is placebo effect. Resource use for ineffective treatments has opportunity costs. High certainty + unfavorable balance = strong recommendation.",
          incorrect: "Wenn die Gewissheit HOCH ist und die Bilanz eindeutig ung√ºnstig ist (kein Nutzen, chirurgische Risiken, Kosten), unterst√ºtzt GRADE eine starke Empfehlung. Die Patientenzufriedenheit mit Placebo rechtfertigt nicht die weitere Anwendung invasiver Verfahren. Starke Beweise sollten zu starken Empfehlungen f√ºhren."
        }
      }},
      { type: "concept", theme: "dark", content: {
        title: "Von Gewissheit zu Empfehlungen",
        subtitle: "Evidenzqualit√§t ist nur ein Teil der Gleichung",
        text: "GRADE separates certainty of evidence from strength of recommendations. A recommendation considers:<br><br>‚Ä¢ Certainty of evidence<br>‚Ä¢ Balance of benefits vs. harms<br>‚Ä¢ Patient values and preferences<br>‚Ä¢ Resource use and feasibility",
        highlight: "Even LOW certainty evidence can support a STRONG recommendation (e.g., parachutes) if benefits clearly outweigh harms."
      }},
      { type: "story", theme: "dark", content: {
        label: "Fall 5: Die Transfusionsschwelle", title: "When Less Is More",
        text: "For decades, blood transfusion thresholds were set at hemoglobin <10 g/dL‚Äîthe '10/30 rule.' The practice seemed logical: more blood should be better for anemic patients. Then came the RCTs.",
        followup: "The TRICC trial (1999) and subsequent studies showed <strong>restrictive transfusion (Hb <7 g/dL)</strong> was as safe or safer than liberal transfusion in most patients. The evidence accumulated: <strong>Risk of bias:</strong> Low in major trials. <strong>Inconsistency:</strong> Low across settings. <strong>Indirectness:</strong> Some subgroups less studied. <strong>Imprecision:</strong> Resolved with multiple trials. <strong>Publication bias:</strong> Unlikely given consistent direction. Certainty: <strong>MODERATE to HIGH</strong> for most populations. Guidelines changed. A practice that had seemed obviously beneficial was actually harmful."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ü©∏", title: "Szenario: Das Restriktive Strategie",
        xp: 25,
        scenario: "Mehrere RCTs zeigen, dass restriktive Bluttransfusionen genauso sicher sind wie gro√üz√ºgige Transfusionen, wobei in einigen Untergruppen die Mortalit√§t geringer ist. F√ºr Patienten mit akutem Koronarsyndrom gibt es jedoch nur eine kleine RCT mit breiten Konfidenzintervallen, die klinisch wichtige Schwellenwerte √ºberschreiten.",
        question: "How should certainty differ between general hospital patients and ACS patients?",
        options: [
          { letter: "A", text: "Gleiche Sicherheit ‚Äì die Gesamtbeweiskraft gilt f√ºr alle Patienten.", correct: false },
          { letter: "B", text: "Niedriger f√ºr ACS ‚Äì Ungenauigkeit und Indirektheit erfordern eine separate Bewertung", correct: true },
          { letter: "C", text: "H√∂her f√ºr ACS ‚Äì sie haben durch Transfusionskomplikationen mehr zu verlieren", correct: false },
          { letter: "D", text: "ACS kann nicht bewertet werden ‚Äì unzureichende Beweise f√ºr irgendeine Schlussfolgerung", correct: false }
        ],
        feedback: {
          correct: "Richtig! ACS-Patienten haben biologische Gr√ºnde f√ºr unterschiedliche Reaktionen (myokardialer Sauerstoffbedarf). Eine kleine ungenaue RCT in dieser Population bedeutet, dass Indirektheit (Extrapolation von allgemeinen Patienten) oder Ungenauigkeit (direkter ACS-Beweis) beide eine geringere Sicherheit rechtfertigen. GRADE ist bev√∂lkerungsspezifisch.",
          incorrect: "GRADE erfordert die Bewertung der Sicherheit f√ºr jede spezifische Bev√∂lkerung. ACS-Patienten reagieren m√∂glicherweise anders als allgemeine Krankenhauspatienten. Eine kleine ungenaue Studie direkt an ACS-Patienten bietet nicht die gleiche Sicherheit wie die breitere Evidenzbasis f√ºr andere Bev√∂lkerungsgruppen."
        }
      }},
      { type: "quiz", theme: "dark", content: {
        question: "Was ist die wichtigste Lehre aus der Erfahrung mit Hydroxychloroquin bei COVID-19?",
        options: [
          { text: "Beobachtungsstudien sind immer unzuverl√§ssig", correct: false },
          { text: "Proper GRADE assessment should precede clinical adoption and policy", correct: true },
          { text: "Repurposed drugs don't work for new diseases", correct: false },
          { text: "Medien sollten nicht √ºber medizinische Themen berichten Studien", correct: false }
        ],
        xp: 20,
        feedback: {
          correct: "Genau. Eine nicht randomisierte, offene Studie mit 36 ‚Äã‚ÄãPatienten und selektiven Ausschl√ºssen wies nach jeder GRADE-Bewertung SEHR GERINGE Sicherheit auf. Eine systematische Bewertung der Sicherheit vor der Einf√ºhrung h√§tte den weitverbreiteten Einsatz einer unwirksamen Behandlung verhindert und das Vertrauen der √ñffentlichkeit aufrechterhalten.",
          incorrect: "Die Lektion ist nicht, dass kleine Studien wertlos sind ‚Äì sie m√ºssen vielmehr einer ordnungsgem√§√üen Bewertung der Sicherheit unterzogen werden. Eine strenge GRADE-Bewertung h√§tte diese Sicherheit sofort als SEHR NIEDRIG eingestuft. Vor der klinischen Einf√ºhrung muss eine systematische Bewertung erfolgen, insbesondere in Krisenzeiten, in denen der Druck am h√∂chsten ist."
        }
      }}
    ]
  },
  {
    id: 10, title: "Final Assessment", subtitle: "Testen Sie Ihr K√∂nnen", xp: 250,
    slides: [
      { type: "title", theme: "dark", content: { title: "Final Assessment", subtitle: "Demonstrate your mastery of GRADE certainty assessment" }},
      { type: "concept", theme: "dark", content: {
        title: "Die letzte Herausforderung",
        subtitle: "Apply everything you've learned",
        text: "Dieses Modul stellt komplexe Szenarien vor, die eine integrierte GRADE-Bewertung erfordern. Sie m√ºssen mehrere Dom√§nen gleichzeitig ber√ºcksichtigen und differenzierte Urteile f√§llen.",
        highlight: "Streben Sie eine Genauigkeit von 80 % an, um das GRADE-Master-Abzeichen zu erhalten!"
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üìä", title: "Challenge 1: The New Cancer Drug",
        xp: 35,
        scenario: "A new cancer drug shows median survival improvement from 11 to 14 months in a single industry-funded RCT (n=600). Primary outcome was changed mid-trial from overall survival to progression-free survival. Three of seven pre-specified secondary outcomes were not reported. The survival benefit was a post-hoc analysis.",
        question: "What certainty rating is appropriate for overall survival benefit?",
        options: [
          { letter: "A", text: "HIGH‚ÄîRCT showing survival benefit", correct: false },
          { letter: "B", text: "MODERATE‚Äîsingle trial but clinically meaningful", correct: false },
          { letter: "C", text: "LOW‚Äîdowngrade for risk of bias (outcome switching, selective reporting)", correct: true },
          { letter: "D", text: "VERY LOW‚Äîmultiple serious concerns", correct: false }
        ],
        feedback: {
          correct: "Correct! Key risk of bias concerns: (1) primary outcome changed mid-trial, (2) unreported secondary outcomes, (3) survival benefit was post-hoc. Each suggests selective reporting. Starting HIGH, downgrade one or two levels for serious risk of bias. Industry funding adds concern but isn't sufficient alone for downgrading.",
          incorrect: "The trial shows classic selective reporting: changing primary endpoint, hiding unfavorable secondary outcomes, promoting post-hoc survival analysis. These risk of bias concerns require downgrading even when the finding itself is statistically significant."
        }
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üîç", title: "Herausforderung 2: Das Meta-Analyse-R√§tsel",
        xp: 35,
        scenario: "A meta-analysis of 20 RCTs (n=15,000) shows significant mortality reduction (RR 0.85, 95% CI 0.76-0.95). However: I¬≤=68%, prediction interval 0.62-1.15, funnel plot shows slight asymmetry, 4 trials registered but never published.",
        question: "Which domains require downgrading and by how much?",
        options: [
          { letter: "A", text: "Inconsistency (‚àí1), publication bias (‚àí1): HIGH ‚Üí LOW", correct: true },
          { letter: "B", text: "Imprecision only (‚àí1): HIGH ‚Üí MODERATE", correct: false },
          { letter: "C", text: "Inconsistency (‚àí2): HIGH ‚Üí LOW", correct: false },
          { letter: "D", text: "Publication bias only (‚àí1): HIGH ‚Üí MODERATE", correct: false }
        ],
        feedback: {
          correct: "Correct! Inconsistency: I¬≤=68% with prediction interval crossing 1.0 (could show harm) warrants one downgrade. Publication bias: 4 registered but unpublished trials plus funnel asymmetry warrants one downgrade. Two domains = two downgrades = HIGH ‚Üí LOW.",
          incorrect: "Das Vorhersageintervall (0,62‚Äì1,15) √ºberschreitet 1,0 ‚Äì das Die n√§chste Studie k√∂nnte Sch√§den zeigen. Das ist eine schwerwiegende Inkonsistenz. Die Trichterasymmetrie plus 4 unver√∂ffentlichte registrierte Studien ist ein direkter Beweis f√ºr einen Publikationsbias. Beide Bereiche erfordern eine Herabstufung."
        }
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üíâ", title: "Herausforderung 3: Die Wirksamkeit des Impfstoffs",
        xp: 35,
        scenario: "A vaccine trial (n=40,000) shows 95% efficacy against symptomatic disease (RR 0.05, 95% CI 0.03-0.08). Low risk of bias, consistent subgroup results, direct outcome. However, follow-up is only 3 months, and durability of protection is unknown.",
        question: "How should certainty be rated for short-term vs. long-term efficacy?",
        options: [
          { letter: "A", text: "HIGH for both‚Äîlarge, well-conducted trial", correct: false },
          { letter: "B", text: "HIGH for short-term; VERY LOW for long-term (no data)", correct: false },
          { letter: "C", text: "HIGH for short-term efficacy; LOW for 12-month efficacy (indirect/imprecise)", correct: true },
          { letter: "D", text: "MODERATE for both‚Äîduration uncertainty affects all conclusions", correct: false }
        ],
        feedback: {
          correct: "Correct! Short-term efficacy: large RCT, low bias, precise, direct = HIGH. Long-term efficacy: either indirect (extrapolating from 3 months) or imprecise (no data). GRADE is outcome-specific‚Äîdifferent time horizons may have different certainty ratings.",
          incorrect: "GRADE bewertet die Sicherheit f√ºr bestimmte Ergebnisse. Drei-Monats-Daten belegen direkt die 3-Monats-Wirksamkeit (HIGH). Die Zw√∂lfmonatswirksamkeit erfordert eine Extrapolation (Indirektheit) oder es liegen keine direkten Daten vor (Ungenauigkeit). Derselbe Versuch unterst√ºtzt unterschiedliche Gewissheit f√ºr unterschiedliche Fragen."
        }
      }},
      { type: "decision", theme: "dark", content: {
        icon: "‚öñÔ∏è", title: "Herausforderung 4: Das Beobachtungs-Upgrade",
        xp: 35,
        scenario: "Cohort studies show a procedure reduces mortality from 95% to 15% (RR 0.16). No RCTs exist because the natural history (95% death) makes randomization unethical. Dose-response is present: earlier intervention shows better outcomes. All plausible confounders would make patients receiving intervention sicker (selection of more severe cases).",
        question: "Sollten diese Beobachtungsnachweise aktualisiert werden und auf welches Niveau?",
        options: [
          { letter: "A", text: "No upgrade‚Äîobservational evidence stays LOW", correct: false },
          { letter: "B", text: "Upgrade to MODERATE‚Äîone upgrading factor (large effect)", correct: false },
          { letter: "C", text: "Upgrade to HIGH‚Äîall three upgrading factors clearly present", correct: true },
          { letter: "D", text: "Upgrade to MODERATE‚Äîobservational can never reach HIGH", correct: false }
        ],
        feedback: {
          correct: "Correct! All three upgrading factors: (1) Large effect‚ÄîRR 0.16 (84% relative reduction from 95% to 15%). (2) Dose-response‚Äîearlier = better. (3) Confounding direction‚Äîsicker patients receive intervention, which would bias AGAINST benefit if anything. Multiple upgrading factors can raise observational evidence to HIGH.",
          incorrect: "Dies erf√ºllt alle drei Upgrade-Kriterien. Die Effektgr√∂√üe (RR 0,16) ist sehr gro√ü ‚Äì 95 % bis 15 % Mortalit√§t. Dosis-Wirkungs-Verh√§ltnis vorhanden. Und verwirrende Ergebnisse laufen im Gegensatz zum beobachteten Effekt ab (krankere Patienten erhalten den Eingriff). Beobachtungsnachweise k√∂nnen HOHE Sicherheit erreichen, wenn alle Kriterien eindeutig erf√ºllt sind."
        }
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üéØ", title: "Herausforderung 5: Das zusammengesetzte Ergebnis",
        xp: 35,
        scenario: "An RCT shows significant reduction in 'major adverse cardiovascular events' (MACE: CV death, MI, stroke). However, decomposition reveals: CV death RR 1.02 (95% CI 0.85-1.22), MI RR 0.82 (0.72-0.94), Stroke RR 0.95 (0.80-1.13). The MACE benefit is driven entirely by MI.",
        question: "How should certainty differ for MACE vs. individual components?",
        options: [
          { letter: "A", text: "Same certainty‚ÄîMACE is the primary outcome", correct: false },
          { letter: "B", text: "MACE HIGH; CV death/stroke may be rated MODERATE (imprecision)", correct: false },
          { letter: "C", text: "MI HIGH; CV death/stroke LOW (CI includes substantial harm/benefit); MACE MODERATE (driven by MI)", correct: true },
          { letter: "D", text: "Alle Komponenten HOCH ‚Äì sie stammen aus derselben gut durchgef√ºhrten RCT", correct: false }
        ],
        feedback: {
          correct: "Correct! GRADE is outcome-specific. MI evidence is precise (0.72-0.94 excludes 1.0). CV death and stroke CIs are wide and cross 1.0‚Äîwe can't exclude no effect or harm. MACE driven entirely by MI means the composite obscures component-specific uncertainty. Different outcomes warrant different ratings even from the same trial.",
          incorrect: "Zusammengesetzte Ergebnisse k√∂nnen komponentenspezifische Unsicherheit verschleiern. Die RCT zeigt eine deutliche MI-Reduktion, aber Unsicherheit hinsichtlich kardiovaskul√§rer Todesf√§lle und Schlaganf√§lle. Patienten und √Ñrzte m√ºssen wissen, ob das Medikament Todesf√§lle oder nur nicht t√∂dliche Ereignisse verhindert. GRADE bewertet jedes Ergebnis separat."
        }
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üìâ", title: "Herausforderung 6: Der fragile Befund",
        xp: 35,
        scenario: "A meta-analysis of 5 small RCTs (total n=800, 48 events) shows statistically significant mortality benefit (RR 0.55, 95% CI 0.32-0.95, p=0.03). The fragility index is 2. A single large RCT (n=3,000) is underway.",
        question: "What certainty rating is appropriate while awaiting the large trial?",
        options: [
          { letter: "A", text: "HIGH‚Äîstatistically significant benefit from RCTs", correct: false },
          { letter: "B", text: "MODERATE‚Äîsome imprecision but consistent direction", correct: false },
          { letter: "C", text: "LOW‚Äîserious imprecision (48 events, fragility index 2, below OIS)", correct: true },
          { letter: "D", text: "Kann nicht bewertet werden ‚Äì warten Sie auf die gro√üe Studie", correct: false }
        ],
        feedback: {
          correct: "Correct! 48 events is far below typical OIS (200-400 for mortality). Fragility index of 2 means 2 different outcomes would flip the result. The CI is wide (0.32-0.95). This is classic imprecision requiring downgrade. We can make provisional conclusions while acknowledging the large trial may change everything.",
          incorrect: "Statistical significance doesn't guarantee precision. The fragility index of 2 means the 'significant' result is extremely unstable. 48 events is grossly underpowered for mortality conclusions. GRADE requires downgrading for imprecision‚Äîwe should be honest about uncertainty while awaiting better data."
        }
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üß¨", title: "Herausforderung 7: Das Ersatzergebnis",
        xp: 35,
        scenario: "A drug dramatically improves bone mineral density (+8% annually). Observational data suggest each 1% density improvement correlates with 5% fracture reduction. No fracture outcome trials have been conducted. The drug class has previously produced agents where density improved but fractures increased.",
        question: "What certainty applies to fracture prevention?",
        options: [
          { letter: "A", text: "MODERATE‚Äîstrong surrogate relationship", correct: false },
          { letter: "B", text: "LOW‚Äîindirect evidence, but plausible mechanism", correct: false },
          { letter: "C", text: "VERY LOW‚Äîserious indirectness (surrogate only) PLUS known discordance in drug class", correct: true },
          { letter: "D", text: "Cannot rate until fracture trials complete", correct: false }
        ],
        feedback: {
          correct: "Correct! Surrogate outcomes require downgrading for indirectness. But here there's added concern: the drug class has precedent for density-fracture discordance (like sodium fluoride). This history of surrogate-outcome discordance in the same class warrants serious downgrading. Starting LOW (observational), downgrade further for known class discordance.",
          incorrect: "Der Natriumfluorid-Fall (Dichte nach oben, Frakturen nach oben) ist direkt relevant ‚Äì dieselbe Medikamentenklasse mit bekannter Diskordanz zwischen Surrogat-Ergebnis. Wenn eine Medikamentenklasse gezeigt hat, dass der Ersatz sich gegens√§tzlich zu den Ergebnissen entwickeln kann, sind die Ersatzdaten f√ºr ein neues Medikament in dieser Klasse √§u√üerst unsicher."
        }
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üè•", title: "Herausforderung 8: Die Evidenz auf Systemebene",
        xp: 35,
        scenario: "Eine Stepped-Wedge-Cluster-RCT zeigt, dass ein Krankenhausprotokoll die 30-Tage-Mortalit√§t reduziert (OR 0,75, 95 %-KI 0,62‚Äì0,91). Zwanzig Krankenh√§user beteiligten sich. Allerdings wurde die Intervention an den verschiedenen Standorten unterschiedlich umgesetzt, die Ergebnisse wurden unverblindet bewertet und 5 Krankenh√§user zogen sich mitten in der Studie zur√ºck.",
        question: "Welche GRADE-Dom√§nen sind von diesen methodischen Merkmalen betroffen?",
        options: [
          { letter: "A", text: "Risk of bias only‚Äîother domains unaffected", correct: false },
          { letter: "B", text: "Risk of bias (unblinded, attrition) + inconsistency (implementation variation)", correct: true },
          { letter: "C", text: "Imprecision only‚Äî20 hospitals may be insufficient", correct: false },
          { letter: "D", text: "Indirectness‚Äîcluster trials don't apply to individual patients", correct: false }
        ],
        feedback: {
          correct: "Correct! Risk of bias: unblinded outcome assessment introduces detection bias; 5 hospital withdrawals are attrition bias. Inconsistency: variable implementation across sites may cause heterogeneity (different hospitals implementing different versions). Both domains warrant scrutiny.",
          incorrect: "Unverblindete Beurteilung und Fluktuation (5 Krankenh√§user schieden aus) sind klassische Bedenken hinsichtlich des Risikos einer Verzerrung. Variable Implementierung ist ein Problem der Inkonsistenz ‚Äì wenn Krankenh√§user unterschiedlich implementiert werden, ist die ‚ÄûIntervention‚Äú nicht einheitlich und die Ergebnisse k√∂nnen je nach Implementierungstreue variieren."
        }
      }},
      { type: "stats", theme: "dark", content: {
        title: "GRADE in Numbers",
        stats: [
          { value: "4", label: "Certainty levels" },
          { value: "5", label: "Downgrading domains" },
          { value: "3", label: "Upgrading factors" },
          { value: "‚àû", label: "Lives protected by rigorous assessment" }
        ],
        caption: "Systematic certainty assessment protects patients from overconfident medicine."
      }},
      { type: "refrain", theme: "black", content: { text: "Bei der Gewissheit kommt es nicht darauf an, wie viele Beweise vorhanden sind. Es geht darum, wie sehr wir ihm vertrauen sollten." }},
      { type: "quiz", theme: "dark", content: {
        question: "Was sind die grundlegenden Erkenntnisse, die GRADE f√ºr die evidenzbasierte Medizin liefert?",
        options: [
          { text: "Gr√∂√üere Studien sind immer besser", correct: false },
          { text: "RCTs sind die einzig g√ºltigen Beweise", correct: false },
          { text: "Sicherheit muss systematisch bewertet werden, mit transparenter Begr√ºndung f√ºr jeden Bereich", correct: true },
          { text: "Meta-analyses provide definitive answers", correct: false }
        ],
        xp: 25,
        feedback: {
          correct: "Exactly. GRADE transforms implicit judgments into explicit, transparent assessments. By systematically considering risk of bias, inconsistency, indirectness, imprecision, and publication bias‚Äîand documenting reasoning‚ÄîGRADE makes certainty assessment reproducible and debatable. This transparency is its core contribution.",
          incorrect: "Der grundlegende Beitrag von GRADE ist strukturierte Transparenz. Anstelle vager Qualit√§tssiegel erfordert es eine systematische Bewertung spezifischer Bereiche mit expliziter Begr√ºndung. Dies macht sichere Urteile reproduzierbar, diskutierbar und verbesserungsf√§hig, wenn sich Beweise ansammeln."
        }
      }}
    ]
  }
];

// ===== NAVIGATION STATE =====
let currentModule = 0;
let currentSlide = 0;
let consecutiveCorrect = gameState.consecutiveCorrect || 0;

// ===== SAVE/LOAD =====
function saveGame() {
  safeSetStorage('gradeGame_v1', gameState);
}

function resetProgress() {
  if (confirm('Reset all progress and achievements?')) {
    gameState = { ...DEFAULT_STATE, answeredQuestions: {}, badges: [], completedModules: [] };
    saveGame();
    currentModule = 0;
    currentSlide = 0;
    renderAll();
  }
}

// ===== COURSE PROGRESS =====
function updateCourseProgress() {
  const totalModules = MODULES.length;
  const completedCount = gameState.completedModules.length;
  const pct = Math.round((completedCount / totalModules) * 100);
  const fillEl = document.getElementById('courseProgressFill');
  const pctEl = document.getElementById('courseProgressPct');
  if (fillEl) fillEl.style.width = pct + '%';
  if (pctEl) pctEl.textContent = pct + '%';
}

// ===== XP & LEVELING =====
function addXP(amount) {
  gameState.xp += amount;
  checkLevelUp();
  saveGame();
  updateStatsDisplay();
  showXPPopup(amount);
}

function checkLevelUp() {
  for (let i = LEVELS.length - 1; i >= 0; i--) {
    if (gameState.xp >= LEVELS[i].xp && gameState.level < LEVELS[i].level) {
      gameState.level = LEVELS[i].level;
      showLevelUp(LEVELS[i]);
      break;
    }
  }
}

function showXPPopup(amount) {
  const popup = document.getElementById('xpPopup');
  document.getElementById('xpAmount').textContent = `+${amount}`;
  popup.classList.add('show');
  setTimeout(() => popup.classList.remove('show'), 1500);
}

function showLevelUp(levelData) {
  triggerConfetti();
}

// ===== BADGES =====
function awardBadge(badgeId) {
  if (gameState.badges.includes(badgeId)) return;
  gameState.badges.push(badgeId);
  saveGame();
  const badge = BADGES.find(b => b.id === badgeId);
  if (badge) showBadgeModal(badge);
  updateBadges();
}

function showBadgeDetails(badgeId) {
  const badge = BADGES.find(b => b.id === badgeId);
  if (badge) showBadgeModal(badge);
}

let _badgeModalTrapHandler = null;

function showBadgeModal(badge) {
  const modal = document.getElementById('badgeModal');
  document.getElementById('badgeModalIcon').textContent = badge.icon;
  document.getElementById('badgeModalTitle').textContent = badge.name;
  document.getElementById('badgeModalDesc').textContent = badge.desc;
  modal.classList.add('show');
  triggerConfetti();

  // Focus trap for accessibility
  const focusableElements = modal.querySelectorAll('button, [tabindex]:not([tabindex="-1"])');
  if (focusableElements.length > 0) {
    focusableElements[0].focus();
  }

  // Remove any previous handler before adding a new one
  if (_badgeModalTrapHandler) {
    modal.removeEventListener('keydown', _badgeModalTrapHandler);
  }

  _badgeModalTrapHandler = function(e) {
    if (e.key === 'Escape') {
      closeBadgeModal();
      return;
    }
    if (e.key === 'Tab') {
      const firstFocusable = focusableElements[0];
      const lastFocusable = focusableElements[focusableElements.length - 1];
      if (e.shiftKey && document.activeElement === firstFocusable) {
        e.preventDefault();
        lastFocusable.focus();
      } else if (!e.shiftKey && document.activeElement === lastFocusable) {
        e.preventDefault();
        firstFocusable.focus();
      }
    }
  };
  modal.addEventListener('keydown', _badgeModalTrapHandler);
}

function closeBadgeModal() {
  const modal = document.getElementById('badgeModal');
  if (_badgeModalTrapHandler) {
    modal.removeEventListener('keydown', _badgeModalTrapHandler);
    _badgeModalTrapHandler = null;
  }
  modal.classList.remove('show');
}

// ===== STREAK =====
function updateStreak() {
  const today = new Date().toDateString();
  if (gameState.lastActive !== today) {
    const yesterday = new Date(Date.now() - 86400000).toDateString();
    if (gameState.lastActive === yesterday) {
      gameState.streak++;
      if (gameState.streak >= 3) awardBadge('streak_3');
      if (gameState.streak >= 7) awardBadge('streak_7');
    } else if (gameState.lastActive) {
      gameState.streak = 1;
    } else {
      gameState.streak = 1;
    }
    gameState.lastActive = today;
    saveGame();
  }
}

// ===== CONFETTI =====
function triggerConfetti() {
  if (window.matchMedia('(prefers-reduced-motion: reduce)').matches) return;
  const container = document.getElementById('confettiContainer');
  const colors = ['#D4AF37', '#22c55e', '#3b82f6', '#f59e0b', '#ef4444', '#7c3aed'];
  for (let i = 0; i < 50; i++) {
    const confetti = document.createElement('div');
    confetti.className = 'confetti';
    confetti.style.left = Math.random() * 100 + '%';
    confetti.style.background = colors[Math.floor(Math.random() * colors.length)];
    confetti.style.animationDelay = Math.random() * 0.5 + 's';
    container.appendChild(confetti);
    setTimeout(() => confetti.remove(), 3500);
  }
}

// ===== COMBO =====
function updateComboDisplay() {
  const comboEl = document.getElementById('comboDisplay');
  const countEl = document.getElementById('comboCount');
  if (consecutiveCorrect >= 2) {
    countEl.textContent = consecutiveCorrect;
    comboEl.classList.add('show');
  } else {
    comboEl.classList.remove('show');
  }
}

// ===== MOBILE SIDEBAR =====
function toggleSidebar() {
  document.querySelector('.sidebar').classList.toggle('open');
  document.getElementById('sidebarOverlay').classList.toggle('show');
  var btn = document.querySelector('.sidebar-toggle, .hamburger, .mobile-menu-btn'); if (btn) btn.setAttribute('aria-expanded', btn.getAttribute('aria-expanded') === 'true' ? 'false' : 'true');
}

// ===== RENDER =====
function renderAll() {
  updateStreak();
  renderSidebar();
  renderSlides();
  updateStatsDisplay();
  updateBadges();
  updateCourseProgress();
}

function updateStatsDisplay() {
  const levelData = LEVELS.find(l => l.level === gameState.level) || LEVELS[0];
  const nextLevel = LEVELS.find(l => l.level === gameState.level + 1);

  document.getElementById('levelIcon').textContent = levelData.icon;
  document.getElementById('levelTitle').textContent = levelData.title;
  document.getElementById('levelNum').textContent = gameState.level;

  const currentXP = gameState.xp - levelData.xp;
  const neededXP = nextLevel ? (nextLevel.xp - levelData.xp) : 500;
  const pct = Math.min(100, (currentXP / neededXP) * 100);

  document.getElementById('xpFill').style.width = pct + '%';
  document.getElementById('xpCurrent').textContent = currentXP;
  document.getElementById('xpNeeded').textContent = neededXP;

  document.getElementById('correctCount').textContent = gameState.correctAnswers;
  document.getElementById('decisionCount').textContent = gameState.decisionsCompleted;
  document.getElementById('gradesCount').textContent = gameState.gradesAssigned || 0;
  document.getElementById('streakCount').textContent = gameState.streak;

  const streakEl = document.getElementById('streakDisplay');
  streakEl.classList.toggle('active', gameState.streak > 0);
}

function updateBadges() {
  const grid = document.getElementById('badgesGrid');
  grid.innerHTML = BADGES.map(b => {
    const earned = gameState.badges.includes(b.id);
    return `<button class="badge-item ${earned ? 'earned' : ''}" type="button" ${earned ? `onclick="showBadgeDetails('${b.id}')"` : ''} aria-label="${b.name}: ${b.desc}" title="${b.name}: ${b.desc}" style="min-width:44px;min-height:44px">${b.icon}</button>`;
  }).join('');
}

function renderSidebar() {
  const list = document.getElementById('moduleList');
  list.innerHTML = MODULES.map((mod, i) => {
    const completed = gameState.completedModules.includes(mod.id);
    const locked = i > 0 && !gameState.completedModules.includes(MODULES[i-1].id);
    const estMins = Math.round(mod.slides.length * 1.5);
    return `
      <div class="module-item ${i === currentModule ? 'active' : ''} ${completed ? 'completed' : ''} ${locked ? 'locked' : ''}"
           onclick="${locked ? '' : `goToModule(${i})`}"
           tabindex="${locked ? -1 : 0}"
           role="button"
           aria-disabled="${locked ? 'true' : 'false'}">
        <div class="module-number">${completed ? '‚úì' : (locked ? 'üîí' : mod.id)}</div>
        <div class="module-info">
          <div class="module-title">${mod.title}</div>
          <div class="module-subtitle">${mod.subtitle}</div>
          <div class="module-xp">+${mod.xp} XP</div>
          <div class="module-time">‚è±Ô∏è ~${estMins} min</div>
        </div>
      </div>
    `;
  }).join('');
}

function renderSlides() {
  const container = document.getElementById('slidesContainer');
  container.innerHTML = MODULES.map((mod, mi) => {
    const progressPct = ((currentSlide + 1) / mod.slides.length) * 100;
    return `
    <div class="module-slides ${mi === currentModule ? 'active' : ''}" data-module="${mi}">
      <div class="slide-progress-bar" style="width: ${mi === currentModule ? progressPct : 0}%"></div>
      ${mod.slides.map((slide, si) => renderSlide(slide, si, mi)).join('')}
      <div class="slide-nav">
        <button class="nav-btn" onclick="prevSlide()" ${currentSlide === 0 ? 'disabled' : ''} aria-label="Previous slide">‚Üê</button>
        <div class="nav-center">
          <div class="slide-counter">${currentSlide + 1} / ${mod.slides.length}</div>
          <div class="progress-dots">
            ${mod.slides.map((_, i) => `<button class="progress-dot ${i === currentSlide ? 'active' : ''}" type="button" onclick="goToSlide(${i})" aria-label="Go to slide ${i + 1}" ${i === currentSlide ? 'aria-current="true"' : ''}></button>`).join('')}
          </div>
        </div>
        <button class="nav-btn" onclick="nextSlide()" aria-label="Next slide">‚Üí</button>
      </div>
      <div class="keyboard-hint" style="position:absolute;bottom:5px;left:50%;transform:translateX(-50%);font-size:0.6rem;opacity:0.4;">‚Üê ‚Üí arrows or swipe to navigate</div>
    </div>
  `;
  }).join('');
  document.getElementById('currentModule').textContent = MODULES[currentModule].title;
  updateSlideVisibility();
}

function renderSlide(slide, index, moduleIndex) {
  const theme = slide.theme || 'dark';
  let html = `<div class="slide ${theme} ${index === currentSlide ? 'active' : ''}" data-slide="${index}">`;

  switch(slide.type) {
    case 'title':
      html += `<div class="content"><h1 class="title gold animate">${slide.content.title}</h1><p class="subtitle animate delay-1">${slide.content.subtitle}</p></div>`;
      break;

    case 'objectives':
      html += `<div class="content">
        <div class="objectives-box animate">
          <div class="objectives-header">
            <div class="objectives-icon">üéØ</div>
            <div class="objectives-title">Learning Objectives</div>
          </div>
          <ul class="objectives-list">
            ${slide.content.objectives.map(obj => `<li>${obj}</li>`).join('')}
          </ul>
        </div>
        ${slide.content.tip ? `<p class="subtitle animate delay-1" style="font-size:0.85rem;max-width:600px">${slide.content.tip}</p>` : ''}
      </div>`;
      break;

    case 'story':
      html += `<div class="content">
        <article class="story-box ${slide.content.success ? 'success' : ''} animate" role="article">
          <div class="story-label">${slide.content.label}</div>
          ${slide.content.title ? `<h2 class="title gold" style="font-size:1.8rem;margin-bottom:0.75rem">${slide.content.title}</h2>` : ''}
          <p class="story-text">${slide.content.text}</p>
          ${slide.content.followup ? `<p class="story-text" style="margin-top:0.75rem;font-style:italic;opacity:0.9">${slide.content.followup}</p>` : ''}
        </article>
      </div>`;
      break;

    case 'stats':
      html += `<div class="content">
        ${slide.content.title ? `<h2 class="title gold animate">${slide.content.title}</h2>` : ''}
        ${slide.content.subtitle ? `<p class="subtitle animate delay-1">${slide.content.subtitle}</p>` : ''}
        <div class="stats-grid animate delay-2">
          ${slide.content.stats.map(s => `<div class="stat-box"><div class="stat-value gold">${s.value}</div><div class="stat-label">${s.label}</div></div>`).join('')}
        </div>
        ${slide.content.caption ? `<p class="subtitle animate delay-3" style="font-size:0.85rem;margin-top:0.75rem">${slide.content.caption}</p>` : ''}
      </div>`;
      break;

    case 'refrain':
      html += `<div class="content" style="justify-content:center;height:100%"><p class="refrain animate">"${slide.content.text}"</p></div>`;
      break;

    case 'concept':
      html += `<div class="content">
        <h2 class="title ${theme === 'light' ? 'navy' : 'gold'} animate">${slide.content.title}</h2>
        ${slide.content.subtitle ? `<p class="subtitle animate delay-1">${slide.content.subtitle}</p>` : ''}
        ${slide.content.text ? `<div class="card ${theme === 'light' ? '' : 'navy-bg'} animate delay-2"><p class="card-text">${slide.content.text}</p></div>` : ''}
        ${slide.content.highlight ? `<div class="story-box warning animate delay-3"><div class="story-label">Key Insight</div><p class="story-text">${slide.content.highlight}</p></div>` : ''}
        ${slide.content.checkpoints ? `
          <div class="timeline animate delay-2" style="margin-top:0.75rem">
            ${slide.content.checkpoints.map(cp => `
              <div class="timeline-item"><div class="timeline-days">${cp.day}</div><div class="timeline-content"><div class="timeline-title">${cp.event}</div></div></div>
            `).join('')}
          </div>
        ` : ''}
      </div>`;
      break;

    case 'checklist':
      html += `<div class="content">
        <h2 class="title gold animate">${slide.content.title}</h2>
        <div class="checklist animate delay-1">
          ${slide.content.items.map(item => `
            <div class="checklist-item">
              <div class="check-icon">‚úì</div>
              <div class="checklist-text">${item}</div>
            </div>
          `).join('')}
        </div>
      </div>`;
      break;

    case 'decision':
      const did = `dec_${moduleIndex}_${index}`;
      const answered = gameState.answeredQuestions[did];
      html += `<div class="content">
        <div class="decision-tree animate">
          <div class="decision-header">
            <div class="decision-icon">${slide.content.icon}</div>
            <div class="decision-title">${slide.content.title}</div>
            <div class="decision-xp">+${slide.content.xp} XP</div>
          </div>
          <div class="decision-scenario">${slide.content.scenario}</div>
          <div class="decision-question">${slide.content.question}</div>
          <div class="decision-options">
            ${slide.content.options.map(opt => {
              const isSelected = answered === opt.letter;
              const showCorrect = answered && opt.correct;
              const showIncorrect = answered && isSelected && !opt.correct;
              return `
                <div class="decision-option ${isSelected ? 'selected' : ''} ${showCorrect ? 'correct' : ''} ${showIncorrect ? 'incorrect' : ''} ${answered ? 'disabled' : ''}"
                     onclick="answerDecision('${did}', '${opt.letter}', ${opt.correct}, ${slide.content.xp})"
                     tabindex="0"
                     role="button"
                     aria-disabled="${answered ? 'true' : 'false'}">
                  <div class="option-letter">${opt.letter}</div>
                  <div class="option-text">${opt.text}</div>
                </div>
              `;
            }).join('')}
          </div>
          <div class="decision-feedback ${answered ? 'show' : ''} ${answered && slide.content.options.find(o => o.letter === answered)?.correct ? 'correct' : 'incorrect'}" role="alert" aria-live="polite">
            <div class="feedback-title">${answered && slide.content.options.find(o => o.letter === answered)?.correct ? '‚úì Correct!' : '‚úó Not quite'}</div>
            <div class="feedback-text">${answered && slide.content.options.find(o => o.letter === answered)?.correct ? slide.content.feedback.correct : slide.content.feedback.incorrect}</div>
          </div>
        </div>
      </div>`;
      break;

    case 'quiz':
      const qid = `quiz_${moduleIndex}_${index}`;
      const qAnswered = gameState.answeredQuestions[qid];
      html += `<div class="content">
        <div class="quiz-container animate">
          <div class="quiz-question">${slide.content.question}</div>
          <div class="quiz-options">
            ${slide.content.options.map((opt, oi) => {
              const isSelected = qAnswered === oi;
              const showCorrect = qAnswered !== undefined && opt.correct;
              const showIncorrect = qAnswered !== undefined && isSelected && !opt.correct;
              return `
                <div class="quiz-option ${showCorrect ? 'correct' : ''} ${showIncorrect ? 'incorrect' : ''} ${qAnswered !== undefined ? 'disabled' : ''}"
                     onclick="answerQuiz('${qid}', ${oi}, ${opt.correct}, ${slide.content.xp})"
                     tabindex="0"
                     role="button">
                  ${opt.text}
                </div>
              `;
            }).join('')}
          </div>
          <div class="quiz-feedback ${qAnswered !== undefined ? 'show' : ''} ${qAnswered !== undefined && slide.content.options[qAnswered]?.correct ? 'correct' : 'incorrect'}" role="alert" aria-live="polite">
            ${qAnswered !== undefined && slide.content.options[qAnswered]?.correct ? slide.content.feedback.correct : slide.content.feedback.incorrect}
          </div>
        </div>
      </div>`;
      break;
  }

  html += '</div>';
  return html;
}

function updateSlideVisibility() {
  const container = document.querySelector('.module-slides.active');
  if (!container) return;

  container.querySelectorAll('.slide').forEach((slide, i) => {
    slide.classList.toggle('active', i === currentSlide);
  });

  const progressBar = container.querySelector('.slide-progress-bar');
  if (progressBar) {
    const pct = ((currentSlide + 1) / MODULES[currentModule].slides.length) * 100;
    progressBar.style.width = pct + '%';
  }

  container.querySelector('.slide-counter').textContent = `${currentSlide + 1} / ${MODULES[currentModule].slides.length}`;
  container.querySelectorAll('.progress-dot').forEach((dot, i) => {
    dot.classList.toggle('active', i === currentSlide);
  });
  container.querySelector('.nav-btn').disabled = currentSlide === 0;
}

// ===== ANSWERS =====
function answerDecision(did, letter, correct, xp) {
  if (gameState.answeredQuestions[did] !== undefined) return;
  gameState.answeredQuestions[did] = letter;
  gameState.decisionsCompleted++;
  gameState.gradesAssigned = (gameState.gradesAssigned || 0) + 1;

  // Award first_grade badge on first decision
  if (gameState.decisionsCompleted === 1) awardBadge('first_grade');

  if (correct) {
    gameState.correctAnswers++;
    consecutiveCorrect++;
    addXP(xp);
    if (consecutiveCorrect >= 5) awardBadge('perfect_5');
    if (gameState.decisionsCompleted >= 15) awardBadge('decision_maker');
  } else {
    consecutiveCorrect = 0;
  }
  gameState.consecutiveCorrect = consecutiveCorrect;
  saveGame();
  renderSlides();
  updateComboDisplay();
  updateStatsDisplay();
}

function answerQuiz(qid, choice, correct, xp) {
  if (gameState.answeredQuestions[qid] !== undefined) return;
  gameState.answeredQuestions[qid] = choice;

  if (correct) {
    gameState.correctAnswers++;
    consecutiveCorrect++;
    addXP(xp);
    if (consecutiveCorrect >= 5) awardBadge('perfect_5');
  } else {
    consecutiveCorrect = 0;
  }
  gameState.consecutiveCorrect = consecutiveCorrect;
  saveGame();
  renderSlides();
  updateComboDisplay();
}

// ===== NAVIGATION =====
function goToModule(index) {
  if (index > 0 && !gameState.completedModules.includes(MODULES[index-1].id)) return;
  currentModule = index;
  currentSlide = 0;
  renderSlides();
  renderSidebar();
}

function goToSlide(index) {
  currentSlide = index;
  updateSlideVisibility();
}

function nextSlide() {
  const mod = MODULES[currentModule];
  if (currentSlide < mod.slides.length - 1) {
    currentSlide++;
    updateSlideVisibility();
  } else {
    completeModule();
  }
}

function prevSlide() {
  if (currentSlide > 0) {
    currentSlide--;
    updateSlideVisibility();
  }
}

function completeModule() {
  const mod = MODULES[currentModule];
  if (!gameState.completedModules.includes(mod.id)) {
    gameState.completedModules.push(mod.id);
    addXP(mod.xp);

    // Module-specific badges
    if (mod.id === 3) awardBadge('bias_hunter');
    if (mod.id === 4) awardBadge('consistency_king');
    if (mod.id === 5) awardBadge('directness_detective');
    if (mod.id === 6) awardBadge('precision_master');
    if (mod.id === 7) awardBadge('publication_sleuth');
    if (mod.id === 8) awardBadge('upgrader');
    if (mod.id === 10) awardBadge('grade_master');
    if (gameState.completedModules.length === MODULES.length) awardBadge('finisher');

    saveGame();
    triggerConfetti();
    updateCourseProgress();
  }

  if (currentModule < MODULES.length - 1) {
    goToModule(currentModule + 1);
  }
}

// ===== KEYBOARD =====
document.addEventListener('keydown', (e) => {
  const isRoleButton = e.target && e.target.getAttribute && e.target.getAttribute('role') === 'button';
  const isFormControl = e.target && e.target.closest && e.target.closest('button, a, input, textarea, select, [role="radio"], [role="option"]');
  if (isRoleButton || isFormControl) {
    if ((e.key === ' ' || e.key === 'Enter') && isRoleButton) { e.preventDefault(); e.target.click(); }
    return;
  }
  if (e.key === 'Escape') {
    closeBadgeModal();
    document.querySelector('.sidebar').classList.remove('open');
    document.getElementById('sidebarOverlay').classList.remove('show');
    return;
  }
  if (e.key === 'ArrowRight' || e.key === ' ') { e.preventDefault(); nextSlide(); }
  else if (e.key === 'ArrowLeft') { e.preventDefault(); prevSlide(); }
});

// Second keydown handler removed (first handler covers role="button" elements)

// ===== TOUCH =====
let touchStartX = 0;
document.addEventListener('touchstart', (e) => { touchStartX = e.changedTouches[0].screenX; }, { passive: true });
document.addEventListener('touchend', (e) => {
  const diff = touchStartX - e.changedTouches[0].screenX;
  if (Math.abs(diff) > 50) { diff > 0 ? nextSlide() : prevSlide(); }
}, { passive: true });

// ===== INIT =====
renderAll();
</script>
</body>
</html>
